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Thesis summary 
Alzheimer’s Disease (AD) is the most common form of dementia currently affecting 
more than 35 million people worldwide. Hypometabolism is a major feature of AD and 
appears decades before cognitive decline and pathological lesions. This has a 
detrimental impact on the brain which has a high energy demand.  
 
Current models of AD fail to mimic all the features of the disease, which has an 
impact on the development of new therapies. Human stem cell derived models of the 
brain have attracted a lot of attention in recent years as a tool to study 
neurodegenerative diseases. 
 
In this thesis, neurons and astrocytes derived from the human embryonal carcinoma 
cell line (NT2/D1) were utilised to determine the metabolic coupling between neurons 
and astrocytes with regards to responses to hypoglycaemia, neuromodulators and 
increase in neuronal activity. 
 
This model was then used to investigate the effects of Aβ(1-42) on the metabolism  
of these NT2-derived co-cultures as well as pure astrocytes. Additionally primary 
cortical mixed neuronal and glial cultures were utilised to compare this model to a 
widely accepted in vitro model used in Alzheimer’s disease research. 
Co-cultures were found to respond to Aβ(1-42) in similar way to human and in vivo 
models. Hypometabolism was characterised by changes in glucose metabolism, as 
well as lactate, pyruvate and glycogen. This led to a significant decrease in ATP and 
the ratio of NAD+/NADH. These results together with an increase in calcium 
oscillations and a decrease in GSH/GSSG ratio, suggests Aβ-induces metabolic and 
oxidative stress. This situation could have detrimental effects in the brain which has a 
high energy demand, especially in terms of memory formation and antioxidant 
capacity.  
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Chapter 1: Introduction 
1.1 The overview/prevalence of Alzheimer’s Disease 
 
Alzheimer’s disease (AD) is a neurodegenerative disease and is the most common 
form of late-life functional mental deterioration in humans. According to the World 
Alzheimer’s Report currently more than 35 million people live with Alzheimer’s 
disease globally, as well as other types of dementia. These numbers are predicted to 
double every 20 years, reaching 65.7 million in 2030 and 115.4 million in 2050 
(International, 2009). 
 
1.2 Symptoms and pathology 
 
Symptoms of AD include progressive memory loss, impaired cognitive function, 
decline in language function, changes in behaviour that includes agitation, 
aggression, paranoia, delusion and apathy (Selkoe, 2001). 
 
These symptoms are associated with the presence of two types of lesions in the 
brain, neurofibrillary tangles (NFTs) and amyloid (neuritic) plaques. NFTs are 
composed of tau protein, which are localized within neurons and were discovered in 
the early investigations of the disease by silver staining. Amyloid plaques are 
extracellular depositions of fibrillar amyloid-beta (Aβ) and were discovered by the use 
of Congo Red dye (Puchtler et al., 1962). However, in recent years it has become 
clear that amyloid plaques and neurofibrillary tangles are only ‘tombstones’ marking 
the site of neuronal death (Selkoe, 2001). 
 
Alzheimer’s disease, unlike other neurodegenerative diseases such as Parkinson’s 
disease, does not affect a single transmitter class and is highly heterogeneous 
(Selkoe, 2001). Some studies suggest that Aβ deposition drives tau aggregation 
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(Gotz et al., 2001). The accumulation of both tau and Aβ results in oxidative stress 
and inflammation which in turn cause energetic failure and synaptic dysfunction 
(Querfurth and LaFerla, 2010). Furthermore, increased oxidative stress, impaired 
protein-folding, together with a deficiency in clearance of damaged proteins, combine 
to increase the accumulation of amyloid and tau proteins (Hoozemans et al., 2009, 
López Salon et al., 2000). 
 
1.2.1 Neuritic plaques 
 
Neuritic plaques or amyloid plaques are one of the two pathologic lesions found in 
postmortem brains of Alzheimer’s patients and are composed of fibrillar Aβ (Glenner 
and Wong, 1984). 
 
Amyloid plaques are associated with dystrophic neurites which are found within the 
plaque and around it. Dystrophic neurites are characterized by the presence of 
enlarged lysosomes, multiple mitochondria and paired helical filaments (Selkoe, 
2001). Plaques are also surrounded by other types of cells such as astrocytes and 
microglia. Both types of cells express markers characteristic for their activation i.e. 
CD45 and HLA-DR for microglia and a dramatic increase in glial fibrillary acidic 
protein (GFAP) for astrocytes. Microglia are usually found close to the amyloid core 
while astrocytes often surround the plaque, with some of the processes extending 
towards the core of the plaque (Nagele et al., 2004). The length of time it takes to 
accumulate Aβ(1-42) and form plaques in AD brains is unknown, but they are 
thought to form gradually over months or years (Nagele et al., 2004). 
 
The neuritic plaques are mainly composed of A(β1-42) which is a slightly longer and 
more hydrophobic and therefore prone to aggregation (Snyder et al., 1994). The size 
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of the plaque varies widely from 10 to 120 µm in diameter (Selkoe, 2001). Aβ and its 
aggregation will be further discussed in chapter 2. 
 
1.2.2 Neurofibrillary tangles 
 
Neurofibrillary tangles (NFTs), the intracellular aggregates that occur in AD and other 
neurodegenerative diseases termed tauopathies, are formed by paired helical 
filaments (PHFs) (Kurt et al., 1997). The major component of PHFs was identified in 
the 1980’s as the microtubule-associated protein tau (Grundke-Iqbal et al., 1986). 
Normally tau is a soluble and abundant protein in axons and is involved in 
stabilization of microtubules and vesicle transport. However, in Alzheimer’s Disease, 
tau is hyperphosphorylated which makes the protein insoluble and prone to self-
association (Grundke-Iqbal et al., 1986). Additionally, hyperphosphorylation of tau 
leads to a decrease in the binding of tau to microtubules. The degree of tau 
phosphorylation depends on the balance between the activities of protein kinases 
and phosphatases. The abnormal tau hyperphosphorylation seen in AD could be 
cause by either an upregulation of tau kinases or a downregulation of tau 
phosphatases. Tau kinases include glycogen synthase kinase-3 (GSK-3), mitogen 
activated protein kinase (MAPK), cyclin-dependent kinase 5 (CDK5), protein kinase 
C (PKC), Jun N-terminal kinases or calcium/calmodulin-dependent protein kinase 
(CaMKII). Tau phosphatases include protein phosphatase-1 (PP-1), protein 
phosphatase-2 (PP-2) and protein phosphatase-5 (PP-5) (Huang and Jiang, 2009).  
It is unclear whether there is an association between Aβ and hyperphosphorylated 
tau. However, there is a growing body of evidence that Aβ can interact with tau and 
accelerate formation of NFTs as well as induce its hyperphosphorylation. Aβ has 
been shown to induce activation of both GSK-3 isosymes. As GSK-3β is one of the 
tau kinases, thus its activation can lead to hypephosphorylation of tau (Kremer et al., 
2011).  
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However, it has also been found that tau deficiency prevents Aβ-induced cognitive 
defects (Shipton et al., 2011). In addition, tau appears to be necessary for amyloid to 
disrupt axonal transport in vitro (Vossel et al., 2010). However, the relationship 
between Aβ and tau in onset and progression of Alzheimer’s Disease requires further 
investigation.  
 
1.3 APP processing 
 
The 37-43 amino acid amyloid-beta (Aβ) peptide is derived from Amyloid Precursor 
Protein (APP) by sequential proteolytic cleavage in a physiologically normal pathway 
(Shoji et al., 1992, Haass et al., 1993a). APP comprises a heterogeneous group of 
type I membrane glycoproteins which are ubiquitously expressed. This 
heterogeneous group arises from alternative splicing, yielding three major isoforms of 
695, 751 and 770 residues. These isoforms are also post-translationally modified to 
include N- and O-linked glycosylation, phosphorylation, sulphation and complex 
proteolysis (Weidemann et al., 1989, Hung and Selkoe, 1994). Isoforms of 751 and 
770 residues are widely expressed in non-neuronal cells as well as neurons. 
However, neuronal cells express higher levels of the 695 amino acids isoform which 
are expressed at a low level in non-neuronal cells (Haass et al., 1991). The 751 and 
770 isoforms contain an additional exon which codes for 56-amino acid motif 
homologous to the Kunitz-type serine protease inhibitors (KPI). Isoforms such as 
751/770 are found in human platelets and can act as inhibitors of factor XIa which is 
a serine protease in the coagulation pathway (Smith et al., 1990). APP is highly 
conserved and found in all mammals and is a member of a larger gene family, the 
amyloid precursor-like proteins (APLPs) (Slunt et al., 1994). 
APP is a membrane protein with an amino terminus orientated to the 
lumen/extracellular space and its carboxyl terminus within the cytosol (Dyrks et al., 
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1988). APP has been shown to be initially targeted into the secretory pathway; 
however, it is processed proteolytically at other sites within the cell (Weidemann et 
al., 1989). APP can be processed by three proteases called α-, β- and γ-secretases 
(Haass, 2004) during two processing pathways: the amyloidogenic pathway and the 
non-amyloidogenic pathway (Fig. 1.1). Non-amyloidogenic processing of APP 
involves γ-secretase and α-secretase which cleaves approximately in the middle of 
the Aβ sequence thus abolishing its production (Nunan and Small, 2000). This 
cleavage generates the truncated carboxy-terminal fragment (C83), which lacks the 
amino-terminal region of Aβ. Subsequent processing within a membrane by γ- 
secretase produces a peptide called p3 (Haass et al., 1993b) as well as APP 
intracellular domain (AICD) (Gu et al., 2001) which is released into the cytosol. AICD 
has been found to have a function in nuclear signaling (von Rotz et al., 2004) (Fig. 
1.1). 
 
Aβ is generated via the amyloidogenic pathway by the consecutive action of β- and 
γ-secretases (Haass, 2004) (Fig. 1.1). The main β-secretase in the human brain is β-
site APP cleaving enzyme (BACE) 1, which cleaves full length APP at Asp1 of the 
amyloid beta sequence (Nunan and Small, 2000). The cleavage of APP by BACE1 
leads to shedding of the APP ectodomain (sAPPβ) and generation of a C-terminus 
fragment, C99 which is sequentially cleaved by γ- secretase. The latter cleavage 
occurs within the hydrophobic environment of cell membranes. The γ- secretase 
cleavage of C99 fragment results in the formation of the Amyloid Precursor Protein 
Intracellular Domain (AICD) fragment and two Aβ variants, either 40 or 42 amino 
acids in length (Cole and Vassar, 2007). These are released to extracellular fluids 
such as plasma or cerebrospinal fluid (CSF) (Seubert et al., 1992) (Fig. 1.1). 
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Figure 1.1 APP processing via non-amyloidogenic and amyloidogenic pathway. 
Diagram reproduced from Debby Van Dam & Peter Paul De Deyn (2006) 
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1.3.1 β-secretase 
 
Following its identification, β-secretase was given several different names including 
memapsin, aspartyl protease 2 or BACE1 (β-site APP cleaving enzyme-1) (Vassar et 
al., 1999). BACE1 is a membrane-bound aspartyl protease which has its active site in 
the lumen/extracellular space (Hong et al., 2000). In addition to BACE1, a 
homologous protease, BACE2 has been identified (Cole and Vassar, 2007). BACE2 
does not play a role in the amyloidogenic pathway and has been shown to have an 
anti-amylodogenic activity in non-neuronal cells (Farzan et al., 2000). 
 
BACE1 is ubiquitously expressed, with the highest levels found in the brain and 
pancreas. BACE1 mRNA levels are highest in neurons but this enzyme is also found 
at lower levels in glia (Cole and Vassar, 2007). The physiological function of BACE1 
is not well understood. High expression of BACE1 postnatally (Willem et al., 2006) 
has been found to be related to myelination (a process which occurs after birth). It 
has been shown that BACE1 knockout mice demonstrate a significant 
hypomyelination (Willem et al., 2006). Other physiological roles of BACE1 such as 
regulation of voltage-dependent sodium channels are currently under investigation 
(Kim et al., 2007). 
 
BACE1 is translocated into the endoplasmic reticulum (ER) as an immature pro-
enzyme. During maturation it undergoes post-translational modifications which 
include N-glycosylation and palmitoylation (Capell et al., 2000). Once the pro-peptide 
is removed from the immature BACE1, it reaches the PM and is enriched in lipid rafts 
(Riddell et al., 2001). BACE1 is then internalized and is recycled to trans-Golgi 
network (TGN) via endosomes (Walter et al., 2001). As an aspartyl protease, BACE1 
has an acidic pH optimum and has optimal activity at about 4.5. This limits 
localization of BACE1 activity to acidic compartments of the secretory pathway (Cole 
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and Vassar, 2007). Additionally, BACE1 can cleave APP within late Golgi 
compartments (Haass et al., 2012). 
 
1.3.2 γ-secretase 
 
γ-secretase mediated cleavage of APP occurs within the transmembrane domain 
(TMD). γ-secretase is a protease complex and consists of four core components – 
endoproteolyzed presenilin (a heterodimer of N- and C-terminal fragments), nicastrin 
(NCT), anterior pharynx defective (APH)-1α or APH-1β and the PS enhancer (PEN)-
2. PS1 and PS2 contain two critical aspartyl residues which form a catalytic subunit 
of γ-secretase (Wolfe et al., 1999). 
 
 All four of these components are necessary for full γ-secretase activity (Edbauer et 
al., 2003) however, little is known about NCT, APH-1 and PEN-2 function. NCT is 
thought to act as a substrate-binding receptor of γ-secretase (Shah et al., 2005) and 
PEN-2 is involved in PS endoproteolysis and stabilization (Prokop et al., 2004). Very 
little is currently known about APH-1 function. 
 
The processing of APP by γ-secretase involves multiple steps. It has been shown 
that γ-secretase substrates are cleaved several times within their transmembrane 
domains. Cleavages at ε-, ζ-, and γ-sites have been described (Sastre et al., 2001, 
Weidemann et al., 2002). Additionally, the final γ-cleavage can occur at different 
sites, between 37 and 43 amino acids of the Aβ sequence. This produces Aβ 
proteins that differ in length and are more prone to aggregation and toxicity such as 
Aβ(1-42) (Haass and Selkoe, 2007). 
 
γ-Secretase has been found to cleave APP at the plasma membrane (PM) as well as 
in endosomal/lysosomal system (Pasternak et al., 2004, Kaether et al., 2006). 
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However, it has been shown the ε-cleavage differs in endosomes and PM (Fukumori 
et al., 2006), possibly due to different pH or lipid composition. Due to the complex 
morphology of neurons, little is known about subcellular site of γ-secretase 
processing (Haass et al., 2012). γ-secretase is present in synapses and distal axons 
(Frykman et al., 2010) but the precise site of processing by both β-, and γ-secretases 
has yet to be determined. 
 
1.3.3 α-secretase 
 
Anti-amyloidogenic processing of Aβ involves cleavage by proteases called α-
secretases. This enzyme cleaves within Aβ domain, between Lys16 and Leu17 
residues (Wang et al., 1991). This cleavage produces large APP amino-terminal 
domain (sAPPα) and C83. α-secretases are plasma membrane (PM)-bound 
proteases (Sisodia, 1992) and include several zinc metalloproteinases such as 
ADAM9, ADAM10, TACE/ADAM17 and ADAM19 (Allinson et al., 2003). However, 
studies suggest that in neurons the main α-seretase is ADAM10 (Kuhn et al., 2010) 
and its expression has been found throughout the cortex and hippocampus 
(Marcinkiewicz and Seidah, 2000). Other substrates for α-secretase include Notch 
receptors, tumor necrosis factor α, cadherins and IL-6 receptor. Due to the wide 
variety of α-secretase substrates cleavage is considered to be sequence 
independent and depends upon the proteins α-helical conformation as well as the 
distance of the hydrolyzed bond from the membrane (Sisodia, 1992). 
 
In neurons the predominant pathway for processing of APP appears to be the 
amyloidogenic pathway due to higher expression of BACE1, whilst in other cells the 
non-amyloidogenic pathway dominates (Haass et al., 2012). However, neuronal 
overexpression of ADAM10 reduces amyloidogenic processing of APP and Aβ 
production (Postina et al., 2004).  
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APP processing via amyloidogenic or anti-amyloidogenic pathways can be 
modulated by activation of receptors such as serotonin/5-hydroxytrypamine (5-HT4) 
receptor, metabotropic glutamate receptors as well as muscarinic acetylocholine 
receptors (Allinson et al., 2003). Signalling downstream of these receptors regulates 
sAPPα and Aβ secretion via intermediates that include protein kinase C, inositol 
1,4,5-triphosphate and cytosolic calcium (Allinson et al., 2003).  
 
1.4 Biosynthesis and trafficking 
 
APP undergoes post-translational modifications during its transit from the ER to PM. 
However, only a small number of APP molecules reach the PM (~10%), whilst the 
majority localizes to the Golgi apparatus and trans-Golgi network (TGN) (Haass et 
al., 2012). Once APP reaches the PM it can be processed by α- and γ-secretases. 
APP that is not cleaved immediately, is internalized as it contains “YENPTY” 
internalization motif near its carboxy-terminal region (Lai et al., 1995). Once 
internalized, APP is delivered to endosomes (Haass et al., 2012).  
 
It has been shown that in non-neuronal polarized cells APP is targeted to the 
basolateral side of the cell (Haass et al., 1994). Secretases are also differentially 
sorted, with BACE1 being targeted to the apical surface (Capell et al., 2002) and 
ADAM10 being targeted basolaterally (Wild-Bode et al., 2006). γ-secretase has been 
found on both apical and basolateral surfaces (Capell et al., 2002). This suggests 
that Aβ generation is markedly reduced in polarized cells (Capell et al., 2002). 
However, it has been found that the Swedish mutation that occurs just before BACE1 
cleavage site (Fig. 1.2) affects the sorting of APP. The Swedish mutant version of 
APP when expressed in the polarized MDCK cell line was sorted to the apical 
surface, increasing both sAPPβ and Aβ generation (De Strooper et al., 1995). 
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Neuronal cells are highly polarized into soma, axons and dendrites and each of these 
compartments has different physiological functions (Haass et al., 2012). A complex 
system of microtubules, kinesin and dynein motor proteins and sorting signals 
ensures a highly controlled delivery of specific proteins to different compartments in 
neurons (Haass et al., 2012) and disturbances in this system has been previously 
linked to AD (Morfini et al., 2009).  
 
Polarized trafficking of APP in neurons is poorly understood. In the soma the 
trafficking of APP appears to be similar as in nonneuronal cells. APP is transported 
from ER to Golgi and then to the TGN. However, once APP leaves the TGN it is then 
transported to axons and dendrites in post-Golgi transport vesicles (Kins et al., 
2006). This delivery relies upon the use of the fast axonal transport system (Koo et 
al., 1990). In contrast to non-neuronal cells, in neurons the basolateral sorting signal 
in APP sequence appear to have no known function.  
 
1.5 Genetics of familial Alzheimer’s Disease 
 
Investigation into the inherited forms of AD has provided insights into the processes 
and genes associated with this disease. AD is inherited in the autosomal dominant 
fashion and accounts for about 5-10% of all AD cases (Selkoe, 2001). However, it is 
believed that the majority of sporadic AD patients have genetic determinants which 
could predispose them to the disease as opposed to directly causing it. Very often 
these two forms of AD are indistinguishable from each other, except for the earlier 
onset of the diseases in the familial AD. Presently, inherited alterations in four genes 
have been credibly linked to increases in the production and/or the cerebral 
deposition of the Aβ peptides - APP, PS1, PS2 and ApoE (Selkoe, 2001). 
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Families carrying missense mutations in the APP gene generally have an early onset 
of the disease before the age of 65. Some missense mutations in APP affect 
cleavage sites and are located either immediately before the β-secretase site, or just 
after the α-secretase or γ-secretase cleavage sites (Fig. 1.2). Mutations at the amino 
terminus of the Aβ region that affect the β-secretase site (such as the Swedish 
mutation) increase the production of Aβ(1-42) and Aβ(1-40) by favoring cleavage by 
β-secretase as opposed to α-secretase (Citron et al., 1992). Mutations affecting the 
γ-secretase site (located just beyond the carboxyl terminus of Aβ) such as Austrian, 
Iranian, London or Florida mutations selectively enhance the production of Aβ 
species ending at residue 42 which aggregate more rapidly (Selkoe, 2001). 
Mutations such as Arctic (Nilsberth et al., 2001) or Dutch (Levy et al., 1990) which 
are found in mid region (Fig. 1.2), affect the sequence of Aβ and were found to 
change its structure, and thus increase its aggregation (Haass et al., 2012). 
 
Missense mutations in the presenilin genes are the most common cause of familial 
AD. They cause the earliest and most aggressive forms of AD with early symptoms 
showing at the age of 50 and death of patients in their 60s. Presently 75 missense 
mutations have been identified in the presenilin1 gene which is located on 
chromosome 14, while only 3 in presenilin-2 gene on chromosome 1 (Selkoe, 2001). 
Mutations in the presenilins leads to a 1.5 – 3-fold increase in the number of plaques 
compared to sporadic cases of AD (Lemere et al., 1996). 
 
e4 allele of apolipoprotein E (ApoE4) was discovered in human cerebrospinal fluid as 
a protein that binds immobilized Aβ peptides. The inheritance of one or two e4 alleles 
of ApoE increases the probability of developing AD and results in an earlier mean 
age of onset than in subjects carrying e2 and or e3 alleles (Corder et al., 1993). The 
mechanism by which ApoE4 interacts with Aβ is not known. It is possible that this 
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isoform somehow enhances the deposition of Aβ or affects its clearance leading to 
increased numbers of plaques in the brain (Castellano et al., 2011).  
 
1.6 Risk factors for late onset Alzheimer’s Disease and treatments 
 
The primary risk factor for Alzheimer’s disease and most forms of dementia is 
advanced age. After the age of 65 the prevalence of disease doubles every five 
years (International, 2009). 
 
Late-onset Alzheimer’s disease (LOAD) is also associated with genetic factors. One 
of the biggest genetic factors discovered is the ApoE4, where one allele results in a 
2.5-fold increase in risk, whilst two alleles cause a 16-fold increase.  
 
Results from four large genome-wide association studies (GWAS) have discovered 
nine novel loci associated with the late-onset form of the disease. These include 
clusterin (CLU), phosphatidylinositol-binding clathrin assembly protein (PICALM), 
complement receptor 1 (CR1), bridging integrator 1 (BIN1), ATP-binding cassette 
transporter (ABCA7), membrane-spanning 4-domains subfamily A (MS4A cluster), 
CD2-associated protein (CD2AP), sialic acid-binding immunoglobulin-like lectin 
(CD33) and ephrin receptor A1 (EPHA1) (Harold et al., 2009, Lambert et al., 2009, 
Seshadri et al., 2010, Naj et al., 2011, Hollingworth et al., 2012). These ten genes 
have been found to be associated with three biological pathways, which include; 
immune system function (CLU, CR1, ABCA7, MS4A cluster, CD33, EPHA1), 
cholesterol metabolism (APOE, CLU, ABCA7) and synaptic dysfunction and cell 
membrane processes (PICALM, BIN1, CD33, CD2AP, EPHA1) (Morgan, 2011).  
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Figure 1.2 Representative APP mutations. Reproduced from Debby Van Dam & 
Peter Paul De Deyn (2006) 
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In addition to genetic factors, some epidemiological studies also suggest that 
environmental factors such as education or head injury may also be involved in the 
onset of Alzheimer’s Disease (International, 2009). 
 
No treatments are currently available that could cure, or slow down or prevent the 
progressive course of dementia. Treatments available are at best partially effective, 
as they can only ameliorate the symptoms of the disease to some extent 
(International, 2009). The scarcity of effective treatments could be due in part to lack 
of realistic or relevant models of the disease which translate into a limited 
understanding of the cellular processes that are at the root of the early stages of the 
disease. 
 
1.7 Mitoenergetics and oxidative stress in Alzheimer’s Disease 
 
Decreased brain metabolism is a feature of AD that is present before the onset of 
clinical symptoms and cognitive decline. Emerging evidence from studies on 
mitochondrial function, demonstrate changes in activities of enzymes involved in 
oxidative phosphorylation and TCA cycle in AD. In addition, mutations in mtDNA and 
changes in morphology of mitochondria may be responsible for the apparent 
hypometabolism and oxidative stress that is seen in the brains of AD individuals. 
 
1.7.1 Mitochondria 
 
Mitochondria are essential in many cellular processes, which include energy 
metabolism, oxidation of fatty acids, calcium homeostasis, apoptosis and cell 
signalling (Anandatheerthavarada and Devi, 2007). As neurons have a high-energy 
demand, mitochondria are crucial for their functioning, especially at the synapses. 
Synapses are enriched with mitochondria and by producing ATP and sustaining 
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calcium homeostasis play an important role in neurotransmission 
(Anandatheerthavarada and Devi, 2007).  
 
1.7.2 Intracellular Aβ 
 
Many studies have focused on the intracellular Aβ and have revealed that the 
majority of intracellular Aβ is the 1-42 form (Gouras et al., 2000), which is mainly 
produced within membranes such as the plasma membrane (Kaether et al., 2006), 
the secretory pathway (Khvotchev and Sudhof, 2004) or endosomal compartments 
(Pasternak et al., 2004). However, due to the orientation of APP and the secretases 
involved in its cleavage it has been difficult to explain the presence of Aβ in the 
cytosol. Some studies have shown that Aβ integrates into lipid membranes (Arispe et 
al., 1993) which can lead to a loss of membrane integrity in endosomal 
compartments and the subsequent leakage of Aβ into the cytosol (Yang et al., 1998). 
 
1.7.3 Mitochondria in AD 
 
In early AD, Aβ induces oxidative stress which is associated with mitochondrial 
dysfunction (Manczak et al., 2006). Both APP and Aβ have been found within 
mitochondrial membranes where they can block transport of nuclear-encoded 
proteins. Aβ has also been shown to affect the electron-transport chain (ETC) but it 
also binds to mitochondrial proteins ultimately causing an increase in ROS 
production and mitochondrial damage (Reddy and Beal, 2008).  It has been 
suggested that mitochondrial dysfunction, low ATP production and oxidative damage 
at the synapses leads to cognitive decline in AD patients (Reddy and Beal, 2008). 
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1.7.4 Aβ and APP inside mitochondrial membranes and matrix 
 
Mitochondria require a large number of proteins for physiological functioning and 
unlike other organelles, contain their own genome. Mitochondrial DNA (mtDNA) only 
codes for 13 polypeptides which are a part of the ETC (Anandatheerthavarada and 
Devi, 2007). Hence, mitochondria depend upon proteins encoded by the nuclear 
genome. It has been shown that about 1500 nuclear-encoded polypeptides are 
transported into mitochondria under normal, physiological conditions (Gabaldon and 
Huynen, 2004). This transport is tightly regulated and in most cases requires 
functional outer and inner-membrane import channels (Anandatheerthavarada and 
Devi, 2007).  
 
An important feature of the proteins that are targeted to mitochondria, is that they 
need to be in an unfolded conformation for the translocation to occur. Translocation 
of proteins to inner membrane and matrix also requires ATP and functional 
mitochondrial membrane potential (Anandatheerthavarada and Devi, 2007).    
 
Many studies have shown the presence of APP and Aβ within mitochondrial 
membranes (Anandatheerthavarada et al., 2003, Devi et al., 2006, Manczak et al., 
2006). Anandatheerthavarada et al. (2003) used in vitro mitochondrial-import and in 
vivo neuronal-expression studies to first demonstrate that both endogenous and 
ectopically expressed wild-type and Swedish APP695 localize to the plasma 
membrane and mitochondria of human HCN-1A neurons. Additionally, it was shown 
that the mitochondrial APP is orientated so that the NH2-terminal faces inside the 
mitochondria while COOH-terminal faces the cytosol and that APP is in contact with 
mitochondrial inner and outer translocase proteins. In the same study, the authors 
demonstrated that the acidic domain (sequence 220–290 of APP) causes 
transmembrane arrest with the 73-kD portion of COOH-terminal facing the 
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cytoplasmic side. Subsequent studies have confirmed this orientation of 
mitochondrial APP (Park et al., 2006).  
 
A study on human brain tissue has also shown a significant increase in full-length 
and C-terminal truncated (lacking Aβ domain) APP accumulation in the mitochondria 
of AD patients in comparison with aged-matched controls (Devi et al., 2006). 
Similarly Aβ has also been found inside mitochondria in neuronal cultures (Manczak 
et al., 2006), transgenic mice (Caspersen et al., 2005, Manczak et al., 2006) and 
human AD brains (Lustbader et al., 2004).  
 
APP arrest across mitochondrial import channels leads to inhibition of the transport of 
nuclear-encoded cytochrome c oxidase subunits IV and Vb. These findings were 
associated with a decrease in cytochrome c oxidase activity as well as increased 
levels of H2O2. (Devi et al., 2006). These results were also in line with previous in 
vitro studies on HCN neuronal cells, where accumulation of APP695 in mitochondria 
was linked to a decrease in mitochondrial membrane potential, ATP levels and 
mitochondrial cytochrome c oxidase activity. 
 
It is still unclear whether Aβ accumulates inside the mitochondrial matrix or 
exclusively in the membrane compartments (Muirhead et al., 2010). Walls et al. 
(2012) have shown that Aβ may be associated with the matrix as it co-localized with 
matrix chaperone Hsp60. Aβ has also been found to interact with other mitochondrial 
matrix proteins such as Abeta-binding alcohol dehydrogenase (ABAD) which suggest 
its localization in the matrix (Lustbader et al., 2004). However, Aβ has not been 
detected in the mitochondrial matrix on its own. One of the possible explanations 
could be the presence of mitochondrial proteinases which could degrade Aβ such as 
PreP or IDE (Qiu et al., 1998, Falkevall et al., 2006). Other studies also found that in 
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rats, mitochondrial Aβ is transported via the translocase of the outer membrane 
(TOM) and localizes in the mitochondrial cristae (Hansson Petersen et al., 2008).  
It is also not understood whether Aβ is produced locally in mitochondria or imported 
from the cytosol. At present evidence supports both possibilities (for review see 
(Muirhead et al., 2010) and requires further investigation. 
 
To summarize, mutant APP and/or Aβ can enter mitochondria and interact with 
mitochondrial proteins, disrupt ETC, increase ROS production and inhibit generation 
of ATP (Reddy and Beal, 2008). 
 
1.7.5 Aβ interactions with mitochondrial proteins 
 
The most well characterized protein interacting with Aβ in mitochondria is Abeta-
binding alcohol dehydrogenase (ABAD). This protein has been previously found in 
ER and mitochondria and is expressed in all tissue types (Yan et al., 1997). ABAD is 
an enzyme which catalyzes reduction of aldehydes and ketones as well as the  
oxidation of alcohols and has a wide range of diverse substrates (Muirhead et al., 
2010). In mitochondria, it is believed to have a function in energy production and 
homeostasis, particularly during the third step of beta-oxidation of fatty acids (He et 
al., 1998). This makes ABAD important during glucose deficiency, where there is a 
need for other energy sources (Du Yan et al., 2000). ABAD was also found to protect 
against neurodegeneration in mouse models of ischaemic stress (Du Yan et al., 
2000) or from the loss of dopaminergic neurons in mice treated with MPTP (Tieu et 
al., 2004). 
 
Both Aβ(1-42) and Aβ(1-40) have been found to interact with ABAD (Lustbader et al., 
2004) and inhibit its activity (Yan et al., 1999) and it has been demonstrated that the 
residues 13-22 of Aβ are critical for this inhibition (Oppermann et al., 1999). Inhibition 
	  
	  
36	  
of ABAD requires micromolar concentrations of Aβ even though binding occurs at 
nanomolar concentrations (Yan et al., 1997). This suggests that aggregation of Aβ 
might be an important aspect of inhibition. However, the cytotoxic effects of Aβ are 
not simply a result of ABAD inhibition. Overexpression of ABAD in its inactive form in 
the presence of Aβ did not increase its toxicity in comparison to Aβ alone (Yan et al., 
1999). This suggests a downstream effect mediated by the active enzyme, which is 
bound to Aβ (Yan et al., 1999). This hypothesis has been supported by studies on 
overexpression of ABAD and Aβ, which resulted in increased DNA fragmentation and 
apoptosis (Yan et al., 1997, Yan et al., 1999) as well as increased levels of hydrogen 
peroxide, decreased mitochondrial function, decreased glucose utilization and ATP 
production and ultimately cell death (Takuma et al., 2005). In addition, inhibition of 
ABAD-Aβ binding has also been found to protect against mitochondrial dysfunction 
and improve spatial memory (Yao et al., 2011). 
 
A second protein that binds to Aβ in mitochondria is cyclophilin D (CypD). It is a 
peptidylprolyl isomerase F that is found in mitochondria where it can translocate to 
the inner mitochondrial membrane during opening of the mPTP (mitochondrial 
permeability transition pore) during oxidative stress (Connern and Halestrap, 1994). 
mPTP has been shown to play a central role in both necrotic and apoptotic cell death 
(Leung and Halestrap, 2008) and some studies have demonstrated that CypD 
deficiency protects against Ca2+ and oxidative stress induced cell death (Schinzel et 
al., 2005). 
 
CypD has been found to bind Aβ with Aβ(1-42) with greater affinity than Aβ(1-40) and 
increased levels of CypD have been reported in AD brains (Du et al., 2008). The 
interaction of Aβ and CypD leads to an increase in ROS production, which in turn 
induces translocation of CypD to the inner mitochondrial membrane and mPTP 
opening and cell death (Du et al., 2008). CypD deficiency in AD transgenic mice 
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protects against Aβ and oxidative stress-induced death and improves learning and 
memory (Du et al., 2008). 
 
1.7.6 Mitochondrial bioenergetics in AD 
 
There is increasing evidence suggesting that mitochondrial bioenergetics and brain 
metabolism affect processing of APP (Gabuzda et al., 1994, Gasparini et al., 1997). 
One of the functions of mitochondria is the oxidation of reduced NADH to NAD+. This 
process is important in other bioenergetics pathways such as glycolysis which 
require NAD+ (Selfridge et al., 2013). NADH is produced during glycolysis, the TCA 
cycle and other reactions is oxidized by complex I through electron donation. 
Additionally, the malate-aspartate shuttle transfers NAD+ reducing agents into 
mitochondria. A number of studies have demonstrated that during mitochondrial 
dysfunction the ratio of NAD+/NADH decreases (Braidy et al., 2011, Stefanatos and 
Sanz, 2011).  
 
NAD+ is utilized or plays an important role in the activation of many enzymes 
including sirtuins. The role of sirtuins in neuroprotection and longevity has been 
intensively studied and they have been considered as a therapeutic targets in AD 
(Lombard et al., 2011, Zhang et al., 2011). Sirtuin 1 has been found to have a role in 
APP processing. It upregulates expression of ADAM10, which encodes α-secretase, 
and co-activates the retinoic acid receptor β (RARβ), which is a regulator of ADAM10 
transcription (Donmez et al., 2010). It has also been shown that in AD mice 
overexpressing SIRT1 there is a reduction in amyloid plaque and Aβ(1-42) burden as 
well as increased levels of α-secretase . On the other hand deletion of SIRT1 results 
in increased mortality at 3-5 months of age. It has been concluded that by decreasing 
the NAD+/NADH ratio and reducing the amount of NAD+ available to sirtuin 1, 
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mitochondrial dysfunction could lead to decreased levels of α-secretase and allow β-
secretase cleavage and production of Aβ(1-42) (Selfridge et al., 2013). 
 
The electron transport chain (ETC) is located in the inner mitochondrial membrane 
and is made up of five complexes (I-V). These complexes consist of multiple subunits 
and all contain subunits encoded by nuclear and mtDNA, with the exception of 
complex II which is only encoded in the nuclear genome (Tomitsuka et al., 2003). All 
five complexes show impairment in AD patients (Mao and Reddy, 2011). Parker et al. 
(1990) demonstrated a reduction in the activity of in cytochrome c oxidase (COX, 
complex IV) in platelets from AD patients, which was later confirmed in AD brains 
(Kish et al., 1992). Since then, COX activity has been shown to be systematically 
reduced in AD (Curti et al., 1997, Wong-Riley et al., 1997, Bosetti et al., 2002). 
However, it is still unclear whether a decrease in COX activity is a result of a genetic 
mutation or toxic insults such as Aβ (Selfridge et al., 2013).  
 
Cytochrome c oxidase has 13 subunits, 10 of which are encoded in the nuclear 
genome and 3 by mtDNA. Swerdlow et al. (1997) used a cybrid approach to 
investigate the mtDNA effect. They isolated platelets from AD patients and controls 
and fused them with human NT2 cells, which were initially depleted of their 
endogenous mtDNA. This study revealed a decrease in the activity of COX and 
mitochondrial membrane potential, as well as an increase in free radicals and 
oxidative stress and activation of apoptosis pathways. Since then other studies using 
cybrid lines with mitochondria from AD patients have shown similar results (Khan et 
al., 2000, Cardoso et al., 2004).  
 
COX inhibition has been shown to reduce non-amyloidogenic APP processing 
(Gabuzda et al., 1994, Gasparini et al., 1997) by preventing α-secretase cleavage 
and allowing β-secretase action. Free radicals have been found to further activate β-
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secretase. However, results from studies on transgenic AD mice expressing mutant 
APP and presenilin 1, but lacking COX in neurons, have shown significantly fewer 
amyloid plaques, reduction in Aβ(1-42) levels and reduced oxidative stress (Fukui et 
al., 2007). This suggests that COX impairment may not be responsible for Aβ 
accumulation in AD brain. 
 
Interestingly, a study on APOE4 carriers demonstrated lower COX activity which was 
low even in the absence of fibrillar Aβ suggesting that either a reduction in COX 
activity appears early in the disease or that mtDNA contributes to it.  
 
The changes in metabolism associated with Alzheimer’s Disease are discussed in 
further detail in section 4.1 
 
1.7.7 Ageing and mitochondria 
 
Ageing is considered the primary risk factor for AD. Mitochondria have long been 
thought to contribute to ageing via the accumulation of mutations in mtDNA and an 
increased production of ROS (Lin and Beal, 2006).  
 
Ageing phenotypes have been linked to mtDNA changes and tissues from aged 
individuals have been shown to have lower respiratory function (Kujoth et al., 2006). 
An increase in the number of point mutations and deletions has also been found in 
cells from aged individuals and evidence has shown that 8-hydroxy-2-
deoxyguanosine (damaged DNA) is also increased (Kujoth et al., 2006). It has been 
suggested that mutations in mtDNA that are involved in ageing phenotypes could 
also contribute to AD (Reddy and Beal, 2008).  
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Age related changes in mitochondria include a decline in ETC function. The activity 
of complex I and IV decreases whilst complex II is preserved (Navarro and Boveris, 
2007). In addition, mitochondrial mass also appears to be affected (Barrientos et al., 
1997) and oxidative stress markers such as protein carbonylation, lipid oxidation and 
mtDNA oxidation increase (Boveris and Navarro, 2008). Oxidation of mtDNA makes 
it very susceptible to mutation as oxidized bases can be misread during replication 
(Ozawa, 1997). Oxidative stress could be a major contributor to the high mutation 
rate of mtDNA which is 10 times the rate of that observed in nuclear DNA (Mecocci et 
al., 1993). 
 
Mitochondrial function and dynamics change with advancing age.  These changes 
affect bioenergetics and metabolism which in turn increase Aβ production and thus 
contribute to the development of AD. 
 
1.7.8 mtDNA in AD 
 
Studies on ageing and mitochondrial function have led to the mitochondrial cascade 
hypothesis of sporadic Alzheimer’s Disease (Swerdlow and Khan, 2004). It proposes 
that a person’s genes determine mitochondrial function and durability, which in turn 
determine how mitochondrial functions change with age and as a result initiate AD 
(Swerdlow and Khan, 2004). As this hypothesis is based on inheritance of mutations, 
the possibility that maternally inherited mtDNA may influence AD has been 
investigated. However, the results are not conclusive. Some studies have shown that 
there is no evidence of maternally-inherited AD risk factor or that it is in fact 
paternally-inherited (Ehrenkrantz et al., 1999). Whereas other studies however have 
demonstrated a strong link between maternal inheritance and AD risk (Edland et al., 
1996). One particular study investigating COX activity in subjects with an AD-affected 
mother, found a 30% decrease in COX activity in comparison to patients with an AD-
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affected father or no history of the disease (Mosconi et al., 2011). Unfortunately, 
these studies cannot directly prove that mtDNA is a risk factor, although they indicate 
that it should be further investigated (Selfridge et al., 2013). 
 
1.7.9 Oxidative stress in AD 
 
The brain is especially sensitive to oxidative damage due to its high lipid content and 
high oxygen metabolism as well as low antioxidant defences (Floyd, 1999). Oxidative 
damage has been found to occur early in AD before Aβ depositions and plaque 
pathology appear (Nunomura et al., 2001). Several studies have demonstrated 
oxidized RNA, nuclear and mtDNA, lipids and proteins in brains of AD patients 
(Mecocci et al., 1994, Sayre et al., 1997, Nunomura et al., 1999). The mechanisms 
underlying the increase in ROS production have been extensively studied and are 
explained in more detail in section 4.1. Oxidative stress was also shown to increase 
the expression of β-secretase and in turn production of Aβ(1-42) by activation of c-
Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) 
(Tamagno et al., 2005) as well as increase tau phosphorylation through activation of 
glycogen synthase kinase 3 (GSK-3) (Lovell et al., 2004). Further investigations have 
shown that activation of JNK leads to upregulation of APP, BACE1 and presenilin 1 
through demethylation of their promoters and histone deacetylation (Guo et al., 
2011).  
 
1.8 Animal models of AD 
 
Alzheimer’s disease is unique to humans. However, it is very difficult to study the 
disease in patients as we do not understand how or when the disease starts. To 
overcome this, a wide range of animal models of the condition has been developed 
and used to study its mechanisms and progression and to develop treatments. Such 
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models of AD can be broadly split into three types: natural, genetic and interventional 
models (Laurijssens et al., 2012).  
 
Natural models include polar bears, dogs, cats, goats, sheep and some of the non-
human primates such as mouse lemurs or rhesus monkeys. These animals 
spontaneously develop some of the pathology related to AD (Van Dam and De Deyn, 
2011). For example, dogs have recently been used as AD model due to the similarity 
in canine and human brain ageing. An additional advantage, is the fact that the Aβ 
sequence is conserved between dogs and humans (Johnstone et al., 1991). Dogs 
have been shown to develop Aβ and diffusible plaque depositions and the extent of 
the Aβ depositions correlates with cognitive impairment (Laurijssens et al., 2012). 
 
Progress in the understanding of the genetic factors that contribute or cause AD have 
resulted in many attempts to develop animal models that overexpress genes, which 
are involved in the familial forms of AD. Transgenic (tg) mouse models are widely 
used to study AD and remain the model of choice for numerous studies (Duff and 
Suleman, 2004). Mice have been extensively used as transgenic models and have 
had an important influence on our understanding of mechanisms involved in Aβ 
production, deposition and clearance. Rodent models have been of a great value for 
studying the disease and mice are relatively easy and cheap to maintain, have short 
life spans and are easy to manipulate genetically. However, their life span makes the 
relevance of the model to diseases of ageing questionable.  
 
In addition, the development of human AD may not be faithfully reflected in the 
mouse models as mice overexpressing APP were found to develop plaques if the 
level of APP is 8-fold over the normal APP level. In comparison, humans with only a 
50 per cent increase in APP (individuals with Down syndrome that have three copies 
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of APP gene) have a very rapid progression of the disease (Duff and Suleman, 
2004). 
 
Due to the complexity of the disease it has been difficult to create an ideal mouse 
model which mimics all aspect of the pathology of the human disease.  Mouse 
models fail to convincingly demonstrate the neuropathological hallmarks of AD 
(Dodart et al., 2002a). Mutant animals either develop plaques (APP or PS mice 
mutants) but no tangles, whereas tau mutants show the presence of tangles but no 
plaques. Several laboratories have created double APP/PS tg mice which showed 
accelerated neuropathology but still have not demonstrated the multiple 
characteristics of AD (Duff and Suleman, 2004). A triple transgenic mouse 
(APP/PS/Tau) was created by Oddo et al. (2003). This model develops extracellular 
plaques as well as neurofibrillary tangles and demonstrates impaired synaptic 
plasticity. This model has been successfully used in studies on inflammation, 
oxidative stress and mitochondrial function in AD (Laurijssens et al., 2012). 
Nevertheless the progressive loss of neurons in hippocampus and specific cortical 
regions is not present in many of the transgenic models, which is a major limitation of 
these models. 
 
Another genetic model often used in studies of AD is Drosophila melongaster. This 
fruit-fly has a well organised brain and despite the differences in anatomical 
organisation to human brain, it has a similar basic cell biology (Sang and Jackson, 
2005). However a major limitation is that hippocampal functions that are impaired 
early in the AD cannot be studied in invertebrates. 
 
Interventional animal models are based on the introduction of substances into the 
brain or the induction of lesions in specific brain regions (Laurijssens et al., 2012). 
These models involve introduction of Aβ peptide into the brain of e.g. rat (Nakamura 
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et al., 2001) or rhesus monkey (Li et al., 2010). However, despite the fact that some 
of the clinical symptoms can be induced in animals, these models lack resemblance 
to AD pathology (Duyckaerts et al., 2008). 
 
1.9 In vitro models of AD 
 
In addition to difficulties in modelling the changes described above in patients as well 
as in vivo, in vitro models often lack the complexity to efficiently recapitulate the 
interactions between brain cells during disease. Such models should at minimum be 
human and be able to produce both neurons and astrocytes individually as well as in 
co-culture. Both cell types should be functional, demonstrating activities such as 
action potential firing as well as responses to both neurotransmitters and 
gliotransmitters and should demonstrate the metabolic coupling that is hypothesised 
to occur in the brain. 
 
Currently many in vitro cell culture systems are used for research and these include 
primary cultures of dissociated or reaggregated neurons and glia, clonal cell culture 
lines and stem cells. 
 
1.9.1 Transformed cells 
 
Transformed cells are continuous cell lines which are derived from neuroblastomas, 
gliomas and pheochromocytomas. Transformed cell lines usually have a life span of 
about 50 divisions, however some have been immortalized. The major advantages of 
transformed cells include their homogeneity and the ease with which they are grown 
and maintained in the laboratory. However, as these cells are derived from neoplastic 
tissue, they are abnormal and as such their similarity to in vivo phenotypes is 
questionable (Harry et al., 1998). 
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A number of transformed cells have previously been used to model AD.  Such lines 
include neuronal (SH-SY5Y), astrocytic (U-373) and monocytic (THP-1) cells. A 
number of studies have utilised these cells to investigate the effect of Aβ on co-
cultures of either neuronal SH-SY5Y cells or astrocytic U373 as well as monocytic 
THP-1 (Klegeris and McGeer, 2001, Messmer and Reynolds, 2005).  
 
Other studies have combined the use of primary cell cultures and transformed cells 
such as human microglia isolated from temporal lobe tissue and the monocytic THP-
1 cell line in order to study the influence of cytokines on SH-SY5Y neuroblastoma 
cells (Klegeris and McGeer, 2005). 
 
Whilst these cells have provided important information about the effects of Aβ these 
cells are derived from neoplastic tissue and continue to divide in culturetheir similarity 
to in vivo phenotypes is questionable (Harry et al., 1998). 
 
1.9.2 Primary cultures 
 
Primary cultures are derived from dissociation of brain tissue. The plating efficiency 
and characteristics depend upon many factors including culture environment, type of 
tissue, and dissociation technique (Harry et al., 1998). One of the major 
disadvantages of primary culture is the accessibility of the tissue samples. 
Additionally, as the cells are fully differentiated and post-mitotic, it is not possible to 
expand them in culture. Additional risks include variability in the state of preservation 
of the source tissue and the risks of handling, in terms of communicable human 
neurological diseases, such as Kuru and Creutzfeld-Jakob disease.  
 
The majority of AD research is based on primary cell culture, which is mainly murine 
in origin, although in some cases human tissue has been used. Cells derived from 
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tissue samples from AD patients are probably the best source of information about 
the disease. However, such samples are not easy to obtain. In the UK several brain 
tissue resources (banks) have been established e.g. by the Medical Research 
Council, the Alzheimer's Society, the Alzheimer's Research UK and Brains for 
Dementia Research (BDR). Nevertheless there is currently a severe shortage of live 
brain tissue available for dementia research.  
 
1.10 Stem cell models of AD 
 
Human stem cells possess almost unlimited self-renewal capacity as well as potential 
to differentiate into any cell type. As such they provide an ideal model for the 
development of postmitotic cells of CNS. The therapeutic potential of stem cells has 
been extensively studied. Stem cells represent also a very dynamic system that 
would be useful for the identification of new molecular targets and the development 
of novel drugs, which can be tested in vitro for safety or to predict or anticipate 
potential toxicity in humans (Wobus and Boheler, 2005).  
 
Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSC) 
derived from human patients with Alzheimer’s Disease or Down Syndrome are 
currently used to create models for investigation of Alzheimer’s Disease 
(Nikoletopoulou and Tavernarakis, 2012, Wang and Doering, 2012). hESCs have 
been shown to efficiently differentiate into functional neurons and glia in a similar way 
to in vivo development (Verkhratsky and Butt, 2013, Oberheim et al., 2006). 
However, the excitement and optimism surrounding hESCs has been steadily 
decreasing due to a number of ethical issues surrounding their use. However, recent 
developments in the development of iPS cells overcome any of the ethical issues 
faced by the use of hESC.  
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1.10.1 Induced pluripotent stem cells 
 
An important limitation in Alzheimer’s Disease research is the availability of live 
human, patient specific cells. However, the development of iPS cell technology 
makes it possible to study human CNS neuronal cells, that carry information from 
patients with specific mutations or disease (Wang and Doering, 2012).  
 
In most cases iPS cells are produced from primary fibroblasts cultured from a skin 
biopsy. The transduction of the fibroblasts with retroviruses encoding Oct4, Sox2, 
Klf4 and cMyc converts the cells into a pluripotent state (Takahashi and Yamanaka, 
2006). These reprogrammed cell lines appear to divide indefinitely and in theory can 
be differentiated into any cell type of the body. Thus iPS cells can be a source of 
patient specific neurons and glia and be used to created models of disease, 
platforms for drug screening as well as sources for potential cell therapies (Wang and 
Doering, 2012). As the progress in cell reprogramming is accelerating, different 
reprogramming approaches are being tested such as DNA integration-free delivery 
systems as well as different reprogramming factors (Okita et al., 2011). 
 
1.10.1.1 Differentiation 
 
Reliable protocols for differentiation of iPS cells into specific cell types are one of the 
challenges in the field of stem cells. In terms of modelling AD, the cells of interest 
include microglia, neurons and astrocytes. As glutamatergic and basal forebrain 
cholinergic neurons are believed to degenerate early in the disease these cells have 
been of great interest for scientists seeking to model AD.  
iPS cells have been found to readily differentiate into MAP2-positive neurons and 
GFAP-positive astrocytes. However, the cultures also contain a high percentage of 
uncharacterized cells (Israel and Goldstein, 2011). Many groups have focused on 
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differentiating iPS cells into specific neuronal subtypes. Dopaminergic neurons have 
been derived from iPS cells by a combination of SHH, GSK-3β inhibitor and FGF8 
treatments (Xi et al., 2012). In addition, recent studies on motor neurons have shown 
that functionally mature motor neurons can be differentiated from iPS cells by 
protocols involving RA and SHH (Karumbayaram et al., 2009). More recently iPS 
cells have also been directed into cortical fate by dual inhibition of SMAD signalling 
(Chambers et al., 2009) or RA-based multistep protocol (Shi et al., 2012). 
 
1.10.1.2 Modelling neurodegenerative diseases 
 
Disease-specific iPS cells have been successfully generated from a number of 
neurodevelopmental disorders including Rett syndrome, Fragile X syndrome, Down 
syndrome or Angelman syndrome (Wang and Doering, 2012). In addition, iPS cell 
lines have also been generated from inherited neurodegenerative disorders such as 
spinal muscle atrophy, amyotrophic lateral sclerosis, Huntington’s disease, 
Parkinson’s Disease as well as Alzheimer’s disease (Wang and Doering, 2012). 
 
Alzheimer’s disease research has focused heavily upon familial AD (FAD) patients. 
Indeed, iPS cells have been produced from patients with PS1 and PS2 mutations 
(Yagi et al., 2011). These cells were differentiated into neurons, characterized and 
were found to produce higher levels of Aβ(1-42). Aβ(1-42) secretion was blocked by 
a γ-secretase inhibitor which also shows that FAD derived iPS cells can be used as 
an effective model of AD. Other studies have produced iPS cells from patients with 
duplication of the APP gene (Israel et al., 2012). Neurons derived from these cell 
lines demonstrated increased levels of phospho-Tau and active glycogen synthase 
kinase-3β (aGSK-3β). Treatment of the cells with β-secretase inhibitors reduced the 
phospho-Tau and aGSK-3β levels. Neurons differentiated from iPS cells with PS1 
mutation demonstrated a partial loss of γ-secretase function which resulted in lower 
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levels of Aβ(1-40) and an increase in the ratio of Aβ(1-42)/Aβ(1-40) ratio (Koch et al., 
2012). 
 
iPS cells are a very promising platform for modelling neurodegenerative diseases. 
However, they also have some limitations. In cases of disease that is caused by 
known mutations, it is likely that iPS cells derived from these patients will recapitulate 
the phenotype of the disease. It has been shown that cortical neurons derived from 
iPS cells taken from Down syndrome patients, demonstrate  abnormal processing of 
APP and secretion of Aβ(1-42) peptide, which forms extracellular and intracellular 
insoluble aggregates (Oberheim et al., 2009). However, in the case of late-onset 
disease, patient derived iPS cells may not show typical brain pathology, such as 
Lewy bodies in PD or amyloid plaques in AD (Dolmetsch and Geschwind, 2011, Ming 
et al., 2011). Further research in this area may answer important questions as to the 
environmental/epigenetic impact on progression of the disease in these patients. 
 
1.10.1.3 Drug screening 
 
iPS cells could provide a highly desirable platform for discovery and testing of novel 
drugs (Wichterle and Przedborski, 2010, Ming et al., 2011, Wang and Doering, 
2012). However, to make this technology useful it is very important to validate the 
phenotypes of iPS cells, as well as the neurons and glia derived from them. Ensuring 
a uniform population of neurons and glia that will be essential for successful high-
throughput drug screening studies (Wang and Doering, 2012). 
 
1.10.1.4 Cell therapy 
 
In addition to their modelling potential, iPS cells could also provide a source of 
autologous cells for replacement therapies in patients with neurodegenerative 
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diseases. Studies have already been undertaken in animal models and early results 
are very promising e.g. improvement of behavioral symptoms in rat models of 
Parkinson’s Disease (Hargus et al., 2010). In addition, transplantation of glial cells for 
neuroprotection may be possible (Inoue, 2010). In the area of cell therapy there are 
also other challenges that have to be overcome before iPS cells can be successfully 
used. The use of oncogenic genes and retroviruses for cell reprogramming could 
increase the risk of cancer (Ming et al., 2011). However, as mentioned above other 
reprogramming strategies are under investigation. In addition, the purification of the 
specific cell type and improved differentiation protocols are also required. However, 
improved understanding of genetic mutations associated with the neurological 
disease and technologies to correct them is required before the cells could be used 
for replacement therapies (Wang and Doering, 2012). 
 
1.10.1.5 Accessibility 
 
A recent paper by Wray et al. (2012) presents a readily available resource of 
fibroblast cell lines with mutations linked to many different neurological disorders. 
New cell lines are being added to the fibroblast cell bank that has been created at the 
National Institute for Neurological Disorders and Stroke (NINDS) Repository at the 
Cornell Insitute for Medical Research. This initiative represents one of many that has 
been established in the past couple of years and demonstrates how quickly the field 
of iPS cells is progressing. 
 
1.10.2 NT2/D1 line 
 
One form of stem cell that has not been fully explored in the context of Alzheimer’s 
Disease is the NT2/D1 line.  This is a clonally derived embryonal carcinoma (EC) cell 
line, isolated from Tera-2 cells (Andrews et al., 1984), which after treatment with 
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retinoic acid can differentiate into several cell types, including neurons (Andrews, 
1984). 
 
Further studies have shown that NT2/D1 cells have the ability to differentiate into 
both neurons (NT2.N cells) and astrocytes (NT2.A) following treatment with retinoic 
acid and mitotic inhibitors. The presence of mature neurons was previously 
confirmed by the expression of markers such as Neurofilament (NF) and Microtubule-
associated protein 2 (MAP2) (Bani-Yaghoub et al., 1999). NT2.N cells were shown 
previously to possess TTX-sensitive Na+ channels (Rendt et al., 1989) and form both 
glutamatergic excitatory (71%) and GABAergic inhibitory (29%) functional synapses 
(Hartley et al., 1999). This cell line has been also shown to express APP, BACE and 
produce Aβ (Satoh and Kuroda, 2000, Wertkin et al., 1993). The presence of NT2A 
cells was confirmed by Cx43 and GFAP staining (Bani-Yaghoub et al., 1999). Further 
characterization of astrocytes derived from NT2/D1 cell line detected mRNA 
encoding glutamate transporters GLT-1/EAAT2 and GLAST/EAAT1 and the 
functionality of the transporters was confirmed (Sandhu et al., 2002). 
 
A recent report from my laboratory (Hill et al., 2012) has shown that NT2 derived 
neurons and astrocytes interact in co-culture. Investigation of NT2.A cells has shown 
that these cells exhibit glial cell type morphology and appropriate functional 
properties. In particular NT2.A has been found to respond to neuronal activity and 
exogenous neurotransmitters by calcium elevations and also demonstrate 
spontaneous calcium oscillations. Additionally, NT2.A cells generated calcium waves, 
which spread via gap junctions to neighbouring astrocytes in a purinergic dependent 
manner (Hill et al., 2012).  
 
The NT2/D1 cell line has previously been used to study AD, however most research 
has focused on pure neuronal cultures (Satoh and Kuroda, 2000, Turner et al., 1996, 
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Wertkin et al., 1993). As astrocytes have been shown to enhance neuronal survival 
as well as axonal growth and synaptogenesis, it is essential to include them in 
studies on neurological diseases. Additionally, increasing numbers of studies have 
highlighted the important role of astrocytes in the AD (Bushong et al., 2002, Colombo 
and Reisin, 2004). Thus research in this thesis was focused on co-cultures of 
neurons and astrocytes in order to better understand the interactions of the cell types 
in AD. The importance of NT2/D1 derived astrocytes in toxicity screening has 
previously been evaluated (Woehrling et al., 2010). In this study astrocytes appeared 
to support neurons through maintenance of ATP, GSH, mitochondrial membrane 
potential and control of ROS levels following toxic insult. As such it is essential to 
consider them in neurodegenerative research (Woehrling et al., 2010). 
 
As the majority of neurons in the brain are postmitotic it can be considered that the 
proposed co-culture model is more relevant to human CNS structure and function 
than the more commonly used continuous cell lines such as the SH-SY5Y 
neuroblastoma model (Woehrling et al., 2010). Additionally NT2/D1 cell line is 
relatively cheap to maintain and differentiate in comparison to other stem cell lines 
available. The differentiation process is also reproducible and faster than in iPS cells. 
Generation of iPS cells require up to 85 days with further differentiation into 
functional neurons for up to 8 weeks and into GFAP-positive astrocytes up to 3 
months. In comparison, NT2/D1 cells differentiate into co-cultures of functional 
neurons and astrocytes within 2 months. The easy access to the NT2/D1 cell line and 
the previously reported characterisation of the neurons and astrocytes derived from 
these stem cells, are an additional advantage. All these characteristics make the 
NT2/D1 stem cell line a good model to study neuronal and astrocytic interactions as 
well as neurological disease.  
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1.11 Aims and objectives of the study 
 
The aim of this PhD is to create a heterogeneous cellular model of the human 
nervous system for investigating the effects of Aβ on neurons and astrocytes.  
 
As one of the earliest changes in AD is related to changes in metabolism the NT2/D1 
derived neurons and astrocytes will be characterized, in terms of their metabolic 
coupling. The main focus of this part of the study is the astrocyte neuron lactate 
shuttle (ANLS) that has been shown to be involved in memory formation. ANLS has 
not been previously studied in vitro on a human stem cell derived model. As such 
one of the aims of this thesis is to establish whether NT2.D1 derived neurons and 
astrocyte co-cultures are metabolically competent and demonstrate functional 
metabolic coupling. NT2.N/A and NT2.A cells will be investigated for the expression 
of the main components of the ANLS model as well as functional characteristics 
consistent with their neuron-astrocyte metabolic coupling. This study will establish 
whether, stem cell derived astrocytes provide metabolic support to their neuronal 
counterparts, thus providing a human model to study this process and its relationship 
to neurodegeneration. 
 
The effects of chronic exposure of the NT2.N/A to Aβ(1-42) will be studied in order to 
determine its effects of cellular metabolism. Aβ(1-42). Preparations will be 
characterized in order to establish protocols to produce oligomers and also determine 
its aggregation over time in culture. Investigation of the effects of Aβ(1-42) will 
include changes in metabolic markers, gene expression, oxidative stress and 
functionality of astrocytes in terms of calcium responses. These experiments will be 
performed on a mixed NT2.N/A co-cultures as well as pure astrocytes (NT2.A) and 
primary cortical mixed neuronal and glial cultures, which will be used to compare this 
model to a widely accepted cell culture preparation. 
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Chapter 2: Amyloid-beta and Alzheimer’s disease  
2.1 Introduction 
 
2.1.1 Amyloid-beta – discovery and structure 
 
Aβ was first isolated from meningeal vessel walls and was partially sequenced in 
1984 (Glenner and Wong, 1984). This discovery eventually led to the amyloid 
hypothesis proposed by John Hardy and David Allsop (1991). In their original study, 
Glenner and Wong used the chaotropic salt guanidine hydrochloride to solubilize Aβ 
and then enriched it chromatographically (Glenner and Wong, 1984). The monomeric 
amyloid subunit ran as a ~4kDa band on SDS-PAGE gel. In this study Aβ was 
sequenced to residue 24 (Glenner and Wong, 1984).  
 
Many other labs have now independently isolated and sequenced amyloid from 
plaques from AD brains. Several papers have been published on the methods for 
isolation of amyloid plaques, which have been shown to be insoluble in many 
denaturants (Allsop et al., 1983). Masters et al. (1985), used a nonionic detergent 
extraction of brain, followed by a pepsin digestion, and sucrose density gradient 
fractionation to isolate the amyloid plaque core which was partially soluble in 10% 
sodium dodecyl sulphate (SDS) and 2-mercaptoethanol (BME) and fully soluble in 
70% formic acid. The solubilized core was shown to run at ~4 kDa but also at ~8, 12, 
and 16 kDa, demonstrating for the first time the aggregation of the monomeric Aβ 
into SDS-stable oligomers (Masters et al., 1985). A subsequent study by Selkoe et al. 
(1986) estimated the protein content of a single plaque to be 60 – 130 pg. The first 
biochemical analyses of Aβ isolated from meningeal vessels and cerebral plaques 
showed that in both cases the amyloid subunit was a hydrophobic protein of about 
4kDa. It was also shown to have a unique sequence and to be prone to aggregation 
into dimers, trimmers and tetramers, as well as higher oligomers and amyloid fibrils. 
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The complexity of Aβ aggregation is determined by the microenvironment in which it 
is produced. It has been shown that small amounts of Aβ can be produced in the ER 
and other organelles in the secretory pathway. However, the majority of Aβ is 
produced from APP that has been trafficked to the cell surface and is then 
internalized and processed by β- and γ-secretases in the acidic environment of 
endosomes (Haass et al., 2012).  
 
As mentioned above, Aβ has been shown to self-associate and can form a range of 
different aggregated forms, from dimers to fibrils (Powers and Powers, 2008). The 
biochemical properties of Aβ however, vary depending on the residues of the 
hydrophobic carboxyl terminus. Aβ(1-40) is the major species of Aβ that is produced 
in the brain and is far less prone to aggregation than Aβ(1-42). 
 
It was initially proposed that Aβ fibrils mediated Aβ toxicity. However, more recent 
data has demonstrated the toxicity of non-fibrillar, soluble oligomers of Aβ (Shankar 
and Walsh, 2009). Indeed, analysis of AD brains has shown that levels of oligomers 
correlate more strongly with the degree of cognitive impairment and synaptic loss 
than amyloid plaques (Lue et al., 1999, Wang et al., 1999).  
 
2.1.1.1 Aβ fibrils 
 
The molecular structure of Aβ fibrils has been extensively studied. Aβ fibrils have a 
cross-β structure where individual β strands are orientated perpendicular to the long 
axis of the fibril (Ahmed et al., 2010). The Aβ(1-42) unit within the fibril has a U-
shaped structure with two ß-strands connected and Phe19 in contact with Leu34 
(Ahmed et al., 2010). 
 
Kinetic studies of Aβ suggest that its aggregation is characteristic of nucleation-
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dependent polymerization. The process has been shown to start with a lag phase, 
followed by elongation into mature fibrils (Hellstrand et al., 2010a). Studies on 
synthetic Aβ(1-40) and Aβ(1-42) fibrils have demonstrated similar protofilament 
structure with approximately 2.5 peptide per cross-β repeat per protofilament 
(Schmidt et al., 2009). 
 
The conversion of α-helices within normally soluble protein into β-sheet enriched 
aggregates appears to be common in several neurodegenerative diseases (Masters 
and Selkoe, 2012).  
 
2.1.1.2 Aβ oligomers 
 
Over the past decade studies on Aβ have moved from an initial focus on fibrils and 
plaques to the smaller, soluble oligomers which demonstrate toxic effects on 
membranes including synapses (Masters and Selkoe, 2012).  
 
The presence of SDS-stable dimers and trimers in the soluble fractions from isolated 
plaques (Funato et al., 1999, Enya et al., 1999), suggests that these SDS-stable 
oligomers are the building blocks of insoluble amyloid plaques and could mediate 
neuronal dysfunction (Moechars et al., 1999, Mucke et al., 2000). Evidence 
supporting the toxicity of soluble, oligomeric Aβ comes from studies on transgenic 
PDAPP (Aβ precursor protein (APP) mini-gene driven by a platelet-derived (PD) 
growth factor promoter) mice where memory deficits were reversed by a single 
intraperitoneal injection of anti-Aβ antibody (Dodart et al., 2002b). As amyloid 
deposits were not affected, it was suggested that the antibody was acting only on 
soluble oligomers of Aβ and that the clearance of these toxic species reversed 
memory deficits (Dodart et al., 2002b). 
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Many different forms of Aβ aggregates have been described (Masters and Selkoe, 
2012). However, many of these studies have focused on synthetic Aβ and have used 
non-physiological concentrations of single length peptide under in vitro conditions. 
The presence of similar Aβ species in the brain has not been confirmed (Masters and 
Selkoe, 2012). Studies have demonstrated that natural Aβ oligomers isolated from 
AD brain are more potent in cytotoxicity assays than synthetically produced Aβ 
(Lambert et al., 1998). Similarly, natural Aβ oligomers are more toxic than protofibrils 
(Walsh et al., 1997). Protofibrils require high nanomolar concentrations to induce 
toxic effects, suggesting that they contain aggregated forms that do not interact with 
neuronal membranes to the same extent as less aggregated oligomers.  
 
Despite these findings many groups study Aβ aggregation using synthetic peptides at 
supraphysiological concentrations due to difficulties in isolating naturally occurring 
peptides (Castano et al., 1986, Kirschner et al., 1987). The methods used for 
studying the aggregation of Aβ monomers into oligomers vary in terms of 
temperature, salts as well as detergents and metal ions (Sahoo et al., 2009, Ahmed 
et al., 2010).  
 
Another advantage of synthetic peptides is the possibility of introducing amino acids 
substitutions such as those found at Glu22 and Asp23 which mimic “Arctic” and 
“Iowa” FAD mutations (Fig. 1.2) and have been shown to increase the rate of 
aggregation (Peralvarez-Marin et al., 2009).  
 
Recombinant Aβ (produced in bacteria) has been used to study Aβ aggregation 
(Picone et al., 2009, Walsh et al., 2009). This recombinant Aβ has been particularly 
useful in research on low n-oligomers such as dimers and tetramers (Streltsov et al., 
2011). However, as recombinant peptides are derived from bacteria, these 
preparations can contain impurities, which can interact and co-purify with the Aβ. In 
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addition, this recombinant Aβ has been found to aggregate quicker and is also more 
toxic, which raises questions about its similarity to natural Aβ peptides (Finder et al., 
2010). 
 
Natural Aβ oligomers extracted from cortex of AD brains have been shown to inhibit 
long-term potentiation (LTP), enhance long-term depression (LTD) as well as reduce 
dendritic spine density (Shankar et al., 2008). Interestingly amyloid plaque cores from 
the same brains did not affect LTP unless they were solubilized which demonstrates 
that plaques have low toxicity although oligomers released from them remain toxic 
(Shankar et al., 2008). Other studies have shown that Aβ oligomers extracted from 
AD brains can induce hyperphosphorylation of tau. This leads to collapse of the 
microtubule skeleton and dystrophy (Jin et al., 2011). 
 
In addition to studies on dimers and trimers, attention has also turned to the toxic 
effects of nonomers and dodecamers. These species has been found in the brains of 
Tg2576 mice starting at 6 months of age when the first changes in performance on 
the Morris-water maze begin to appear (Lesne et al., 2006). Additionally, when 
dodecamers were purified and injected into the ventricle of normal wild type rats, 
their spatial memory performance decreased (Lesne et al., 2006). However, the 
appearance of dodecamers does not correlate with changes in other types of 
memory or synaptic dysfunction as these changes are seen long before the 
appearance of dodecamers (Jacobsen et al., 2006). 
 
In the brain, a range of different oligomers exists in equilibrium with fibrils and 
plaques. This has been supported by the finding that a halo of dystrophic neuritis 
surrounds plaques, which decrease with distance from the plaque. This halo has 
been shown to be immunoreactive for antibodies that are selective for small 
oligomers (Koffie et al., 2009). 
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In addition to natural brain derived Aβ oligomers, oligomers derived from APP 
transfected cells in vitro have also been investigated. SDS-stable low-n oligomers 
have been detected in medium from a variety of cell lines (Podlisny et al., 1995, 
Townsend et al., 2006), including the Chinese hamster ovarian (CHO) cell line 
expressing mutant human APP (V717F). These cells (renamed to 7PA2) secrete 
nanomolar levels of SDS- stable Aβ oligomers (Podlisny et al., 1995) that have been 
confirmed on SDS gels as dimers, trimers and tetramers (Walsh et al., 2002). 
Injection of the conditioned medium from these cells into the lateral ventricle of the 
wild type rat has been shown to inhibit hippocampal LTP (Walsh et al., 2002). 
Additionally, immunodepletion of the conditioned medium with anti-Aβ antibody 
blocked the effect of oligomers on LTP. Interestingly, pre-treatment of the conditioned 
medium with insulin degrading enzyme (IDE), which degrades monomeric Aβ but not 
oligomers had no effect on the toxic effect of Aβ on LTP (Walsh et al., 2002). In 
addition, cell derived oligomers of Aβ have also been found to decrease the number 
of spines when neurons were incubated with sub-nanomolar levels (Shankar et al., 
2007). 
 
2.1.2 Aβ interactions with other molecules 
 
Aβ has been found to interact with a variety of molecules which include metal ions, 
cell membranes, lipoproteins and membrane-associated proteins. Aβ plaques show 
immunoreactivity with many different molecules. These could arise from different 
cells which are associated with plaque formation such as neurons (axons and 
denrites), reactive astrocytes and microglia (Masters and Selkoe, 2012). Additionally, 
a recent interactome study of APP demonstrated over 200 entities interacting with 
different parts of APP, a significant number of which have been shown to interact 
with Aβ domain (Perreau et al., 2010). 
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2.1.2.1 Metal ions 
 
Metal ions are ubiquitously present in human tissues and as such they have been 
intensively studied for possible Aβ associations. The results of these studies are 
controversial. Some studies have detected increases in Cu, Zn or Fe ions in plaques 
(Rajendran et al., 2009). It has been shown that both APP and Aβ contain sequences 
with metal binding motifs (Faller, 2009, Duce et al., 2010) suggesting the potential to 
interact with metal ions. An interesting overlap between brain regions rich in 
glutamatergic terminals, free vesicular zinc and Aβ plaques have been shown in APP 
transgenic mice (Stoltenberg et al., 2007). 
 
Many metal ions interact with Aβ including copper, zinc and iron. The Kd of Cu2+ for 
Aβ is around 10-10M and that includes both soluble and fibrillar Aβ (Rozga et al., 
2010). This suggests that any proteins with higher affinities will compete with Aβ. 
Such proteins include human serum albumin (Perrone et al., 2010) suggesting that in 
CSF or blood Aβ should be unmetallated (Masters and Selkoe, 2012). Aβ has been 
suggested to have more than one copper binding site (Jun et al., 2009). Additionally, 
depending on its stoichiometry, Cu2+ interaction with Aβ can lead to aggregation 
through oligomer forming or fibril-forming pathways (Olofsson et al., 2009, Tougu et 
al., 2009). The main copper binding region is located within Aβ first 16 residues and 
includes His6, His13 and His14 as well as Asp1 and Ala2 (Drew et al., 2009a, Drew 
et al., 2009b). Additionally Aβ-Cu2+ complex has been found to facilitate the oxidation 
of a biological species and the reduction of molecular oxygen, generating H2O2 
(Jiang et al., 2010). Whilst Cu2+ has been found to induce Aβ aggregation, a 
reduction in intracellular Cu2+ causes inhibition of Aβ oligomer formation (Crouch et 
al., 2009a). 
 
Zn2+ can also bind to Aβ at different regions and drive its aggregation (Miller et al., 
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2010). It has been proposed that the aggregation of Aβ into oligomers can be 
induced by Zn2+ in the vicinity of excitatory glutamatergic synapses and can 
contribute to synaptic degeneration in AD (Deshpande et al., 2009). In addition, zinc 
and Aβ complexes have also been shown to be more resistant to degradation 
(Crouch et al., 2009b) leading to accumulation of Aβ fibrils. 
 
Fe3+ and Aβ complexes have been shown to catalyze the reduction of oxygen and 
production of H202 (Jiang et al., 2009). Additionally, Aβ has been found to have a 
very strong affinity for Fe3+ and Fe2+ which suggests it can compete for iron. This 
could interfere with iron homeostasis, especially as Aβ has 8-times higher affinity to 
Fe2+ than transferrin (Jiang et al., 2009). 
 
2.1.2.2 Other Aβ interactions 
 
As an amphiphilic peptide, once released from a membrane, Aβ can interact with a 
number of different molecules (Masters and Selkoe, 2012). These interactions can be 
caused by phase/interface effects, electrostatic interactions or hydrophobic 
interactions (Masters and Selkoe, 2012). 
 
Most in vitro studies on the aggregation of Aβ are done at supraphysiological 
concentrations. Additionally, microenvironmental conditions in which Aβ aggregates 
in the brain are not taken into account (e.g. high metal ions concentrations at 
synapses). Another variable that is not often considered is the interface between the 
interstitial fluid phase and the surface of the plasma membrane, which is thought to 
be important in aggregation of Aβ. Many studies have shown interface clustering of 
Aβ (Chi et al., 2010) which also affects the speed of fibril formation (Hellstrand et al., 
2010b). The nature of the phase/interface effect strongly influences Aβ folding 
(Kayed et al., 2009) and therefore has to be taken into account in studies on Aβ 
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aggregation (Masters and Selkoe, 2012). 
 
Electrostatic interactions between negatively charged phospholipid head groups or 
sphingolipids and Aβ as well as their effect on aggregation have been extensively 
studied (Kayed et al., 2009, Sureshbabu et al., 2010). It has been shown that smaller 
Aβ oligomers show a tendency to bind charged molecules, while larger oligomers do 
not (Cizas et al., 2010). The electrostatic interaction with phosphatidylserine has 
been shown to mediate the toxicity of Aβ in neuronal cells as the cells can be 
rescued by treatment with Annexin V which has a very high affinity for 
phosphatidylseirine (Ciccotosto et al., 2011). Additionally, gangliosides also have the 
potential to affect the folding of Aβ (Ogawa et al., 2011). 
 
Once Aβ is released from its transmembrane location, it can re-insert itself into the 
hydrophobic lipid bilayer. A number of studies have examined the re-insertion of Aβ 
in order to determine whether this leads to formation of a transmembrane pore or 
whether this re-insertion would cause a disruption in the integrity of the lipid bilayer 
(Masters and Selkoe, 2012). Whilst there have been a number of molecular 
dynamics studies as well as an in vitro artificial lipid membrane models there is a 
significant lack of in vivo studies (Lemkul and Bevan, 2009, Morita et al., 2010). 
It has been previously documented that Aβ interacts with various lipoproteins 
(Apolipoprotein E, A, J) via electrostatic or hydrophobic reactions (Holtzman et al., 
2012). In addition, direct evidence for in vivo interactions of ApoE and ApoA1 with Aβ 
have also been demonstrated (Paula-Lima et al., 2009).  
 
There is also increasing evidence of Aβ interactions with membrane proteins. These 
include NMDA (N-Methyl-D-aspartate) or α7-nicotinic acetylocholine receptors as 
well as cellular prion protein (Hu et al., 2009, Lauren et al., 2009, Liu et al., 2009). 
Many these studies have shown that an antagonist or a downstream regulator of the 
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receptor can prevent the effects of Aβ oligomers (Shankar et al., 2007, Li et al., 
2009). There is no direct evidence of a physical interaction of Aβ with the receptor, 
although, it has been suggested that the binding of Aβ to certain lipids could disturb 
the lipid bilayer and therefore affect membrane associated neuronal receptors 
(Masters and Selkoe, 2012).  
 
2.1.3 Degradation of Aβ 
 
All humans accumulate Aβ during ageing (Funato et al., 1999). The progression from 
normal ageing through mild cognitive disorder to AD is primarily caused by 
acceleration of Aβ accumulation (Saido and Leissring, 2012). Aβ production is 
normally balanced by its degradation by a range of different processes working 
together such as proteolytic degradation, cell-mediated clearance as well as passive 
and active transport. There is increasing evidence to suggest that proteolytic 
degradation is affected in AD and that sporadic forms of AD might develop as a result 
of defective clearance of Aβ (Tanzi et al., 2004). Experiments investigating the rates 
of Aβ production and clearance have shown that in sporadic AD there is a defect in 
clearance of Aβ in CSF (Mawuenyega et al., 2010).  
 
Normally Aβ is degraded by a large number of proteases, each with different 
characteristics. These Aβ-degrading proteases (AβDPs) belong to different families 
such as metallo, serine, aspartyl, cysteine and threonine proteases (Saido and 
Leissring, 2012). AβDPs can be either classified by their enzymological type 
(metalloproteases, aspartyl proteases etc.) or by the species of Aβ they can 
hydrolyze (peptidases, oligopeptidases etc). The metalloproteinases that have been 
found to degrade Aβ include neprilysin, NEP-like peptidases, endothelin- and 
angiotensin-converting enzymes, matrix-metalloproteinases and insulin-degrading 
enzyme. Amongst serine proteases that can degrade Aβ plasmin, acylpeptide 
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hydrolase and myelin basic protein have been described. Cathepsin B (cysteine 
protease) as well as cathepsin D, BACE1 and BACE2 which are aspartyl proteases, 
have also been found to degrade Aβ (Saido and Leissring, 2012).  
 
Whilst Aβ is produced by two proteases which are found in specific subcellular 
compartments of primarily neuronal cells, Aβ degradation involves a large number of 
proteases with different Aβ avidities, optimum pH and subcellular as well as cellular 
localizations (Saido and Leissring, 2012). 
 
AβDPs has been found to be vulnerable to environmental insults and oxidative stress  
(Caccamo et al., 2005). As age is the principal risk factor for AD, and oxidative stress 
has been previously found to increase during ageing (Zhu et al., 2007), it is likely that 
defects in Aβ clearance have a role in AD pathogenesis (Saido and Leissring, 2012). 
 
2.1.3.1 Zinc-metalloproteases – neprilysin 
 
Neprilysin (NEP) is the most well characterized AβDP. It is a member of the M13 
family of zinc-metalloproteases (Hersh and Rodgers, 2008). NEP is a type II 
membrane-associated peptidase with the active site facing the luminal or 
extracellular side of membrane (Roques et al., 1993, Turner et al., 2001). This 
position is ideal for degradation of extracytoplasmic peptides such as Aβ. NEP is 
found almost exclusively in neurons and after its synthesis in the soma, it is axonally 
transported to presynaptic terminals (Fukami et al., 2002). These presynaptic 
terminals and nearby intracellular locations are probably the sites of degradation of 
Aβ by NEP (Iwata et al., 2004). 
 
It has been found that in NEP KO mice levels of both Aβ(1-40) and Aβ(1-42) are 
twofold higher than in controls (Iwata et al., 2001). As such the levels of Aβ 
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correlated with gene dosage of NEP and its activity. It has been suggested that 
intraparenchymal degradation of Aβ by NEP could be as high as ~50% of total 
clearance (Saito et al., 2003). NEP’s therapeutic potential has also been 
investigated. It has been shown that when crossed with a transgenic mouse 
expressing eightfold higher levels of NEP, the J20 APP transgenic mouse 
demonstrated a ~90% reduction in steady-state Aβ with no plaque formation 
(Leissring et al., 2003). However, a more recent study failed to show reversal in 
learning and memory deficits when NEP was overexpressed (Meilandt et al., 2009). 
NEP has been shown to degrade Aβ oligomers in APP-Tg mice (Huang et al., 2006) 
as well as monomers (Saido and Leissring, 2012). Interestingly, in vitro studies have 
shown that NEP is capable of degrading synthetic Aβ oligomers (Kanemitsu et al., 
2003) but not naturally secreted Aβ oligomers (Leissring et al., 2003).  
 
2.1.3.2 Zinc-metalloproteases – insulin degrading enzyme 
 
Another well-studied AβDP is insulin-degrading enzyme (IDE). IDE is another zinc-
metalloproteinase that is mainly found in the cytosol (Authier et al., 1996) and 
mitochondria (Leissring et al., 2004). Due to its unusual structure (clam shell), IDE is 
only able to degrade monomers of Aβ due to its restricted peptidase activity (Saido 
and Leissring, 2012). Other studies have demonstrated its presence in peroxisomes 
(Kuo et al., 1994), endosomes (Hamel et al., 1991) and the endoplasmic reticulum 
(Carpenter et al., 2010). However, these localizations have been less well studied. In 
addition, IDE is also present in the extracellular space (Qiu et al., 1998, Vekrellis et 
al., 2000). 
 
Studies on IDE have shown that it is a major AβDP that is secreted into the medium 
of cells in vitro (Qiu et al., 1998). In primary neuronal cultures, deletion of IDE was 
shown to cause a 90% decrease in the degradation rate of Aβ monomers (Farris et 
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al., 2003). In vivo studies also shown an increase in Aβ levels after IDE deletion, 
however, the increase was less significant than that found in vitro (Farris et al., 
2003). 
 
2.1.4 The importance of Aβ aggregation studies 
 
As discussed above, Aβ aggregation is determined by its microenvironment and has 
been shown to self-associate into different aggregated forms, which differ in their 
toxicity. It is therefore essential to determine what form of Aβ is being used and how 
it will behave in the conditions used in the study. However, many published reports 
do not characterise the form of the peptide that they are using. In many cases the 
characterisation is only limited to the peptide at the initial stage of the study. As AD is 
a chronic disease that develops over decades, it is essential to study the effects Aβ 
following chronic application. As such it is necessary to assess and characterise the 
Aβ preparation and its fate over the experimental period, as changes in the 
aggregation state of Aβ may lead to changes in its toxicity.  
 
2.1.5 Aims and objectives of the study 
 
The aim of this chapter was to investigate the best conditions for preparation and 
aggregation of Aβ(1-42). Several protocols were used to investigate the production of 
oligomers. In addition, western blotting and ThT assays were used to assess the 
stability of these preparations over time. 
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2.2 Material and Methods 
2.2.1 Amyloid – beta 
 
2.2.1.1 Aggregation protocol 
 
Aβ(1-42) and Aβ(1-40) peptides were prepared under conditions to promote its 
solubility and limit the aggregation process (Burdick et al., 1992). Several methods 
for oligomerization of Aβ(1-42) and Aβ(1-40) were investigated. 
 
Aβ(1-42) treated with HFIP (Anaspec, USA) and Aβ(1-40) treated with HFIP 
(Anaspec, USA) were resuspended in 200mM HEPES, pH 8.5 to a concentration of 
100µM. The aliquots were stored at -80°C and used at working concentrations of 0.2, 
2 and 20µM. 
 
Additional methods to make oligomers that were also investigated, including a 
method described by Dahlgren et al. (2002). Briefly Aβ(1-42) treated with HFIP 
(Anaspec, USA) was resuspended in DMSO to a concentration of 5mM. Later phenol 
red-free DMEM was added to the DMSO to bring the peptide to the final 
concentration of 100µM. The peptide was then incubated at 4°C for 24 h. 
 
To obtain the monomeric form of Aβ(1-42), the 5 mM stock in DMSO was diluted 
directly into cell culture media.  
 
2.2.1.2 Aβ(1-42) and Aβ(1-40) aggregation over time 
 
Aggregation of Aβ(1-42) and Aβ(1-40) over time was investigated to determine the 
speed and stability of different protein preparations from section 2.2.1.1 that would be 
expected to form under tissue culture conditions.  
	  
	  
68	  
Aβ(1-42) and Aβ(1-40) prepared in HEPES, Aβ(1-42) prepared in phenol-free media 
and Aβ(1-42) prepared in DMSO were diluted to working concentrations of 0.2, 2 and 
20µM. 100µl of each concentration was added into a 96-well cell culture plate in 
triplicates. The plate was then incubated at 37oC in a humidified atmosphere of 5% 
CO2. Samples were collected at 24, 48, and 72 hours and analyzed using western 
blotting. 
 
2.2.2 Western blotting 
 
To assess the presence of specific aggregates of Aβ following the aggregation 
procedure described in section 2.2.1.1 and 2.2.1.2, polyacrylamide gel 
electrophoresis followed by western blotting was performed on the samples.  
 
2.2.2.1 SDS PAGE 
 
Protein gels were electrophoresed using the Mini Protean® 3 Cell (Biorad, UK). 12% 
gels were cast according to the manufacturer’s guidelines (see Appendix 1). Samples 
were prepared in sample buffer (deionised H2O, 25% glycerol, 62.5mM Tris-HCl pH 
6.8, 2% SDS, 0.01% bromophenol blue and 5% β-mercaptoethanol added fresh) and 
loaded onto the gel, together with PAGE Ruler Plus Prestained Protein Ladder 
(Thermofisher, UK). Electrophoresis was carried out at 200V (fixed), 60mA (max) in 
for approximately 45 minutes until the bromophenol blue reached the bottom of the 
resolving gel. Plates were then carefully separated, and the gel placed in Coomassie 
Brilliant blue stain (0.1% Coomassie, 50% methanol, 7% acetic acid), for 
approximately 1 hour on a slowly rocking platform. Gels were then destained (50% 
methanol, 7% acetic acid) and photographed using G:BOX Chemi HR1.4 (Syngene) 
and GeneSys software (Syngene). 
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2.2.2.2 Discontinuous Native PAGE 
 
Protein gels were electrophoresed using the Mini Protean® 3 Cell (Biorad, UK). 10% 
gels were cast according to the manufacturer’s guidelines (see Appendix 1). Samples 
were prepared in sample buffer (deionised H2O, 40% glycerol, 62.5mM Tris-HCl pH 
6.8, 0.01% bromophenol blue) and loaded onto the gel, together with NativeMark 
Unstained Protein Standard (Life Technologies, UK). Electrophoresis was carried out 
at 200V (fixed), 60mA (max) for approximately 45 minutes until the bromophenol blue 
reached the bottom of the resolving gel. Plates were then carefully separated, and 
the gel placed in Coomassie Brilliant blue stain (0.1% Coomassie, 50% methanol, 
7% acetic acid), for approximately 1 hour on a slowly rocking platform. Gels were 
then destained (50% methanol, 7% acetic acid) and photographed using G:BOX 
Chemi HR1.4 (Syngene) and GeneSys software (Syngene). 
 
2.2.2.3 Western blot transfer. 
 
Proteins for western blot transfer were first separated by SDS PAGE (section 2.2.2.1) 
or native PAGE (section 2.2.2.2). Gels were then equilibrated in transfer buffer 
(25mM Tris, 192mM glycine, 10% methanol) before being transferred to pre-wetted 
(in transfer buffer) nitrocellulose membrane (Millipore, UK) trimmed to the exact 
dimensions of the gel. The gel and nitrocellulose were then sandwiched between four 
pieces of Whatman filter paper and two pieces of sponge, pre-soaked in transfer 
buffer. Transfers were performed using the mini trans-blot electrophoretic transfer 
cell (Biorad, UK) at 30V, 90mA overnight on ice. 
 
 
 
 
	  
	  
70	  
2.2.2.4 Western blot analysis. 
 
Nitrocellulose membranes (section 2.2.2.3) were blocked in TBS (8g NaCl, 0.2g KCl, 
3g Tris-base in 1 litre H2O) 5% powdered milk for 2 hours at room temperature, then 
rinsed in TBS 0.01% Tween (Sigma-Aldrich, UK). They were then placed in TBS 0.01 
Tween, 3% powdered milk containing appropriate primary antibody and incubated 
overnight at 4°C on a shaking platform. Mouse anti-β-amyloid (1-42) (1:1000-1:3000) 
antibodies (6E10 Covance, UK), were used as primary antibody to detect the Aβ(1-
42) as well as Aβ(1-40). This antibody detects amyloid oligomers up to 24mers as 
well as trace high molecular weight species (Chromy et al., 2003). The following day 
membranes were washed 6X for 5 minutes in 100ml TBS 0.01% Tween, to remove 
unbound antibody, and then placed in TBS 0.01% Tween 3% powdered milk, 
containing appropriate secondary antibody for 1 hour at room temperature, with 
agitation. To detect the anti-β-amyloid (1-42) antibody, the secondary antibody, anti-
mouse IgG HRP (Cell Signaling Technology, USA) was used. After extensive washes 
in TBS 0.01% Tween, and then TBS alone, membranes were placed in 
chemiluminescent substrate (GE Healthcare, UK) for 5 minutes. Membranes were 
then immediately sandwiched between acetates and exposed to photographic film 
(Thermofisher, UK) in a developing cassette. To visualize the bound antibody, 
exposed films were developed using developer (Sigma-Aldrich, UK), and following 
extensive washes, fixed using fixer (Sigma-Aldrich, UK) in a darkroom. 
 
2.2.3 ThT assay 
 
Thioflavin T (ThT) is a benzothiazole dye which is has been used as an amyloid stain 
for senile plaques. ThT binds rapidly and specifically to β-sheets and upon binding 
the dye undergoes 120nm red shift in its excitation spectrum and can be selectively 
excited at 450nm, with the fluorescent signal at 482nm (LeVine, 1993). 
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In this study ThT was added to the Aβ(1-42) and Aβ(1-40) reaction mix during the 
aggregation process and fluorescence was monitored at specific time points. 
 
ThT (Sigma-Aldrich, UK) was dissolved in 50mM glycine-NaOH buffer, pH 8.5 to the 
concentration of 5mM. On the day of the experiment the 5mM ThT was diluted to 
1.25µM with 50mM glycine-NaOH buffer, pH 8.5. Aβ(1-42) and Aβ(1-40) were 
prepared as described in section 2.2.1.1 at concentrations 20, 2 and 0.2µM. 20µl of 
each Aβ preparation at each concentration was added to black 96-well plate (Nunc). 
Then 80µl of 1.25µM ThT was then added to each well (to the final concentration of 
1µM in the total assay volume) and the plate was incubated at 37˚C. The 
fluorescence was then read at time point 0, 6, 24, 48, 72 and 96h using SpectraMAX 
GeminiXS microplate luminometer (Molecular Devices, UK) and SoftMaxPro software 
(excitation: 450nm, emission: 485nm). All readings were corrected for background 
and results were expressed as the mean of three samples ± standard error of the 
mean (SEM). Comparison between different time points and treatments was 
performed using two-way analysis of variance (ANOVA) followed by Bonferroni post-
test using GraphPad Prism Software.  Differences were considered significant for p 
values <0.05. 
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2.3 Results 
 
Aggregation of Aβ can be affected by different environmental conditions such as pH, 
concentration or salts. In this study four different protocols were used to aggregate 
Aβ(1-42) and Aβ(1-40) in order to determine which method produces low-n 
oligomers. An additional aim was to monitor the stability of the Aβ preparations over 
time. Methods that were used to assess Aβ(1-42) and Aβ(1-40) aggregation and 
stability included western blotting and Tht fluorescence assay. 
 
Freshly prepared samples of Aβ(1-42) and Aβ(1-40) at a concentration of 20µM were 
run on a SDS-PAGE gel and analysed using western blotting in order to assess the 
composition of each preparation (Fig. 2.1). Aβ(1-42) prepared in 100mM HEPES at 
pH 8.5 (Fig. 2.1, lane 1) demonstrated a large proportion of monomers at around 
~4kDa and high n-oligomers at the top of the gel (~130-250 kDa). Aβ(1-40) (Fig. 2.1, 
lane 2) which was also prepared in 100 mM HEPES showed large amounts of 
monomers but few oligomers or large aggregates. Aβ(1-42) that was dissolved in 
culture medium and aggregated overnight at 4°C demonstrated a large proportion of 
monomers (~4kDa) as well as a mixture of oligomeric species representing 
monomers, dimers, trimers and tetramers as well as a small amount of larger 
aggregates at the top of the gel (Fig. 2.1, lane 3). Aβ(1-42) that was dissolved in 
DMSO (Fig. 2.1, lane 4) showed a distinct monomeric band as well as a number of 
faint oligomeric bands including dimer, trimers and tetramers.  
 
Amyloid prepared using the four different protocols was used to prepare Aβ solutions 
that were incubated in culture media for up to 72h at 37°C to mimic the conditions of 
cell culture. Samples were taken at 24, 48 and 72 hours and then run on a SDS-
PAGE and native gel and analysed using western blotting. 
 
	  
	  
73	  
 
 
 
 
 
 
 
 
 
Figure 2.1 Representative western blot analysis of four fresh preparations of 
Aβ(1-42) and Aβ(1-40). Aβ preparations were separated using denaturing non-
reducing conditions. 1) Aβ(1-42) in HEPES, 2) Aβ(1-40) in HEPES, 3) Aβ(1-42) in 
F12 media and aggregated overnight at 4°C, 4) Aβ(1-42) in DMSO. 
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Figure 2.2 Representative western blot analysis of Aβ(1-42) dissolved in F12 
media and aggregated overnight at 4°C. The preparation was then aged for up to 
72h and separated using (A) native, non-reducing conditions, (B) denaturing, non-
reducing conditions. 
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Aβ(1-42) prepared in culture medium and aggregated overnight at 4°C produced a 
range of different sized aggregates at 24h, ranging from ~40kDa to 1236kDa (Fig. 
2.2A). At 48h the pattern of aggregation was similar to that seen at 24h.  However, at 
72h there was a steady increase in aggregation towards higher n-oligomers, with 
more intense staining above 720kDa and much less staining between 66kDa and 
720kDa. On the SDS-PAGE gel there was a similar steady increase in aggregation 
with more low-n oligomers (trimers and tetramers) at around 15kDa band as well as 
larger aggregates above the 35kDa band (Fig. 2.2B). 
 
The analysis of Aβ(1-42) prepared in HEPES and run on a native gel demonstrated 
lower amounts of small oligomers towards the bottom of the gel but with larger 
aggregates above 480kDa (Fig. 2.3A). Again there was a time dependent steady 
increase in the size of aggregation pattern with little staining below 480kDa ladder at 
72h. When analysed on an SDS-PAGE gel over the incubation period there was a 
steady increase in the amount of low-n oligomers (trimers and tetramers) at around 
15kDa with minor increases in the larger aggregates observed (Fig. 2.3B). 
 
Aβ(1-42) that was dissolved in DMSO prior to incubation demonstrated a rapid 
aggregation pattern, with no staining below 480kDa ladder at 24h and at 72h staining 
was only limited to a band at the top of the native gel (1048 and 1236 kDa) (Fig. 
2.6A). Samples run on an SDS-PAGE gel showed a steady increase in oligomers 
and large aggregates over the incubation period (Fig. 2.4B). 
 
Analysis of the aggregation pattern of Aβ(1-40) prepared in HEPES at pH 8.5 by 
SDS-PAGE gel followed by western blotting analysis demonstrated a complete 
absence of oligomers (Fig. 2.5B). At all 3 time points the only band that was present 
was at ~4 kDa. 
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Figure 2.3 Representative western blot analysis of Aβ(1-42) dissolved in HEPES. 
The preparation was then aged for up to 72h and separated using (A) native, non-
reducing conditions, (B) denaturing, non-reducing conditions. 
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Figure 2.4 Representative western blot analysis of Aβ(1-42) dissolved in DMSO. 
The preparation was then aged for up to 72h and separated using (A) native, non-
reducing conditions, (B) denaturing, non-reducing conditions. 
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Figure 2.5 Representative western blot analysis of Aβ(1-40) dissolved in HEPES. 
The preparation was then aged for up to 72h and separated using (A) native, non-
reducing conditions, (B) denaturing, non-reducing conditions. 
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Under native conditions Aβ(1-40) showed a different aggregation pattern over time, 
with more smaller aggregates at around 66kDa and an increase in larger aggregates 
present at the top of the gel. Additionally, the smallest species found on the native 
gel were below 20kDa ladder (Fig. 2.5A). 
 
In order to further characterise ‘aged’ Aβ samples, the different preparations of Aβ 
were analysed using the ThT assay. ThT fluorescence increases upon binding to β-
sheet structures and is therefore is a good indicator of Aβ aggregation. In this 
experiment the different Aβ preparations were incubated with ThT for up to 96h. The 
fluorescence of each sample was measured at 6, 24, 48, 72 and 96 hours (Fig. 2.6-
2.8). At a concentration of 20µM the Aβ(1-42) prepared in DMSO aggregated rapidly, 
with the highest fluorescence at 72h and a slight decrease in fluorescence at 96h 
(Fig. 2.6). Aβ(1-42) prepared in media and pre-aggregated at 4°C showed a similar 
pattern. The highest fluorescence was recorded at 48h with a subsequent decrease 
in fluorescence at 72 and 96h. Aβ(1-42) prepared in HEPES showed a slight 
increase in fluorescence but overall remained stable over time. Aβ(1-40) showed no 
increase in fluorescence which was in line with previous western blotting analysis.  
 
At a concentration of 2µM the Aβ(1-42) prepared in DMSO and in media showed 
very similar pattern with a steady increase in aggregation over time (Fig. 2.7). In 
contrast, Aβ(1-42) and Aβ(1-40) prepared in HEPES showed little aggregation and 
was stable over all 6 time points.  
 
At a concentration of 0.2µM concentration none of the preparations demonstrated 
any increase in fluorescence over time (Fig. 2.8). However, there was a difference in 
the fluorescence displayed by each individual sample. 
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Figure 2.6 Aggregation of 20µM Aβ(1-42) and Aβ(1-40) preparations using ThT 
fluorescence. Each point is an average of 3 replicates ± SEM. p<0.0001 (****). For 
complete ANOVA see Appendix 2. 
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Figure 2.7 Aggregation of 2µM Aβ(1-42) and Aβ(1-40) preparations using ThT 
fluorescence. Each point is an average of 3 replicates ± SEM. p<0.0001 (****). For 
complete ANOVA see Appendix 3. 
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Figure 2.8 Aggregation of 0.2µM Aβ(1-42) and Aβ(1-40) preparations using ThT 
fluorescence. Each point is an average of 3 replicates ± SEM. p<0.05 (*). For 
complete ANOVA see Appendix 4. 
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Aβ(1-42) dissolved in DMSO showed the highest fluorescence, followed by Aβ(1-42) 
prepared in media and Aβ(1-40) prepared in HEPES. Surprisingly Aβ(1-42) that was 
prepared in HEPES showed the lowest level of fluorescence of all four preparations.  
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2.4 Discussion 
 
Numerous studies have demonstrated that Aβ(1-42) can aggregate and form 
oligomers which are toxic to CNS. Indeed, a number of studies have also shown that 
the formation of oligomers is a general phenomenon which applies to multiple 
proteinopathies (Conway et al., 2000, Kirkitadze et al., 2002). Although Aβ(1-42) 
oligomers are specifically associated with AD, an understanding of the aggregation 
process and its impact on pathology may inform other proteinopathies. 
 
Aβ(1-40) and Aβ(1-42) are both produced naturally and are present in the brains and 
CSF of all humans during their life (Haass et al., 1992, Seubert et al., 1992). As such 
the presence of Aβ alone is not the cause of neurodegeneration.  Indeed, a number 
of studies have shown that Aβ aggregation is essential for its toxicity. 
  
Studies have shown that Aβ oligomers are toxic to cells at much lower 
concentrations that fibrils (Lambert et al., 1998) and are also able to rapidly block 
long-term potentiation. In addition, the concentration of oligomers has been shown to 
be up to a 70-fold higher in AD brain compared to controls (Gong et al., 2003). 
 
The experimental handling of Aβ(1-42) is problematic due to its amphipathic 
sequence as well as its propensity to self-aggregate. These characteristics also 
make it very challenging to characterize its structure and function. As the toxicity of 
Aβ relies so heavily on its aggregation and form, it is essential to study and 
characterize different protocols for its preparation. In this study 4 different protocols 
were used in order to determine optimum conditions for oligomer production. 
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2.4.1 Hexafluoroisopropanol treatment (HFIP) 
 
A critical factor for consistent preparation of oligomeric Aβ(1-42) is the ability to 
obtain exclusively monomeric peptide at the start of the process. Failure to eliminate 
fibril-nucleating seeds in previous studies has been shown to result in rapid fibril 
formation (Koo et al., 1999).  
 
In order to minimize variability between different batches of synthetic Aβ and to 
remove any secondary or tertiary structure which could speed up Aβ aggregation, the 
peptide was dissolved in HFIP, a chemical which has been previously used for 
solubilisation of amylin (Nilsson et al., 2001) and prion peptides (Wille et al., 2000). 
This treatment has been found to dissolve higher aggregates, eliminating the 
‘nucleating seeds’ and removing any secondary or tertiary structures (Dahlgren et al., 
2002). Using Aβ(1-42) and Aβ(1-40) treated with HFIP different protocols for 
aggregation were investigated in terms of oligomer production and speed of 
aggregation. 
 
2.4.2 Aβ(1-42) in HEPES  
 
Aggregation of HFIP-treated Aβ(1-42) dissolved in 100mM HEPES led to formation 
of a range of species, including monomers/dimers, low oligomers (trimers/tetramers) 
as well as high oligomers and possibly protofibrils which accumulated at the top of 
the gels. Previous studies have shown that Aβ(1-42) in PBS or HEPES forms a 
broad range of structures including oligomers, protofibrils and fibrils regardless of 
HFIP pre-treatment (Chromy et al., 2003). When Aβ(1-42) is dissolved in HEPES at 
high monomer concentration (100 µM), it aggregates to a mixture of soluble 
oligomers of Aβ (i.e. amyloid-beta derived diffusible ligands, ADDLs) as well as 
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protofibrils. However, at lower concentrations only ADDLs are formed (Chromy et al., 
2003).  
 
Aβ(1-42) dissolved in 100mM HEPES has previously been used (Dineley et al., 
2001) and has been found to activate α7 nicotinic acetylcholine receptors with higher 
concentrations being less effective at the receptor activation. Incubation with the α7 
nicotinic acetylcholine receptor antagonist methyllycaconatine and the agonist 4-OH-
GTS-21 blocked the Aβ induced activation of the receptor (Dineley et al., 2002). In 
addition, Aβ(1-42) has been found to activate the mitogen-activated protein kinase 
(MAPK) cascade via α7 nicotinic acetylcholine receptor and can upregulate 
expression of α7nAChR as well as downregulating the expression of extracellular 
signal-regulated kinase (ERK2) MAPK. As MAPK is known to play an important role 
in hippocampus synaptic plasticity and learning it has been suggested that the effect 
of Aβ(1-42) on this cascade provides a molecular basis for the disruptions of memory 
formation in AD (Dineley et al., 2001). 
 
2.4.3 Aβ(1-42) in F12 media 
 
Aggregation of Aβ(1-42) in fresh culture medium at 4°C overnight (Dahlgren et al., 
2002) is widely used as a preparation method of Aβ. This method has been found to 
produce a mixture of monomers/dimers, trimers and tetramers as well as some large 
aggregates. However, the previous study only investigated aggregation over 24 
hours. In the present study Aβ(1-42) prepared according Dahlgren et al. (2002) 
demonstrated a similar mixture of monomers and oligomers (trimers, tetramers) on a 
SDS-PAGE gel. However, the study by Dahlgren et al. (2002) did not run the Aβ(1-
42) preparation on a native gel, therefore comparison of the results obtained in this 
thesis with the original paper is not possible.  
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Other studies on synthetic Aβ(1-42) prepared in F12 media has shown that the 
ADDLs (amyloid-beta derived diffusible ligands) formed were SDS-stable and 
consisted of trimers, tetramers, pentamers and other species up to 24mer sizes. AFM 
(atomic force microscopy) and gel electrophoresis showed that these ADDLs were 
stable structures that did not rapidly aggregate into protofibrils. When diluted 
solutions were incubated at 37°C for up to 24h, the smaller oligomers (trimer, 
tetramers) aggregated into larger 12-24mer species (Chromy et al., 2003). Both 
SDS-PAGE and native gels analysed using western blotting from this thesis showed 
a slow time-dependent aggregation of the Aβ(1-42) in F12 media. The results 
obtained in this thesis are therefore in agreement with the previous studies. 
 
2.4.4 Aβ (1-42) in DMSO 
 
Aβ(1-42) pre-treated with HFIP, dissolved in DMSO and used immediately has often 
been used in in vitro studies as a method to produce monomers (Kim et al., 2003, 
Cizas et al., 2010). Western blot analysis of the freshly prepared Aβ in DMSO only 
revealed monomeric/dimeric bands at ~4kDa. However, once the Aβ was added to 
culture media and incubated over time, the monomers aggregated rapidly. This very 
rapid aggregation is especially well presented on a native gel. The SDS-PAGE gel 
showed formation of SDS-stable oligomers (trimers/tetramers) which are normally 
toxic to the cells. It is therefore surprising that previous studies that have used Aβ 
dissolved in DMSO as a monomeric preparation, did not report any toxicity (Kim et 
al., 2003). 
 
2.4.5 Aβ (1-40) in HEPES 
 
SDS-stable oligomers were not detected in the HEPES preparations of Aβ(1-40) and 
this is consistent with previous studies (Chromy et al., 2003). In addition, under 
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native conditions Aβ(1-40) formed much smaller aggregates than Aβ(1-42). This 
supports the view that Aβ(1-40) is less prone to aggregation than Aβ(1-42).  
 
2.4.6 Thioflavin T (ThT) fluorescence analysis 
 
Previous kinetic aggregation studies have shown that the Aβ aggregation pattern 
demonstrates a sigmoidal appearance which is characteristic for nucleation-
dependent polymerization. The process normally starts with a lag phase and is 
followed by an elongation and plateau phase once equilibrium is achieved (Hellstrand 
et al., 2010a). In this thesis the Aβ(1-42) aggregation was studied by ThT 
fluorescence in addition to electrophoresis and western blotting.  
 
The study of Aβ(1-42) and Aβ(1-40) aggregation by ThT fluorescence showed a high 
level of reproducibility between replicates of the same solution. Aggregation of Aβ 
was dependent on both the concentration of the peptide, as well as the preparation 
protocol used. At 20µM the Aβ (1-42) dissolved in DMSO aggregated rapidly. This 
was also demonstrated by Aβ(1-42) prepared by the method described by Dahlgren 
et al. (2002). The Aβ(1-42) prepared in HEPES aggregated at a slower rate than the 
other methods tested. Aβ(1-40) demonstrated little aggregation according to ThT 
fluorescence which was in agreement with the results obtained by western blotting. 
At 2µM there was a similar pattern and in the presence of DMSO Aβ(1-42) 
aggregating rapidly. Surprisingly very similar results were obtained from Aβ(1-42) 
prepared in F12 medium. Again Aβ(1-42) in HEPES showed lower levels of 
aggregation over time. At the lowest concentration (0.2µM) the aggregation pattern 
was similar to other concentrations when measured by ThT fluorescence, with Aβ(1-
42) in DMSO showing the highest fluorescence and Aβ(1-42) in HEPES the lowest. 
However, at this concentration the fluorescence was very low. It has been previously 
reported that Aβ(1-42) has a critical concentration below which fibrils cannot be 
	  
	  
89	  
detected (Hellstrand et al., 2010a). Below a concentration of 0.2µM the fluorescence 
has been found to be below the background level (Hellstrand et al., 2010a) and as 
such the ThT assay is not recommended for the study of Aβ(1-42) aggregation at 
concentrations lower than 0.2µM. Previous studies have also shown that the critical 
concentration for Aβ(1-40) is higher, at 0.7-1.0µM (O'Nuallain et al., 2005) which may 
be due to different peptide length and ionic strength. 
 
2.4.7 Conclusion 
 
Gel electrophoresis and western blotting using antibodies against Aβ(1-42) have 
provided evidence that Aβ(1-42) prepared in F12 and HEPES form oligomers with 
little protofibril/fibril formation. Additionally Aβ(1-42) dissolved in HEPES produced 
more 24mer and higher species, whilst Aβ(1-42) freshly prepared in DMSO and 
diluted in medium rapidly aggregates. Electrophoresis in denaturing gels revealed a 
spectrum of SDS-stable oligomers including monomers, dimers, trimers and 
tetramers. Monomers appear to be a major species in both Aβ preparations. 
However, previous studies have shown that when two-dimensional native-SDS 
analysis was applied, the ADDL preparation contained only small amount of 
monomers (Chromy et al., 2003). This suggests that some of the oligomers can 
dissociate into monomers in the presence of SDS.   
 
In all preparations tested, both native and SDS electrophoresis showed that size and 
Aβ aggregation depends on the incubation period as well as the environment. The 
western blot analysis also revealed a time-dependent increase in both oligomers as 
well as higher aggregates.  
 
The ThT fluorescence assay was in agreement with the western blotting data. Aβ(1-
42) dissolved in DMSO aggregated very quickly. According to western blot analysis, 
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both Aβ(1-42) aggregated in F12 medium and prepared in HEPES showed a similar 
aggregation pattern and oligomer formation. However, Aβ(1-42) pre-aggregated in 
F12 showed a more rapid aggregation pattern using the ThT fluorescence assay than 
Aβ(1-42) prepared in HEPES. These results suggested that Aβ(1-42) prepared in 
F12 aggregated much faster and could lead to the production of larger, less toxic 
forms over time. As experiments using cell cultures were planned to last up to 96h it 
was necessary to use Aβ(1-42) that produced more stable oligomers. Based on the 
results from western blotting and ThT assay, Aβ(1-42) in HEPES was therefore 
chosen for NT2.N/A, NT2.A and primary culture treatments.  
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Chapter 3: Astrocyte-neuron metabolic coupling 
3.1 Introduction 
 
Hypometabolism of the brain in AD has been widely accepted as one of the earliest 
signs of the disease. Changes in brain metabolism appear decades before any 
symptoms or pathological lesions. As astrocytes are essential for neuronal survival 
and are responsible for supply of metabolites to neurons from the blood stream, it is 
essential to investigate the astrocyte-neuron metabolic coupling in terms of AD onset 
and progression. 
 
The astrocyte-neuron lactate shuttle (ANLS) was first described in 1994 by Pellerin 
and Magistretti and has since been extensively studied (Pellerin and Magistretti, 
2012). In principle, the hypothesis states that glutamate release from neurons 
triggers a metabolic cascade which results in the production of lactate in astrocytes 
(Fig. 3.1). Lactate is then released for neurons to take up and use as an energy 
source during high activity associated with synaptic transmission (Pellerin and 
Magistretti, 2012). 
 
In neurons, the release of glutamate leads to the activation of AMPA receptors and 
generation of excitatory postsynaptic potential by Na+ entry. Depolarization leads to 
further Na+ entry that activates the Na+/K+ ATPase, thus increasing the neurons’ 
energy demand.  Neuronal ATP is derived from oxidative phosphorylation and 
causes reduced nicotinamide adenine dinucleotide (NADH) levels in mitochondria to 
drop (Kasischke et al., 2004). Subsequent increases in the activity of the TCA cycle 
leads to an increase in NADH levels that support ATP production. This increase in 
TCA cycle activity leads to a drop in cytoplasmic pyruvate levels, which further 
enhances uptake of glucose and lactate (Pellerin and Magistretti, 2012).  
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In astrocytes, glutamate is taken up via the glutamate transporters GLAST and GLT-
1. Glutamate is cotransported with Na+ ultimately leading to a buildup of intracellular 
sodium levels and activation of Na+/K+ ATPase. This pump requires ATP which is 
provided by membrane-bound glycolytic enzymes (such as phosphoglycerate kinase; 
PGK) which in turn enhance aerobic glycolysis. An increase in aerobic glycolysis 
initially causes a large increase in cytosolic NADH (Pellerin and Magistretti, 2012). 
However, in order to maintain the glycolytic rate the cofactor nicotinamide adenine 
dinucleotide (NAD+) has to be regenerated. Normally this takes place in mitochondria 
via the malate/aspartate shuttle which oxidizes NADH to NAD+. However, astrocytes 
appear to lack key components of that shuttle and instead use the conversion of 
pyruvate to lactate by lactate dehydrogenase (LDH) to regenerate NAD+ (Pellerin, 
2008). Lactate is then released via monocarboxylate transporters (MCT1 and 4) and 
taken up by neurons via MCT2. 
 
During prolonged stimulation, extracellular glucose levels may be too low to sustain a 
constant supply of energy. Hence, neurons rely upon astrocytes to meet their 
energetic needs.  Indeed, astrocytes are the only cells in the brain that can store 
glycogen and it has been shown that during sustained stimulation astrocytes can 
produce lactate from glycogen to support the high energy demands of neurons 
(Pellerin and Magistretti, 2012). 
 
3.1.1 Astrocytes and neuronal support 
 
In the brain, neurons and astrocytes form a complex and symbiotic network. 
Astrocytes have long been thought to be responsible for supply of energy substrates 
to neurons from the blood stream (Andriezen, 1893).  
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A) 
 
B) 
	  
Figure 3.1 Schematic diagram of the ANLS at A) high brain activity and B) low 
brain activity. Release of glutamate from presynaptic terminal, triggers its uptake into 
astrocytes via glutamate transporters. Na+, which is cotransported with glutamate, is 
then removed from astrocytes via Na+/K+ ATPase. This process is energy dependent 
and triggers glucose uptake or glycogen breakdown and glucose subsequent 
metabolism into lactate. Lactate is then released from astrocytes into the synaptic 
cleft via MCT1/4 and taken up by neuron via MCT2. Lactate acts as energy source in 
neurons during high-energy requirements associated with synaptic transmission. 
During low activity some of the glucose taken up by astrocytes is used to synthesize 
glycogen. 1) GLUT1 (glucose transporter); 2) GLAST/GLT-1 (glutamate transporter); 
3) Na+/K+ ATPase; 4) MCT1/4 (lactates transporter); 5) MCT2 (lactate transporter). 
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Indeed, these cells have a very specialized morphology, which allows them to sense 
and respond to changes in their environment (Allaman et al., 2011). Astrocytes 
extend multiple processes that ensheath synapses or form so called ‘end feet’ that 
surround blood vessels. These structures possess specific glucose transporters 
GLUT1 that allow astrocytes to take up glucose from blood stream and then either 
provide it to the extracellular space or store it as glycogen (Magistretti and Allaman, 
2007). Astrocytes have been shown to be critical in maintaining moderate levels of 
glucose in brain extracellular spaces (i.e. 0.5-1.5mM) (Abi-Saab et al., 2002). 
 
Astrocytes also play an important role in many homeostatic processes, such as 
oxidative stress defence, glycogen storage, tissue repair, synapse remodeling and 
many more (Stevens, 2008, Belanger and Magistretti, 2009). They form a syncytium 
via gap junctions (Giaume et al., 2010) for extracellular homeostasis which includes 
Ca2+, K+, glutamate and glucose buffering (Tabernero et al., 2006). Additionally, 
astrocytic coupling contributes to the energetic support of neurons. Astrocytes also 
express glutamate transporters as well as glutamine synthase which make them an 
essential component in glutamate recycling during synaptic activity (Benarroch, 
2005). 
 
3.1.2 Characteristics of metabolism in neurons and astrocytes 
 
Astrocytes and neurons exhibit different characteristics in terms of their energy 
metabolism. Results from enzymatic studies and transcriptomic studies all suggest 
the prevalence of glycolysis and the glycogen pathway in astrocytes and utilization of 
lactate in neurons (Hyden and Lange, 1962, Lovatt et al., 2007). In particular, 
expression of different lactate dehydrogenase (LDH) and monocarboxylate 
transporter (MCT) isoforms in neurons and astrocytes favour this view (Bittar et al., 
1996, Pellerin et al., 2005). At the same time astrocytes do exhibit oxidative potential 
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that is comparable to neurons (Pellerin and Magistretti, 2012). Lovatt et al. (2007) 
showed that astrocytes express high levels of mRNA encoding TCA cycle enzymes, 
even though the same study provided evidence supporting ANLS.  
 
Neurons also exhibit glycolytic activity (Bittner et al., 2010). However, glycolysis in 
neurons is reduced to a minimum due to continuous degradation of the 6-
phosphofructo- 2 – kinase/fructose 2,6-biphosphatase, isoform 3 (PFKFB 3) which is 
an enzyme that activates phosphofructokinase (a rate-limiting enzyme involved in 
glycolysis) (Herrero-Mendez et al., 2009). In neurons, glucose is mainly metabolized 
through the pentose phosphate pathway that produces reducing equivalents which 
are then used in the removal of ROS (Pellerin and Magistretti, 2012). It has been 
shown that upregulation of PFKFB3 in neurons by either inhibition of Cdh1 (involved 
in proteasomal degradation of PFKFB3) or simply by overexpression of PFKFB3 
increases the rate of glycolysis. However, this study also showed that the flow of 
glucose through pentose phosphate pathway was decreased, which led to increases 
in oxidative stress and apoptosis in neurons (Herrero-Mendez et al., 2009). In 
astrocytes, glycolysis is favoured as these cells demonstrate low expression levels 
for essential components of the malate-aspartate shuttle in mitochondria (Xu et al., 
2007). The importance of glucose utilization in astrocytes and oxidative 
phosphorylation in neurons has been demonstrated by experiments using fluorescent 
deoxyglucose analogs. These studies have shown greater fluorescence signals in 
glial cells than neurons (Barros et al., 2009b). An interesting approach has also been 
used by Kasischke et al. (2004). The group used two-photon fluorescence imaging of 
reduced nicotinamide adenine dinucleotide (NADH) to define metabolic profiles of 
neurons and astrocytes. This method demonstrated a separate activation of oxidative 
phosphorylation in neurons and glycolysis in astrocytes (Kasischke et al., 2004). 
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Neurons and astrocytes also differ in glucose utilization following synaptic activity. 
While there is an increase in glucose uptake in astrocytes, no increase or even a 
decrease has been showed in neurons (Loaiza et al., 2003, Chuquet et al., 2010).  
 
Glucose uptake is facilitated by a sodium-independent transport system which can be 
inhibited by cytochalasin B (Hara et al., 1989) and stimulated by thyroid hormone 
(Roeder et al., 1985), potassium ions (Brookes and Yarowsky, 1985), glutamate 
(Pellerin and Magistretti, 1994), endothelin-1 (Tabernero et al., 1996), arachidonic 
acid (Yu et al., 1993) or phorbol esters (Mudd et al., 1990).  
 
Astroglial cells express hexokinase I which is the primary isoform found in the brain. 
Following phosphorylation by hexokinase I, glucose-6-phosphate becomes an 
intermediate form which forms the basis of a number of processes, namely: 
glycolysis, the pentose phosphate pathway and glycogen metabolism. In astroglial 
cells, the activity of the pentose phosphate pathway is relatively low but can be 
increased during oxidative stress (Ben-Yoseph et al., 1994). 
 
3.1.3 Glycogen 
 
Glycogen is a multibranched polysaccharide that acts as the principal storage form of 
glucose in mammalian systems and can be found in most tissues of the body 
including the brain (Brown and Ransom, 2007). The main deposits of glycogen can 
be found in liver and skeletal muscle. When blood glucose levels are normal, excess 
glucose may be stored as glycogen for when glucose intake is reduced. During 
periods of starvation glycogen in the liver is metabolized to release glucose (Brown 
and Ransom, 2007).  
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The function of glycogen depends on its location. The most widely accepted principle 
is that liver glycogen is used to supply glucose to the whole body, whilst skeletal 
muscle glycogen is for use by that tissue. However, recent studies have also shown 
that during intense exercise systemic blood glucose can drop but lactate levels 
increase almost tenfold. Under these conditions net lactate transfer switches from an 
efflux from the brain to a net uptake into the brain (Secher and Quistorff, 2005) which 
suggests a possible additional role for muscle glycogen (Brown and Ransom, 2007). 
 
Glycogen levels in the brain are lower (6-12µmol) (Cruz and Dienel, 2002) than in 
liver (100-500µmol) (Brown and Ransom, 2007) and skeletal muscle (300-350µmol) 
(Chryssanthopoulos et al., 2004) which suggests that brain glycogen is not useful as 
a source of blood glucose and it seems most probable that it is intended for local use 
only (Brown, 2004). 
 
3.1.3.1 Location of glycogen in the brain 
 
In the adult brain glycogen is only present in astrocytes (Cataldo and Broadwell, 
1986). It can also be stored in embryonic neural tissue (Brown and Ransom, 2007), 
however, this storage decreases as the neurons mature. The nature of glycogen 
stored in these cells is unknown, but it has been suggested that at the stage of 
embryonic development neuronal cells have higher metabolic demands and a less 
secure glucose supply (Brown and Ransom, 2007). 
 
As glycogen is mainly stored in astrocytes, the enzymes that are involved in its 
metabolism such as glycogen phosphorylase or glycogen synthase are also found in 
these cells (Pellegri et al., 1996, Pfeiffer-Guglielmi et al., 2003). 
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Neurons do not usually store glycogen with the exception of some cells in the 
brainstem and peripheral nervous system (Sotelo and Palay, 1968). Surprisingly 
neurons do express glycogen synthase, however, glycogen storage is inhibited by 
two different mechanisms in these cells. First, is a proteasome-dependent 
mechanism which involves the malin-laforin complex that degrades glycogen 
synthase (Vilchez et al., 2007). The second mechanism involves phosphorylation of 
glycogen synthase. If either of these two mechanisms is modified, this leads to 
synthesis of glycogen in neurons, which leads to apoptosis. An interesting example is 
Lafora disease which is characterized by accumulation of glycogen deposits in 
neurons and results in myoclonus epilepsy. This disease is caused by a mutation in 
malin-laforin complex which leads to loss of function (Pellerin and Magistretti, 2012). 
 
Glycogen is not evenly distributed evenly throughout the brain. It appears glycogen 
levels are higher in areas with the greatest synaptic density (Phelps, 1972). However 
some studies have also found high levels of glycogen in white matter that lacks 
synapses (Cruz and Dienel, 2002). Overall most studies have found higher levels of 
glycogen in grey as opposed to white matter (Sagar et al., 1987).  
 
3.1.3.2 Role of astrocytic glycogen 
 
Glycogen levels in the brain are relatively low in comparison to liver and skeletal 
muscle. In the absence of glucose, glycogen would be consumed within a few 
minutes (Brown and Ransom, 2007). It is thought that in these cells glycogen serves 
as an energy source during hypoglycaemia (Brown et al., 2003, Choi and Gruetter, 
2003) but also during periods of high brain activity (Brown et al., 2003). Following 
neuronal activation, the cells release many different astrocytic and vascular 
mediators, which not only activate astrocytes but also initiate a vascular response 
which leads to enhancement of cerebral blood flow, which delivers glucose and O2 
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(Dienel and Hertz, 2001, Gordon et al., 2008). These intermediates include K+, 
glutamate, ammonia, lactate, oxygen, but also NO, H2O2 and superoxide (Turner and 
Adamson, 2011). 
 
However, as active brain tissue has the same metabolic demand as exercising 
muscle, the demand for energy is instant, and there are many factors, which can 
affect energy supply (Shulman et al., 2004). Firstly, the signals to increase blood flow 
are not quick enough to supply glucose and oxygen to the brain. This results in initial 
shortage of glucose which could limit brain function. As astrocytes are ideally 
positioned to share substrates with neurons, they use glycogen as an instant energy 
supply (Brown and Ransom, 2007).  
 
Hexokinase is one of the slower glycolytic enzymes which suggests that the initial 
glucose phosphorylation can be rate limiting (Brown and Ransom, 2007). However, 
glycogen phosphorylase demonstrates high activity and can ensure a rapid 
metabolism of brain glycogen (Shulman et al., 2001). It has been shown that even 
under normal glucose conditions, stimulation of brain tissue results in rapid 
breakdown of glycogen (Brown et al., 2003).  
 
Glycogen is metabolized to glucose-6-phosphate (G6P) which can then be converted 
to lactate and released for neuronal uptake (Dringen et al., 1993a). The expression of 
the enzyme glucose-6-phosphatase in the brain is controversial. Even though some 
publications suggest that astrocytes do not express glucose-6-phosphatase (Brown 
and Ransom, 2007), other studies have demonstrated the presence of glucose-6-
phosphatase in astroglial cells (Forsyth et al., 1993) Irrespective of the results, these 
studies failed to show astrocytic release of glucose derived from glucose-6-
phosphate (Wiesinger et al., 1997). 
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The breakdown of glycogen in astrocytes not only ensures an energy supply to 
neurons in form of lactate, but also increases levels of glucose-6-phosphate in 
astrocytes. This in turn reduces the activity of hexokinase I, thus decreasing the 
phosphorylation of glucose by astrocytes. As such, more glucose from blood may be 
available for neuronal uptake (DiNuzzo et al., 2010). 
 
It has also been shown that glycogenolysis in astrocytes is important for the 
astrocyte-neuron lactate transfer during synaptic plasticity and learning (Suzuki et al., 
2011). Indeed inhibition of glycogenolysis by 1,4-dideoxy-1,4-imino-d-arabinitol 
(DAB) leads to a loss of long-term memory (Walls et al., 2008). Additionally, 
experimental block of lactate transport prevents glycogen from supporting neurons 
(Brown et al., 2003). 
 
3.1.3.3 Glycogen synthesis 
 
Glucose enters the brain via glucose transporter 1 (GLUT1) on luminal and abluminal 
sides of endothelial cells (Brown and Ransom, 2007). As endothelial cells have a 
relatively low metabolic rate, the glucose is not phosphorylated and can pass through 
them freely (Brown and Ransom, 2007). Astrocytic end feet that are in close 
proximity to endothelial cells are well positioned to take up glucose when it enters the 
brain. Astrocytes express GLUT1 (Vannucci et al., 1997) and neurons express 
GLUT3 (Brown and Ransom, 2007). As both neurons and astrocytes have a high 
metabolic rate, they phosphorylate glucose immediately, thus trapping it inside the 
cell (Brown and Ransom, 2007). Glucose-6-phosphate is then converted by 
phosphoglucomutase into glucose-1-phosphate (G-1-P) which then binds to uridine 
triphosphate (UTP) forming UDP glucose, which is the source of glycosyl units that 
are used to build the glycogen molecule. This reaction is catalyzed by UDP glucose 
pyrophosphorylase (UDPGPP). Glycosyl residues bind to glycogenin which forms a 
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skeleton of glycogen in the reaction facilitated by glycogen initiator synthase. 
Subsequently the glycogen is extended by glycogen synthase, which then adds the 
UDP glucose to the glycogen molecule forming α-1,4-glycosidic bonds. This releases 
UDP which is then converted to UTP by nucleoside diphosphate kinase. On every 8-
10th glucosyl residue an enzyme amylo-(α-1,4-α-1,6)-transglycosylase forms a 
branch by creating an α-1,6-glycosidic bond. This makes the formation of glycogen 
more efficient but also allows simultaneous breakdown (Brown and Ransom, 2007). 
 
3.1.3.4 Gluconeogenesis in astrocytes  
 
Glucosyl residues, which are the subunits for building glycogen can be derived from 
substrates other than just glucose. These include lactate, pyruvate and amino acids 
such as alanine, serine, threonine, aspartate and glutamate (Wiesinger et al., 1997). 
 
A wide variety of enzymes are required for gluconeogenesis to proceed. These 
include pyruvate carboxylase (PC), phosphoenolpyruvate carboxykinase (PEPCK), 
fructose-1,6-biphosphatase (F1,6Pase) as well as the enzymes of the glycolytic 
pathway. At least the presence of PC and F1,6Pase has been recorded in astrocytes 
(Wiesinger et al., 1997). It has also been shown that astrocytes from mouse brain are 
capable of incorporating glycosyl residues derived from labelled [14C] lactate (Dringen 
et al., 1993b) or alanine, aspartate or glutamate (Schmoll et al., 1995) into glycogen. 
 
3.1.3.5 Glycogen breakdown 
 
The breakdown of glycogen is independent of glycogen synthesis. It involves 
glycogen phosphorylase which cleaves α-1,4-glycosidic bond realeasing glucose-1-
phospate. This reaction proceeds until only four glycosyl units are left before a 
branch. Then another enzyme, oligo-(α-1,4-α-1,4)-glucantransferase removes the 
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last three glucosyl units and attaches them to a different end of the glycogen 
molecule. These units are then released by the action of glycogen phosphorylase. 
The last remaining glucosyl unit before the branch is removed by amylo-α-(1,6)-
glucosidase which releases units as glucose (Brown and Ransom, 2007).  
 
3.1.3.6 Glycogen metabolism regulation 
 
The control of the glycogen metabolism is essential for brain function. The regulation 
of glycogen breakdown and synthesis involves phosphorylation of the two key 
enzymes, glycogen synthase and glycogen phosphorylase. Glycogen synthase exists 
in two forms; the phosphorylated form (GSb) which is inactive and a 
dephosphorylated active form (GSa). Dephosphorylation of GS is controlled by a 
family of phosphatases. Protein phosphatase 1 (PP1) is expressed at high levels in 
astrocytes and it binds glycogen through protein targeting to glycogen (PTG) which 
allows it to dephosphorylate glycogen synthase (Brown and Ransom, 2007). 
 
Glycogen phosphorylase also exists in two forms – phosphorylated active form (GPa) 
and dephosphorylated inactive form (GPb). Phosphorylation of glycogen 
phosphorylase is facilitated by phosphorylase kinase (Brown and Ransom, 2007). 
 
There are a number of neurotransmitters and modulators which promote 
glycogenolysis in astrocytes (Magistretti et al., 1981, Magistretti et al., 1986) These 
include noradrenaline (NA), vasoactive intestinal peptide (VIP) and adenosine. In 
addition, IGF I, IGF II and insulin increase glycogen levels in the brain by acting on 
insulin receptors.  Activation of receptor tyrosine kinase phosphorylates protein PP1 
which in turn activates glycogen synthase (Dent et al., 1990). NA and VIP act by 
elevating levels of cyclic AMP (Sorg and Magistretti, 1992). Additionally, an increase 
in Ca2+ can induce glycogen breakdown. Increased Ca2+ and cyclic AMP levels also 
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act on phosphorylase kinases which activate glycogen phosphorylase (Wiesinger et 
al., 1997).  
 
3.1.4 Lactate 
 
Production of lactate is not only important in supporting neurons but also astrocytes. 
As mentioned above astrocytes show low expression of components of mitochondrial 
aspartate/glutamate carrier which reduces their ability to regenerate NAD+ through 
malate/aspartate shuttle (Pellerin and Magistretti, 2012). Instead, NADH is converted 
to NAD+ during conversion of pyruvate to lactate by lactate dehydrogenase (Pellerin 
and Magistretti, 2012). 
 
Monocarboxylate transporters play a key role in influx and efflux of lactate (Aubert et 
al., 2005). There are three known transporters, MCT1, MCT2 and MCT4 and one 
sodium-dependent transporter named sMCT1 (Martin et al., 2006). These different 
transporters are cell specific. MCT1 is mainly expressed in endothelial cells in blood 
vessels and on astrocytes and oligodendrocytes (Gerhart et al., 1997). MCT2 is 
specific for neurons and it is mainly found on axons and dendrites (Pierre et al., 
2002). Dendritic spines appear especially enriched in this transporter (Bergersen et 
al., 2001). MCT4 is only expressed on astrocytes with most transporters 
concentrated on processes that are in close proximity to synapses (Pellerin et al., 
2005). MCTs are also expressed in the neonatal blood brain barrier but the 
expression of these transporters decreases with time (Pellerin et al., 1998). 
 
The transporters differ in their affinity for lactate. MCT2 is a high-affinity transporter 
with a Km of 0.7mmol/L, whilst MCT1 and MCT4 are both low-affinity transporters 
with a Km of 3.5 and 34mmol/L respectively (Pellerin and Magistretti, 2012). This low 
affinity for lactate leads to extrusion and very rarely uptake of lactate at normal 
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extracellular levels of ~2.5mM (Turner and Adamson, 2011). However, at higher 
levels of lactate (5 to 8mM) astrocytes may increase their uptake from the 
extracellular space (Turner and Adamson, 2011). 
 
LDH isoforms also display cell type specificity and are expressed by different cell 
types. The isoform LDH-5 that is encoded by the LDHA gene is found in astrocytes 
whilst the LDH-1 isoform which has 4 subunits encoded by LDHB gene is expressed 
in neurons (Bittar et al., 1996, O'Brien et al., 2007). Neuronal LDH-1 tends to 
facilitate lactate to pyruvate conversion, while LDH-5 in astrocytes conversion of 
pyruvate to lactate (O'Brien et al., 2007). 
 
This differential localization of MCTs as well as the cell specific expression of 
different isoforms of LDH favours the concept that lactate is produced and released 
from astrocytes and taken up by neurons (Pellerin and Magistretti, 2012). 
 
Expression of neuronal MCT2 can be increased by different stimuli such as 
noradrenaline (NA), insulin, insulin-like growth factor-1 (IGF-1) and brain-derived 
neurotrophic factor (BDNF) (Chenal and Pellerin, 2007, Chenal et al., 2008, Robinet 
and Pellerin, 2010). In vitro studies have also shown that the translocation of MCT2 
to the plasma membrane can be affected by exposing cortical neurons to glutamate 
and glycine (Pierre et al., 2009). As changes to expression and location of MCT2 
appear to occur very quickly, they probably represent a process by which neurons 
adapt to their energetic needs (Pellerin and Magistretti, 2012). Studies on synaptic 
plasticity have shown that GluR2, which is known to be involved in synaptic plasticity 
at glutaminergic synapses (Isaac et al., 2007), interacts with MCT2 (Pierre et al., 
2009). It has also been found that MCT2 affects the distribution and expression of 
GluR2 which supports the idea that energy supply is tightly linked to synaptic 
plasticity (Maekawa et al., 2009). Disruption of MCT4 expression can induce loss of 
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long-term memory. This effect is rescued by administration of lactate but not glucose. 
However, when the neuronal lactate transporter MCT2 was blocked the loss of long-
term memory could not be rescued by administration of lactate (Suzuki et al., 2011). 
 
Lactate has been found to be preferred by neurons over glucose as an oxidative 
energy substrate (Bouzier-Sore et al., 2003b, Bouzier-Sore et al., 2006, Ivanov et al., 
2011). This preference appears to be inefficient as one molecule of lactate can only 
yield 17 ATPs during TCA cycle whilst glucose yields 31 molecules of ATP. However, 
lactate cannot substitute glucose completely and fulfill all neuronal requirements such 
as flux through glycolysis or pentose phosphate shunt (Dienel, 2010). Nevertheless, 
lactate has been shown to be important in many different mechanisms such as 
control of respiration (Erlichman et al., 2008), neurovascular coupling (Gordon et al., 
2008), recovery from hypoxia (Schurr et al., 1997) and neuroprotection (Berthet et 
al., 2009). 
 
3.1.5 Glutamate 
 
More than 85% of the neurons within the cortex are glutamatergic. As such glutamate 
represents a major neurotransmitter within this region (Magistretti, 2009). At the 
postsynaptic sites glutamate can interact with three types of receptors. The A-amino-
3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor changes sodium 
permeability upon glutamate binding. In comparison the N-methyl-D-aspartate 
(NMDA) receptor affects both calcium and sodium permeability which invokes 
excitatory postsynaptic potential. The third type of receptors is the metabotropic 
glutamate receptor which modifies changes in calcium signaling through GTP-
mediated processes (Magistretti, 2009). The action of glutamate is terminated by the 
uptake of glutamate by astrocytes (Danbolt, 2001). As glutamate is highly toxic and 
its accumulation can lead to excitotoxicity (Sattler and Tymianski, 2001), it is 
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essential that the astrocytes remove it from the extracellular space. Glutamate 
uptake is carried out by glutamate transporters GLT-1 and GLAST which use the 
extracellular sodium gradient as the driving force. The stoichiometry is that for one 
molecule of glutamate, astrocytes take up 3 ions of sodium (Magistretti, 2009). 
Glutamate also stimulates glucose utilization. Indeed studies have shown that this 
effect is not receptor mediated as various glutamate receptor agonists and 
antagonists have no effect (Pellerin and Magistretti, 1994). However, glucose 
utilization was enhanced after treatment by D-aspartate but not D-glutamate strongly 
suggesting that the effect is mediated by glutamate transport (Magistretti, 2009). This 
finding is supported by experiments, which have shown that inhibition of glutamate 
transporters by threohydroxyaspartate abolishes glucose utilization in astrocytes 
(Pellerin and Magistretti, 1994). 
 
Uptake of glutamate increases sodium levels inside the cell to such a level that 
Na+/K+ ATPase is activated (Pellerin and Magistretti, 1997, Chatton et al., 2000). 
More specifically glutamate transporter activation mobilizes α2 subunit of Na+/K+ 
ATPase, which co-localizes and interacts with glutamate transporters (Cholet et al., 
2002, Rose et al., 2009). In addition, a specific Na+/K+ ATPase inhibitor ouabain 
completely inhibits glutamate stimulated glucose uptake. 
 
The activation of the Na+/K+ ATPase enhances ATP utilization, which in turn 
stimulates glucose uptake and aerobic glycolysis (conversion of glucose into lactate 
in the presence of oxygen) (Pellerin and Magistretti, 1994, Pellerin and Magistretti, 
1997). 
 
There are several pathways by which astrocytes utilize glutamate after its uptake. 
Glutamate can be used as a metabolic intermediate in the TCA cycle. During this 
process astrocytes convert it into α-ketoglutarate in a process mediated by either 
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glutamate dehydrogenase or aspartate amino transferase. In both cases α-
ketoglutarate can then enter TCA cycle (Magistretti, 2009). 
 
Another pathway for glutamate in astrocytes is conversion into glutamine in process 
facilitated by glutamine synthase, which is almost exclusively localized in astrocytes. 
Additionally, astrocytes can use α-ketoglutarate and amino groups from leucine to 
form glutamate which is then converted into glutamine (Magistretti, 2009). Glutamine 
is then released by astrocytes and taken up by neurons where the enzyme 
glutaminase hydrolyzes it back to glutamate thus maintaining the glutamate pool in 
neurons. 
 
Glutamate is also a substrate that can be utilised in the glutathione (GSH) synthesis 
pathway and therefore an important component of the antioxidant system. 
Metabolism of GSH involves two ATP-requiring steps. The first step is catalyzed by 
glutamate-cysteine ligase (GLC) which uses glutamate and cysteine to form γ-
glutamylcysteine (γGluCys). This dipeptide is then combined with glycine by the 
action of glutathione synthetase (GSS) (Fernandez-Fernandez et al., 2012). 
 
As presented in this chapter metabolic coupling between neurons and astrocytes 
involves many complex mechanisms. To date this hypothesis has only been tested in 
models derived from animals. As such relevant human models are required to study 
the complex cross-talk that occurs between these metabolically distinct cell types  
 
3.1.6 Aims and objectives of the study 
 
The aim of this chapter was to investigate the metabolic properties of NT2.N/A and 
NT2.A cultures and establish whether they demonstrate signs of metabolic coupling 
that could be perturbed in AD. The expression of the main components of the ANLS 
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was investigated as well as the ability to store glycogen by NT2.A cultures. The 
responses of the astrocytic network to known neuromodulators such as glutamate, 
potassium and dbcAMP were tested, in terms of glucose uptake and glycogen 
turnover. Finally, in order to establish whether NT2-derived astrocytes provide 
metabolic support to their neuronal counterparts, the modulation of glycogen was 
investigated during electrical stimulation 
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3.2 Materials and Methods 
3.2.1 Cell culture 
 
3.2.1.1 NT-2/D1 cells 
 
Human teratocarcinoma NT2/D1 cells used in this study were kindly donated by 
Professor Andrews (University of Sheffield, UK).  The cells were cultured in 
Dulbecco's Modified Eagle Medium (DMEM) Glutamax high glucose, with pyruvate 
(Life Technologies, UK) containing 10% heat inactivated foetal bovine serum (Life 
Technologies, UK), 100 units/ml penicillin and 100 µg/ml streptomycin. NT2/D1 cells 
were differentiated according to the method described by Woehrling et al. (2007).  
Briefly, following treatment with 10µM retinoic acid for 4 weeks, NT2 cells were 
replated after scraping into fresh 75cm flasks at a lower density (1:3) in RA free 
medium. After 2 days neuronal clusters were detached from undifferentiated cells by 
sharp striking of the flasks against the palm of the hand. Cells were then plated into 
CellBIND 12-well plates (Corning, USA). After 2 days cells were treated with mitotic 
inhibitors to suppress the proliferation of non-neural cell types. To generate an NT2.N 
monoculture cells were treated with 1 µM cytosine arabinoside (ARAC), 10 µM 
fluorodeoxyuridine (FDU) and 10 µM uridine (U) for 1 week followed by 10 µM 
fluorodeoxyuridine (FDU) and 10 µM uridine (U) for a further 2 weeks. To produce 
NT2.N/A co-cultures, cells were treated with 0.1 µM cytosine arabinoside (ARAC) 
3 µM fluorodeoxyuridine (FDU) and 5 µM uridine (U) for 10 days followed by 3 µM 
fluorodeoxyuridine (FDU) and 5 µM uridine (U) for a further 18 days. After this period 
cells were fed twice a week in normal DMEM without mitotic inhibitors and used 
within 1 month. 
 
Cultures of NT2 astrocytes were isolated from co-cultures according to the method 
developed by Woehrling et al. (2010). NT2.N/A cells were washed 3 X using PBS 
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and then dissociated using Accutase (PAA laboratories, UK). Large NT2.N 
aggregates settled quickly leaving a single cell suspension containing astrocytes that 
were replated into a CellBIND 12 well plate (Corning, USA). After incubation for 4h 
any remaining NT2.N cells were washed off the more adherent NT2.A cells using 
media.  All cells were maintained by incubation at 37oC in a humidified atmosphere of 
5% CO2.  
 
3.2.1.2 Cell treatment 
 
During experiments cells were maintained in Krebs-Ringer’s-HEPES buffer  (115mM 
NaCl, 5mM KCl, 1mM MgCl2, 24mM NaHCO3, 2.5mM CaCl22H20, 25mM HEPES 
supplemented with 5mM glucose) unless otherwise stated. For the experiments cells 
were treated with 10µM 1,4-dideoxy-1,4-imino-d-arabinitol (DAB; Sigma-Aldrich, UK), 
1mM dbcAMP (Tocris, USA), 100µM isoproterenol (Tocris, USA), 1mM or 0.5mM L-
glutamic acid (Sigma-Aldrich, UK), 60mM or 15mM potassium chloride (Sigma-
Aldrich, UK), 100µM ouabain (Tocris, USA) and 100µM DL-threo-β-benzyloxyaspartic 
acid (TBOA; Tocris, USA) 
 
3.2.2 Immunohistochemistry  
3.2.2.1 GFAP / β-tubulin-III staining 
 
The cells cultured on coverslips were washed with PBS and fixed for 10 minutes with 
4% paraformaldehyde. Following fixation coverslips were washed twice with PBS and 
permeabilized with 0.2% Triton/PBS. Cells were then incubated in 2% 
BSA/0.2%Triton/PBS for 1 hour to block non-specific binding of antibody. 
Subsequently, cells were incubated with different primary antibodies for 1 hour at RT. 
The following primary antibodies were used: mouse anti-GFAP (clone GA5 Millipore, 
1:500) and rabbit anti-β-tubulin-III (Abcam, UK, 1:500).  Following incubation, 
	  
	  
111	  
coverslips were washed three times in 2% BSA/0.2%Triton/PBS and then incubated 
with donkey anti-mouse Rhodamine (1:200, Jackson Immunoresearch, Europe) and 
goat anti-rabbit FITC (1:200; Jackson Immunoresearch, Europe).  
 
After washing the nuclei were visualized by Hoechst 33342 staining (Life 
Technologies, UK) for 15 minutes and mounted with ProLong® Gold Antifade 
Reagent (Life Technologies, UK). The cells were examined using the Zeiss LSM510 
confocal laser-scanning microscope and Zeiss Axiovert 200M fluorescent 
microscope. 
 
3.2.2.2 Glycogen staining 
 
Cytologic localization of glycogen was determined using the periodic acid-Schiff 
method (Rosenberg and Dichter, 1985). Briefly, the cells cultured on coverslips were 
washed with ice-cold PBS and fixed for 5 minutes at room temperature in methanol. 
After fixation coverslips were washed three times with 70% (vol/vol) ethanol. Next the 
cells were incubated for 30 minutes at room temperature with 1% (wt/vol) periodic 
acid dissolved in 70% ethanol. After incubation cells were washed three times with 
70% ethanol and stained for 60 minutes at room temperature with 0.5% (wt/vol) basic 
fuchsin (Sigma-Aldrich, UK) dissolved in acid ethanol (ethanol/water/concentrated 
HCl, 80:19:1). Cells were then washed three times with 70% ethanol and the 
coverslips were counterstained for GFAP/Oct-4 as described in section 3.2.2.1 or 
directly examined using the Zeiss LSM510 confocal laser-scanning microscope and 
Zeiss Axiovert 200M fluorescent microscope. 
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3.2.3 Gene expression analysis 
3.2.3.1 RNA extraction 
 
RNA was isolated from undifferentiated NT2/D1 cells as well as treated/untreated 
NT2.N/A co-cultures. RNA was extracted from samples using Trizol® Reagent (Life 
Technologies, UK), chloroform and isopropanol (Fisher, UK). DNA was then 
precipitated by 75% ethanol and diluted in RNA-free water. 
 
RNA was subsequently purified using RNeasy Mini Kit (QIAGEN, UK) in accordance 
with the manufacturer’s instructions, and subsequently quantified using the Nanodrop 
1000 (Thermofisher, UK).  
 
3.2.3.2 Real-time RT-PCR 
 
1 µg of total RNA was reverse transcribed by reverse transcriptase (Primer Design, 
UK) and oligo dT15 primers (Primer Design, UK). Real-Time PCR: cDNAs were 
amplified in a standard 40-cycle SYBR® green real-time PCR reaction using 
prevalidated primers for GLUT1, GLUT3, MCT2, MCT4, MCT1, GLT-1, GLAST and 
GLUL according to the manufacturer's instructions.  The house keeping genes UBC, 
B2M, EIF4A2 and C14orf133 (supplied by PrimerDesign Ltd, UK) were assayed 
under the same conditions as above. The expression of UBC was found to be 
unchanged under the conditions imposed and was therefore used in the 
normalisation of qRT-CR data.  Cycling conditions were as follows: 10min at 95˚C, 
15s at 95˚C and 1min at 60˚C for 40 cycles, 30s at 95˚C, 30s at 55˚C and 30s at 
95˚C. Fold changes >2 fold were considered significant. 
 
 
 
	  
	  
113	  
3.2.4 Fluorescent glucose analogue 6-NBDG uptake 
 
Uptake of the glucose analogue 6-NBDG in NT2.N/A and NT2.A cultures under 
various conditions was investigated using methods previously described (Loaiza et 
al., 2003). Briefly, before the measurement, culture medium was removed and cells 
were washed with Krebs’–Ringer HEPES (KRH) buffer supplemented with 5mM 
glucose. Then glucose in the medium was reduced to 0.5mM and cells were 
incubated for 5 min. Subsequently, the buffer in each well was changed to KRH 
buffer with 0.5mM glucose, 300µM 6-NBDG and treatments: 1mM glutamate (Sigma-
Aldrich, UK), 20µM cytochalasin B (Sigma-Aldrich, UK), 1mM glutamate and 20µM 
cytochalasin B, 1mM glutamate and 100µM ouabain (Tocris, USA). Cultures were 
excited at 488 nm and imaged at 505–550 nm emission at 60min, 180min and 
360min. The plate was read using SpectraMAX GeminiXS microplate luminometer 
(Molecular Devices, UK) and SoftMaxPro software. 
 
3.2.5 Determination of glycogen levels 
 
The method used to determine levels of glycogen in biological samples was 
previously described by Nahorski and Rogers (1972). It is an enzymatic reaction and 
is based on the breakdown of the glycogen into glucose by the enzyme 
amyloglucosidase. Subsequently, glucose undergoes phosphorylation by hexokinase 
in the presence of ATP. The third step involves oxidation of glucose 6-phosphate to 
gluconate-6-phosphate by glucose-6-phosphate dehydrogenase (G6P-DH). 
Fluorescence of the NADPH formed in the final reaction is then read on a fluorometer 
(excitation: 340 nm; emission: 450 nm). This method allows measurement of 
glycogen as well as glucose and glucose-6-phosphate in cell lysate according to the 
enzymes added. 
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3.2.5.1 Sample preparation  
 
NT2.N/A cultures were prepared as described in section 3.2.1.1. Cultures plated on 
12-well plates were then exposed to a range of reagents described in section 3.2.1.2. 
Next plates were incubated for 60min and 180min in DAB and hypoglycaemic 
conditions, 180min during dbcAMP and isoproterenol treatment and 60min during 
potassium and glutamate treatments. Following the treatment cells were washed 
three times with ice-cold PBS and then scraped in 300µl of 30mM ice-cold HCl. 
Subsequently, samples were sonicated for 15 seconds and used for the glycogen 
assay (section 3.2.5.2) and protein determination (section 3.2.5.3). 
 
3.2.5.2 Protocol  
 
The assay was adapted to a 96-well plate (Sigma-Aldrich, UK). Two 10µl aliquots of 
cell lysate were sampled. To the first aliquot 30µl of acetate buffer (0.1M, pH 4.65) 
was added. To the second 30µl of 0.1mg/ml of amyloglucosidase (Sigma-Aldrich, 
UK) in acetate buffer was added. Both samples were incubated for 30min at room 
temperature. After incubation 200µl of Tris-HCl buffer (0.1M, pH 8.1) containing 
MgCl2 (3.3 mM), ATP (0.33mM), NADP (38µM), hexokinase (4µg/ml) and glucose 6-
phosphate dehydrogenase (2µg/ml) were added to both aliquots and incubated for 
30min at room temperature. The third aliquot was used to determine the protein 
concentration (section 3.2.5.3) 
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Standards were prepared using a solution of glucose (1mg/ml; Sigma-Aldrich, UK) 
and 1:2 serially diluted using acetate buffer. Standards were treated as the first 
aliquot i.e. without amyloglucosidase treatment.  
 
The plate was then read using SpectraMAX GeminiXS microplate luminometer 
(Molecular Devices, UK) and SoftMaxPro software. The first aliquot gives the sum of 
glucose and glucose 6-phosphate, and the second the sum of glycogen, glucose and 
glucose 6-phosphate. In this thesis one mole of glycogen corresponds to one mole of 
glycosyl units originating from glycogen. 
 
3.2.5.3 Determination of protein levels 
 
The protein concentration of the sample was determined using the BCA assay 
reagent kit (Thermofisher, UK) in accordance with the manufacturer’s instructions. 
Briefly 25µl of sample, BSA standard (ranging from 25-2000 µg/ml) or 30mM HCl 
which acted as a BSA-free control were added to a 96-well microplate with the 200 µl 
of the working reagent (50:1, Reagent A:B). Reaction was then incubated at 37 °C 
for 30 min and then read at 590nm using a Thermo Multiscan EX 96-well plate reader 
(Thermofisher, UK). 
 
3.2.6 Determination of lactate levels 
 
A Lactate Assay Kit was used to measure lactate levels (Abcam, UK). The method is 
based on the oxidation of lactate by lactate oxidase into pyruvate and hydrogen 
peroxide. The product then interacts with the lactate probe to produce both colour 
and fluorescence. 
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3.2.6.1 Sample preparation  
 
NT2.N/A cultures were prepared as described in section 3.2.1.1. Cultures plated on 
12-well plates were then exposed to a range of reagents described in section 3.2.1.2. 
Next, plates were incubated for 60min and 180min in DAB and hypoglycaemic 
conditions, 180min during dbcAMP and isoproterenol treatment and 60min during 
potassium and glutamate treatments. Following the treatment cell culture media was 
collected and used for the lactate assay (section 3.2.6.2). 
 
3.2.6.2 Protocol 
 
Lactate levels were measured in accordance with the manufacturer’s instructions. 
Briefly, the assay was set up in a 96-well microplate. 50µl of media samples were 
used per well and mixed with 50 µl reaction mix containing 46 µl Lactate Assay 
Buffer, 2 µl Probe and 2 µl Enzyme Mix. 50µl reaction mix was also added to lactate 
standards that were prepared at 0, 0.2, 0.4, 0.6, 0.8 and 1.0 nmol/well. The reaction 
was incubated at room temperature for 30 minutes, protected from light and then 
read at 570nm using a Thermo Multiscan EX 96-well plate reader (Thermofisher, 
UK). All readings were corrected for background and lactate concentration was 
expressed in mM. 
 
3.2.7 Stimulation protocol 
 
Synaptic stimulation was achieved with a computer controlled constant current 
isolated stimulator (STG1002, Multichannel Systems, Germany) and bipolar 
electrodes, which were placed within the petri dish. Stimulation was composed of 
bursts of ten 800µA current pulses delivered at 20Hz every 10s for 30 minutes. Cells 
were maintained in Krebs-Ringer’s-HEPES buffer supplemented with 5mM glucose. 
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For the inhibition of glutamate uptake cells were pre-treated with 100µM TBOA for 
15min and then maintained in Krebs-Ringer’s-HEPES buffer, 5mM glucose and 
100µM TBOA during stimulation 
 
3.2.8 Statistics 
 
Results were expressed as the mean of three samples ± standard error of the mean 
(SEM).  Comparisons between treatments were performed using analysis of variance 
(ANOVA) followed by Dunnet’s or Tukeys post-test or Students T-test using 
GraphPad Prism Software.  Differences were considered significant for p values 
<0.05. 
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3.3 Results 
3.3.1 Characterization of NT2.N/A cultures and components of ANLS 
 
As the astrocyte-neuron lactate shuttle (ANLS) has been shown to be involved in 
memory formation, it is important that models used to investigate Alzheimer’s 
disease and dementia reflect the co-operation of these two cell types. To 
demonstrate the presence of the ANLS in NT2.D1 derived neurons and astrocyte co-
cultures it was essential to establish whether these cells are metabolically competent 
and demonstrate functional metabolic coupling. NT2.N/A and NT2.A cells were 
investigated for the expression of the main components of the ANLS, as well as 
responses of the astrocytic network to known neuromodulators such as glutamate, 
potassium and dbcAMP as well as inhibitors such as ouabain, catachalasin B and 
TBOA. In addition, to establish whether NT2-derived astrocytes provide metabolic 
support to their active neurons, the turnover of glycogen and production of lactate 
were monitored during electrical stimulation. 
 
NT2/D1 derived neurons and astrocytes were identified microscopically by their 
characteristic morphology. Following treatment with retinoic acid and replating, the 
cultures begin to display distinct neuronal and astrocytic morphology. Neurons 
extend axons and dendrites, and astrocytes with projections appear in close 
proximity to aggregations of neuronal perikarya and neurites throughout the culture. 
Under the microscope astrocytes were identified by their flat phase dark appearance, 
whilst neurons were typically phase bright and often seen on top of the astrocytic 
monolayer. These cells were further identified using immunohistochemistry for the 
specific markers GFAP and β-tubulin (Fig. 3.2).  To identify glycogen in NT2/D1 
derived cultures the periodic acid–Schiff method was used to determine the 
localization of glycogen in cultures (Nahorski and Rogers, 1972). Glycogen was 
found to co-localize with GFAP positive cells (Fig. 3.3). No glycogen was found in β-
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tubulin positive cells or undifferentiated Oct-4 positive NT2 cells (data not shown). 
 
Using realtime PCR, cultures were also characterised for the expression of genes 
involved in the astrocyte-neuron lactate shuttle following differentiation. Genes 
included glucose transporters (GLUT1 and GLUT3), monocarboxylate transporters 
(MCT1, MCT2 and MCT4), glutamate transporters (GLT-1 and GLAST) and 
glutamine syntethase (GLUL). A comparison of NT2/D1 stem cells with differentiated 
co-cultures showed a significant upregulation of glutamate transporters (GLAST and 
GLT-1) and a downregulation of GLUT1, MCT1 and GLUT3, whilst other genes 
remained unchanged (MCT4/2 and GLUL) (Fig. 3.4A). However, Ct values for all 
genes tested were relatively low (<30) suggesting a high to moderate expression of 
these genes (Fig. 3.4B). 
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Figure 3.2 Immunofluorescent images of NT2/D1 derived neurons and 
astrocytes. Images showing: (A) β-tubulin positive neurons (green), (B) GFAP (red) 
positive astrocytes, (C) nuclei stained with Hoechst 33342, and (D) an overlay of 
GFAP positive astrocytes and β-tubulin positive neurons (D). Scale bar 40µM. 
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Figure 3.3 Immunofluorescent images of NT2/D1 derived astrocytes.  Images 
showing: (A) GFAP (green) positive astrocytes and staining for (B) glycogen (red) 
using the periodic acid Schiff assay. (C) Representative image of co-localisation of 
glycogen and GFAP (yellow) with nuclei Hoechst 33342 staining (Blue). Scale bar 
33.7µM. 
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Figure 3.4 mRNA expression in NT2/D1 derived neurons and astrocytes in 
comparison to undifferentiated NT2/D1 stem cells.  mRNA expression of Glut1, 
Glut3, MCT2, MCT4, MCT1, GLT-1, GLAST and GLUL as well the house keeping 
gene UBC.  Results are expressed as A) the average fold change ± SEM (n=3) and 
considered significant above 2-fold change B) Ct values ± SEM (n=3). 
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3.3.2 Glutamate stimulates uptake of fluorescent glucose analogue 6-NBDG 
in NT2.N/A cultures  
 
Utilization of glucose in NT2.N/A and NT2.A cultures was monitored using a 
fluorescent glucose analog 6-NBDG. In control cultures dye accumulated 1.68 fold ± 
0.165 over 360min. Following the treatment of the co-cultures with glutamate for 
180min (Fig. 3.5A) 6-NBDG uptake increased 2.09 fold ± 0.144 (p<0.01) and 3.06 
fold ± 0.197 (p<0.001) after 360min. The uptake of 6-NBDG induced by glutamate 
was completely blocked by ouabain, a Na+/K+ ATPase inhibitor, at all 3 time points 
with most significant difference at 360min (glutamate: 3.06 fold ± 0.197; 
glutamate/ouabain: 1.31 fold ± 0.07, p<0.001). Similarly treatment with cytochalasin 
B, a potent inhibitor of GLUT1 and GLUT4 mediated glucose uptake, blocked the 
uptake of 6-NBDG at all time points (Fig. 3.5A). At 360 minutes uptake of glucose in 
cultures with glutamate was increased 3.06 fold ± 0.197 whilst treatment with 
glutamate and cytochalasin B only increased 1.83 fold ± 0.13, p<0.01.  Similar results 
were also obtained in pure astrocyte cultures, with glutamate significantly increasing 
6-NBDG uptake and ouabain and cytochalasin B inhibiting uptake (Fig. 3.5B). 
 
3.3.3 Hypoglycaemia and neuromodulators stimulate turnover of glycogen 
and production of lactate 
 
Lactate release and glycogen levels were measured under hypoglycaemic 
conditions. In order to block glycogen breakdown, cells were also treated with 1,4-
dideoxy-1,4-imino-d-arabinitol (DAB), a selective inhibitor of glycogen phosphorylase. 
Under hypoglycaemic conditions (Fig. 3.6A), cultures released significant amounts of 
lactate (60min: 0.25 ± 0.03, p<0.01; 180min: 0.42 ± 0.05mM, p<0.01) in comparison 
to undetectable levels at time 0 min. In addition, glycogen levels were decreased to 
90.62 ± 2.33% at 60min, p<0.05 and 74.23 ± 4.48% at 180min, p<0.01 (Fig. 3.6B) 
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compared with the control at 0min. DAB treatment reduced the release of lactate in 
comparison to cell without DAB treatment but the decrease was only significant at 
180min (0.24 ± 0.02, p<0.05). Breakdown of glycogen was completely blocked by 
DAB treatment (60min: 102.57 ± 1.28%, p<0.05; 180min: 103.27 ± 0.025%, p<0.01) 
in comparison to cells without DAB treatment.  
 
Treatments with known modulators of glycogen phosphorylase, dbcAMP and the β1 
and β2 adrenergic agonist isoproterenol induced a significant decrease in glycogen 
levels in comparison to non-treated control (dbcAMP: 70.72 ± 2.92%, p<0.001; 
isoproterenol: 77.43 ± 1.54%, p<0.001) (Fig. 3.7B). In comparison, lactate levels 
following exposure to dbcAMP did not show any significant increase (control: 0.77 ± 
0.05mM; dbcAMP: 0.83 ± 0.06mM) whilst isoproterenol treatment resulted in a 
significant decrease in lactate levels to 0.42 ± 0.03mM, p<0.01 in comparison to 
control at 0.77 ± 0.05mM (Fig. 3.7A). 
 
3.3.4 Glutamate and potassium stimulate glycogen breakdown and lactate 
production in NT2.N/A co-cultures 
 
In order to investigate activation of the Na+/K+ ATPase by glutamate, cultures were 
exposed to glutamate in the presence and absence of ouabain (Fig. 3.8). The 
treatment of the cultures with glutamate increased the lactate levels (1mM glutamate: 
0.26 ± 0.01mM p<0.05) but the increase was only significant at the higher 
concentration of glutamate (Fig. 3.8A). Incubation with both 1mM glutamate and 
ouabain blocked the release of lactate (1mM glutamate: 0.26 ± 0.01mM; 1mM 
glutamate + ouabain: 0.18 ± 0.02mM, p<0.01) and reduced the values to control 
levels (control: 0.21 ± 0.01mM).  
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Figure 3.5 Glutamate stimulates uptake of fluorescent glucose analogue 6-
NBDG. A) NT2/D1 derived neuron and astrocyte co-cultures and B) pure 
astrocytes.   The uptake of 300µM 6NBDG was measured using a fluorescent plate 
reader measured at 60, 180 and 360 minutes.  The uptake was measured in the 
presence of glutamate with and without oubain or cytochalasin B.  Results are 
expressed as the mean fold change ± SEM (n=3). p<0.05 (*), p<0.01 (**), p<0.001 
(***). 
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Figure 3.6 Effects of hypoglycaemia on lactate and glycogen levels. Neuron and 
astrocyte co-cultures were starved of glucose for 60 and 180 min in the 
presence/absence of DAB and assayed for A) production of lactate and B) glycogen 
turnover. Results are expressed as A) the mean ± SEM (n=3) and B) the mean 
percentage of control at time 0 ± SEM (n=3). p<0.05 (*), p<0.01 (**), p<0.001 (***). 
ND = not detected. 
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Figure 3.7 Effects of neuromodulators on lactate and glycogen levels. Neuron 
and astrocyte co-cultures were treated with dbcAMP and the β1 and β2 adrenergic 
agonist isoproterenol for 180min and assayed for A) production of lactate and B) 
glycogen breakdown. Results are expressed as A) the mean ± SEM (n=3) and B) the 
mean percentage of non-treated control ± SEM (n=3). p<0.05 (*), p<0.01 (**), 
p<0.001 (***). 
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Treatment with 0.5mM glutamate with or without ouabain demonstrated similar 
results (p<0.01). In addition, treatment with glutamate caused a significant 
breakdown of glycogen (1mM glutamate: 76.75 ± 2.36, p<0.01; 0.5mM glutamate: 
81.73 ± 1.82%, p<0.05).  This effect was completely blocked by ouabain (0.5mM 
glutamate + ouabain: 99.4 ± 3.04%, p<0.01; 1mM glutamate + ouabain: 99.12 ± 
4.74%, p<0.05) (Fig. 3.8B).  
 
To determine whether the effect seen in NT2/D1 neuron and astrocytes cultures was 
mediated by glutamate transporters and not glutamate receptors (Pellerin and 
Magistretti, 1994), cells were exposed to glutamate in the presence of DL-threo-β-
benzyloxyaspartic acid (TBOA), a potent glutamate transport inhibitor (Fig. 3.9). In 
Fig. 3.9A it is clear that TBOA treatment blocks the release of lactate (1mM 
glutamate: 0.4 ± 0.01mM; 1mM glutamate and TBOA: 0.23 ± 0.01mM, p<0.001), 
reducing the levels to those of the control (control: 0.29 ± 0.02mM). Glycogen 
breakdown in response to glutamate was also attenuated (1mM glutamate: 76.75 ± 
2.36%; 1mM glutamate and TBOA: 96.16 ± 2.83%, p<0.01) (Fig. 3.9B). Similar 
inhibition was also seen with lower concentrations of glutamate (p<0.001). 
 
Potassium has also been shown to directly activate Na+/K+ ATPase (Bittner et al., 
2011). The levels of lactate following treatment with ouabain only were actually 
decreased, suggesting a block of a basal Na+/K+ ATPase activity (control: 0.66 ± 
0.01mM; ouabain: 0.5 ± 0.01mM, p<0.05) (Fig. 3.10A). Treatment with potassium at 
both 15 and 60mM triggered a significant increase in lactate (60mM potassium: 0.77 
± 0.05mM, p<0.001; 15mM potassium: 0.86 ± 0.02mM, p<0.01).  This effect was 
completely inhibited in the presence of ouabain (60mM potassium + ouabain: 0.52 ± 
0.01mM, p<0.001; 15mM potassium + ouabain: 0.57 ± 0.04mM, p<0.001) (Fig. 
3.10A). 
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Figure 3.8 Effects of glutamate on neuron and astrocytes co-cultures. Co-
cultures were treated with glutamate for 60min in the presence/absence of ouabain 
and assayed for A) production of lactate and B) glycogen turnover. Results are 
expressed as A) the mean ± SEM (n=3) and B) the mean percentage of non-treated 
control ± SEM (n=3). p<0.05 (*), p<0.01 (**), p<0.001 (***). 
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Figure 3.9 Effects of glutamate on neuron and astrocytes co-cultures. Co-
cultures were treated with glutamate for 60min in the presence/absence of TBOA and 
assayed for A) production of lactate and B) glycogen breakdown. Results are 
expressed as A) the mean ± SEM (n=3) and B) the mean percentage of non-treated 
control ± SEM (n=3). p<0.05 (*), p<0.01 (**), p<0.001 (***). 
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In addition, glycogen levels were significantly reduced following treatment with 
potassium (60mM potassium: 83.25 ± 0.62%, p<0.001, 15mM potassium: 86.28 ± 
0.54%, p<0.01).  This effect was completely blocked with oubain (60mM potassium + 
ouabain: 100.6 ± 2.12%, p<0.001; 15mM potassium + ouabain: 98.29 ± 0.74%, 
p<0.05) (Fig. 3.10B). 
 
3.3.5 NT2.N/A network activity induces glycogen turnover and lactate 
production 
 
In order to investigate whether neuronal activity triggers the breakdown of glycogen 
and release of lactate in NT2.N/A cultures, the cells were stimulated electrically for 
30 minutes in the presence and absence of TBOA (Fig. 3.11). Following electrical 
stimulation, the levels of lactate in the media were significantly increased (0.67 ± 
0.04mM p<0.01) in comparison with control (0.36 ± 0.03mM) (Fig. 3.12A). In addition, 
glycogen levels inside the cells were significantly decreased (77.977 ± 3.62%, 
p<0.01) (Fig. 3.12C). These effects were completely blocked following treatment with 
TBOA (Fig. 3.12B and 3.12C). After pre-treatment of cells with TBOA for 15min and 
electrical stimulation in the presence of TBOA, lactate levels were slightly reduced 
(control: 0.69 ± 0.04mM; stimulation/TBOA: 0.53 ± 0.05mM) although the decrease 
was not significant. Glycogen breakdown was also blocked (stimulation: 77.98 ± 
3.62%; stimulation/TBOA: 109.31 ± 2.9%, p<0.001) and the levels remained similar 
to the control. 
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Figure 3.10 Effects of potassium on neuron and astrocyte co-cultures. Co-cultures 
were treated with potassium for 60min in the presence/absence of ouabain and 
assayed for A) production of lactate and B) glycogen breakdown. Results are 
expressed as A) the mean ± SEM (n=3) and B) the mean percentage of non-treated 
control ± SEM (n=3). p<0.05 (*), p<0.01 (**), p<0.001 (***). 
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Figure 3.11 Schematic diagram of the experimental protocol for electrical 
stimulation. 
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Figure 3.12 Effects of induced network activity on glycogen turnover and lactate 
production in neuron and astrocyte co-cultures. Production of lactate (A,B) and 
breakdown of glycogen (C) were measured in response to high frequency electrical 
activity in the presence and absence of TBOA. Results are expressed as A) the 
mean ± SEM (n=3) and B) the mean percentage of non-treated control ± SEM (n=3). 
p<0.05 (*), p<0.01 (**), p<0.001 (***). 
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3.4 Discussion 
 
 glucose uptake glycogen breakdown lactate production 
glutamate é  ê  é  
potassium  ê  é  
hypoglycaemia  ê  é  
dbcAMP  ê  = 
isoproterenol  ê  ê  
electrical 
stimulation  ê  é  
ouabain ✕  ✕  ✕  
DAB  ✕  ✕  
TBOA  ✕  ✕  
cytochalasin B ✕    
 
Figure 3.13 Summary table of chapter 3 results. é = increase; ê = decrease; 
✕ = block;  = no change 
  
 
The astrocyte-neuron lactate shuttle (ANLS) was first proposed by Pellerin and 
Magistretti (1994) and has since been extensively studied. Experiments supporting 
ANLS have been carried out using brain slices, cultured primary neurons and 
astrocytes as well as isolated nerves and sympathetic ganglia from rat, mouse and 
chick (Pellerin, 2003). To the author’s knowledge, these experiments have never 
been carried out on human stem cell derived cultures.  Human studies have been 
limited to brain imaging techniques such as nuclear magnetic resonance 
spectroscopy (NMR), Positron Emission Tomography (PET) or functional Magnetic 
Resonance Imaging (fMRI) (Bouzier-Sore et al., 2003a, Bonvento et al., 2005).  
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Work in our laboratory has previously demonstrated that neuronal networks derived 
from NT2 cells signal to astrocytes, and that astrocytic networks communicate via 
gap junction mediated and gliotransmitter signalling (Hill et al., 2012).  The results of 
this study show for the first time that human stem cell derived astrocytes synthesize 
glycogen and respond to classical neuromodulators that can induce glycogenesis 
and glycogenolysis in these cells as well as induce glucose uptake and lactate 
production. 
 
In the NT2.N/A co-cultures, neurons and astrocytes display distinct differences in 
glycogen localization. The periodic acid-Schiff stain was co-localized with GFAP 
positive cells, while cells that stained for β-tubulin demonstrated no glycogen 
staining. The presence of glycogen as well as markers associated with its 
metabolism would suggest that these cells are well differentiated and resemble 
mature astrocytes (Brunet et al., 2010).  
 
The importance of glucose utilization in astrocytes has been supported by 
experiments using radiolabelled and fluorescent deoxyglucose analogues (Pellerin 
and Magistretti, 1994, Barros et al., 2009a). Experiments presented here using 6-
NBDG, show that NT2.N/A cultures respond to glutamate by increasing glucose 
uptake, an effect that was blocked by both cytochalasin B and ouabain in a manner 
previously shown in mouse cerebral cortical astrocytes (Pellerin and Magistretti, 
1994) as well as rat neuronal and astrocytic cells (Hara et al., 1989, Roeder et al., 
1985). However it should be noted that cytochalasin B, in addition to blocking 
glucose transport, also inhibits rate of actin polymerization and interaction of actin 
filaments (MacLean-Fletcher and Pollard, 1980). This can further lead to inhibition of 
transport of proteins and nucleotides (Plagemann and Estensen, 1972) as well as 
inhibition of cytokinesis (Carter, 1967) and  a reduction in cell motility (Hosaka et al., 
1980). The cells treated with cytochalasin B should therefore be assessed for any 
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toxicity caused by the compound. 
 
The activation of the Na+/K+ ATPase enhances ATP utilization, which in turn 
stimulates glucose uptake and aerobic glycolysis which results in increased lactate 
production (Pellerin and Magistretti, 1994). Lactate production in astrocytes occurs 
not only as a part of the glycolytic part of glucose degradation but also during 
breakdown of glycogen (Dringen et al., 1993a) which is stimulated during brain 
activation and hypoglycaemia (Swanson et al., 1992, Swanson, 1992b, Cruz and 
Dienel, 2002).   
 
In this study, hypoglycaemic conditions induced glycogenolysis in NT2.N/A cells as 
well as increased the production and release of lactate. This response was 
completely blocked by a known inhibitor of glycogen phosphorylase, 1,4-dideoxy-1,4-
imino-d-arabinitol (DAB) (Walls et al., 2008). These results together with glycogen 
staining suggest that NT2.A cells possess the machinery required for glycogen 
synthesis and glycogen breakdown.  
 
ANLS experiments have previously shown that glutamate stimulates glucose 
utilization and that this effect is not receptor mediated, as various glutamate receptor 
agonists and antagonists have no effect on hexose sugar usage (Pellerin and 
Magistretti, 1994).  
 
NT2.N/A cells also demonstrate an increase in lactate production following treatment 
with both glutamate and potassium. This lactate increase was accompanied by a 
decrease in glycogen levels, suggesting that NT2 astrocytes respond to glutamate 
and potassium not only by increasing glucose uptake but also by degrading glycogen 
as demonstrated in vivo and in primary cultures (Hof et al., 1988, Swanson, 1992b, 
Swanson et al., 1992, Cruz and Dienel, 2002) 
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Figure 3.14 Schematic diagram of regulatory factors of ANLS, glycolysis and 
glycogenolysis. Neuromodulators and inhibitors that were used to investigate ANLS 
in NT2.N/A cocultures are highlighted. 
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Previous studies have shown that glutamate transport activates the Na+/K+ ATPase 
(Pellerin and Magistretti, 1997, Chatton et al., 2000), specifically mobilizing the α2 
subunit of Na+/K+ ATPase, which co-localizes and interacts with glutamate 
transporters (Cholet et al., 2002, Rose et al., 2009, Gegelashvili et al., 2007). 
Additional evidence in support of the glutamate induced Na+/K+ ATPase activation 
comes from studies, which have used ouabain, a specific Na+/K+ ATPase inhibitor. 
The use of ouabain completely inhibited the glutamate stimulated glucose uptake 
(Pellerin and Magistretti, 1997). 
 
In NT2.N/A cells, the glutamate and potassium-induced lactate production and 
glycogen breakdown were both inhibited by ouabain and glutamate-induced lactate 
production was also blocked using TBOA. These results provide further evidence for 
the existence of a functional astrocyte-neuron lactate shuttle and activity of NA+/K+ 
ATPase triggered by glutamate uptake in NT2.N/A cultures. 
 
Experiments involving treatments of the co-cultures with dbcAMP and β1 and β2 
adrenergic agonist isoproterenol demonstrated a decrease in glycogen load in the 
cells. dbcAMP, one of cAMP derivatives, activates glycogen phosphorylase through 
activation of protein kinase A leading to glycogen breakdown (Boer and Sperling, 
2004). NA acts in a similar way, by elevating levels of cyclic AMP which in turn 
activates protein kinase A (Sorg and Magistretti, 1992).  Interestingly, although 
isoproterenol increased glycogen turnover in these cultures there was a decrease the 
level of lactate in the media. At the same time dbcAMP also decreased glycogen 
levels but failed to increase lactate levels in the media samples. This is a suprising 
result as both substances act through activation of protein kinase A. However, both 
dbcAMP and isoproterenol have been shown to stimulate glycolysis and it is possible 
that pyruvate produced has been utilised in TCA cycle instead of lactate production 
(Auffermann et al., 1992, Suemori, 1975). Additionally, it has previously been shown 
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that NA enhances the expression of MCT2 in cortical neurons (Chenal and Pellerin, 
2007). As such, it can be hypothesized that the lactate produced by the increase in 
glycogen metabolism may have been taken up by neurons due to increased MCT2 
expression. Future studies will determine the dynamics of this change in expression 
in pure neuronal cultures. 
 
The effect of neuronal activity on the lactate shuttle and glycogen utilization was 
investigated using electrical stimulation. After 30 minutes, glycogen levels 
significantly decreased whilst lactate levels increased. This suggests that lactate is 
released in response to neuronal activity. It has previously been shown in rat optic 
nerve preparations, that when cultured in glucose deprived aCSF, astrocytic 
glycogen was used as the primary source of lactate.  Indeed, glycogen depletion in 
these cultures led to a failure in compound action potential (CAP) generation 
(Wender et al., 2000). In this study, stimulation-induced glycogen breakdown was 
blocked by administration of TBOA, an inhibitor of the glutamate transporter. These 
results indicate that activity-induced neuronal glutamate release and subsequent 
astrocyte uptake, were capable of inducing glycogen breakdown and lactate 
production. 
 
Glycolysis and glycogenolysis are important processes in normal functioning of the 
brain but also in a number of disease processes such as ischaemia (Lowry et al., 
1964) hypoglycaemia (Gruetter, 2003) and Alzheimer’s (Allaman et al., 2010).  This 
study demonstrates for the first time the metabolic coupling of neurons and 
astrocytes in a human derived stem cell model.  This has important implications in 
the study of memory formation, plasticity, and neurodegeneration in vitro. This model 
may facilitate the future study of the active role and emerging understanding of the 
contribution of astrocytes in brain function as well as in neurodegenerative 
conditions, such as Alzheimer’s disease. It is especially important as changes in 
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brain metabolism are one of the first signs of Alzheimer’s Disease and appear 
decades before any other symptoms (Reiman et al., 2004, Mosconi et al., 2008b, 
Mosconi et al., 2009b). As such understanding of Aβ-associated metabolic changes 
in a human model of the disease may provide important insight into the disease 
process. 
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Chapter 4: Metabolism in Alzheimer’s Disease 
4.1 Introduction 
 
Changes in brain metabolism during ageing and Alzheimer’s Disease have been 
extensively studied for the past 30 years (Cunnane et al., 2011). It is now widely 
accepted that AD is accompanied by brain hypometabolism that varies between 
different regions of the brain. A decline in glucose utilization in the brain as well as 
mitochondrial function appear decades before any symptoms or histopathological 
changes occur, making it a useful biomarker of AD (Mosconi et al., 2008a, Mosconi 
et al., 2009a, Mosconi et al., 2009b, Reiman et al., 2004). Some of the evidence from 
kinetic FDG-PET studies suggests that hypometabolism is accompanied by a 
reduction in the rate of glucose transport (25%) and phosphorylation (23%-36%) 
(Mosconi et al., 2007).  
 
Disturbances in brain metabolism could have long term adverse effects on the 
performance and survival of brain cells. Hypometabolism could also lead to 
decreased production of acetyl-coenzyme A (CoA) and ATP as well as acetylcholine 
which depends on availability of acetyl-coenzyme A and insulin (Cunnane et al., 
2011). As impairment of cholinergic neurotransmission is one of the hallmarks of AD 
(Sims et al., 1983, Sims et al., 1981), hypometabolism would offer an interesting 
explanation. A reduction in ATP could also lead to damage in the ER and Golgi/trans-
Golgi network resulting production of misfolded proteins. Energy deprivation could 
further lead to the induction of BACE1 (Velliquette et al., 2005, O'Connor et al., 
2008), which would lead to an increase in Aβ(1-42) levels linking hypometabolism to 
the amyloid cascade.  
 
Of particular interest in this process is the depletion of key metabolic intermediates 
such as nicotinamide adenine dinucleotide (NAD+), which is essential for oxidative 
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phosphorylation-derived ATP. Depletion of NAD+ could be caused by oxidative stress 
as well as the action of enzymes that require it as a substrate such as poly (ADP-
ribose) polymerase (PARP) (Braidy et al., 2008, Alano et al., 2010). Another 
contributing factor of the energy deficit could be a decrease in activities of important 
glycolytic enzymes such as hexokinase or phosphofructokinase (Liguri et al., 1990, 
Sims et al., 1987) as well as enzymes of TCA cycle and oxidative phosphorylation 
such as pyruvate dehydrogenase (Yao et al., 2009), α-ketoglutarate dehydrogenase 
(Gibson et al., 1998) and cytochrome c oxidase (Yao et al., 2009). 
 
4.1.1  Hypometabolism in AD 
 
The cerebral metabolic rate of glucose (CMRg) in a healthy adult brain is 6-
7mg/100g/min (Owen et al., 1967). The most widely used technique to study brain 
metabolism is Positron Emission Tomography (PET) using a tracer called [18F]-
fluorodeoxyglucose (FDG). This tracer is able to mimic both glucose transport as well 
as phosphorylation (Phelps et al., 1979). FDG can be phosphorylated by hexokinase 
however it cannot be further metabolized (Cunnane et al., 2011). As PET has 
relatively poor spatial resolution, it is often combined with magnetic resonance 
imaging (MRI) or computed tomography (CT). This allows investigation of regional 
CMRg in specific areas of the brain (Cunnane et al., 2011).  
 
FDG-PET studies of patients with AD have shown a progressive reduction in CMRg, 
which correlates with severity of the symptoms and cognitive performance (Mosconi, 
2005). In addition, multiple studies have shown that in comparison with healthy age-
matched controls, individuals with AD display a reduction in regional CMRg levels in 
parieto-temporal and posterior cingulate cortices (PCCs) as well as frontal areas in 
advanced disease (Friedland et al., 1983, Minoshima et al., 1997, Foster et al., 
1984). Abnormalities in CMRg in medial temporal lobes (MTL: the hippocampus, 
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transentorhinal and entorhinal cortices, and parahippocampal gyrus) have been 
recently reported in studies that have used more sensitive PET equipment with 
higher spatial resolution (Mosconi et al., 2008a, Mosconi et al., 2007, Mosconi et al., 
2006a, de Leon et al., 2001, Nestor et al., 2003). 
 
One obvious explanation for a decrease in glucose utilization could be neuronal loss, 
which is one of the hallmarks of AD. However, many studies have shown a reduction 
in CMRg before the onset of the disease, in individuals at risk of developing AD such 
as APOE4 carriers, individuals carrying autosomal dominant mutations that are 
responsible for familial AD (FAD) or patients with mild cognitive impairment (MCI) 
(Mosconi et al., 2008b). 
 
4.1.1.1 Familial AD (FAD) 
 
Studies involving patients with FAD are very limited. Kennedy et al. (Kennedy et al., 
1995) showed that presymptomatic FAD individuals have lower CMRg levels than 
age controls but higher than symptomatic FAD patients, suggesting a progression in 
CMRg impairment with the progression of the disease (Kennedy et al., 1995). 
However, as individuals in this study showed a substantial volume loss of the brain, it 
was not clear whether the decrease in CMRg was significant. A further study by 
Mosconi et al. (2006b) examined individuals with the PS1 mutation from families with 
FAD (on average 13 years before estimated disease onset). CMRg levels and 
volumes in several brain regions including hippocampus, entorhinal cortices (EC), 
posterior cingulate cortices (PCC), parietal and temporal cortices and the whole brain 
were measured in patients with FAD and controls. A significant decrease in CMRg 
was seen in all the regions whilst volume reductions were only found in the parietal 
cortex. CMRg was reduced by 12% in hippocampus and 20% in EC. Based on these 
results the authors concluded that FAD presymptomatic patients show widespread 
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CMRg reduction in the brain regions which typically show hypometabolism in 
symptomatic AD patients (Mosconi et al., 2006b). 
 
4.1.1.2 APOE4 carriers 
 
FDG-PET studies on individuals carrying APOE4 allele showed CMRg reduction in 
the same regions affected in AD which included posterior cingulate, parietal, 
temporal and prefrontal regions (Small et al., 1995, Reiman et al., 1996, Small et al., 
2000, Reiman et al., 2001, Reiman et al., 2004, Reiman et al., 1998). However, the 
hypometabolism was not as severe as that seen in AD. In middle-aged APOE4 
carriers hypometabolism was gradual and associated with cognitive performance 
(Small et al., 1995, Reiman et al., 2001). Studies on presymptomatic carriers of 
APOE4 allele aged 50-63 showed a greater reduction in CMRg (25%) than in healthy 
controls over time period of 2 years (Reiman et al., 2001). 
 
4.1.1.3 Mild Cognitive Impairment (MCI)   
 
MCI is widely accepted as an intermediate state between healthy ageing and AD 
(Mosconi et al., 2008b). Indeed, MCI individuals are also at higher risk of developing 
AD (Petersen et al., 2001, Gauthier et al., 2006). It is defined as a state where 
individuals are able to perform normal activities of a daily life but suffer memory loss, 
which isolates them or other difficulties which exceed those of normal ageing 
(Mosconi et al., 2008b).  
 
MCI patients show mild global and regional hypometabolism in the same brain 
regions as AD patients (Mosconi et al., 2008a, Minoshima et al., 1997, De Santi et 
al., 2001, Nestor et al., 2003, Mosconi et al., 2006a, Drzezga et al., 2003, Drzezga et 
al., 2005), although the regional CMRg levels are more variable and are associated 
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more with cognitive abnormalities of individual subjects (Anchisi et al., 2005, Haxby 
et al., 1990). CMRg decreases in the hippocampus are found among most MCI 
patients while hypometabolism in cortices is more diverse (de Leon et al., 2001, 
Mosconi et al., 2008a, De Santi et al., 2001, Mosconi et al., 2006a). Longitudinal 
FDG-PET studies showed that CMRg reduction is more pronounced in patients with 
MCI that eventually develop AD than in those that do not. The accuracy of the 
prediction varies from 75% to 100% (Minoshima et al., 1997, Herholz et al., 1999, 
Arnaiz et al., 2001, Chetelat et al., 2003, Drzezga et al., 2005, Anchisi et al., 2005) 
 
4.1.1.4 Ageing 
 
FDG-PET studies in normal ageing showed a mild CMRg reduction, which mainly 
involved frontal regions (de Leon et al., 2001, Mosconi et al., 2008a, Herholz et al., 
2002). Only a few studies have monitored progression from normal ageing to MCI 
and MCI to dementia (Mosconi et al., 2008a, Jagust et al., 2006). One such study 
has shown that a reduction in CMRg in EC can predict progression to MCI within 3 
years with sensitivity of 83% and specificity 85% (de Leon et al., 2001). Reduction in 
CMRg in EC, hippocampus and lateral temporal cortex has been found during the 
progression to MCI and the reduction was found to be significant even after 
correction for volume loss (de Leon et al., 2001). Further studies have addressed the 
question as to whether these reductions were related to development of AD. In a 
study by Mosconi et al. (2008a) elderly patients were followed for between 6-14 
years. Over this time course, 11 of these patients developed dementia, 6 of whom 
were diagnosed with AD and 19 developed MCI. The reduction in CMRg in the 
hippocampus was the only regional predictor of future cognitive decline (predicting a 
decline from normal to AD with 81% accuracy, from normal to dementia with 77% 
and from normal to MCI with 71% accuracy). Overall these studies provided direct 
evidence of a progression in hypometabolism which originates in MTL during normal 
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ageing and then progresses to PCC at the MCI stage and spreads to parieto-
temporal cortices in AD (Mosconi et al., 2008a). 
	  
4.1.2 Mitochondrial changes 
 
The main risk factor for AD is age and it is important to investigate common 
pathological mechanisms shared by normal ageing and in disease. As 
hypometabolism is the earliest change seen in AD, it indicates that changes in 
energy metabolism are not just a consequence of neuronal loss but they contribute to 
the development and progression of the disease (Yap et al., 2009).  
The energy required for cell functioning in the majority of eukaryotic cells is 
generated by mitochondria during oxidative phosphorylation. Mitochondria play many 
important roles such as energy production, calcium homeostasis, apoptosis and 
cellular signalling through generation of oxidants such as hydrogen peroxide (H2O2) 
(Cadenas, 2004). Mitochondrial dysfunction has been implicated in normal ageing as 
well as many diseases (Storz, 2006). It has been well documented that gradual 
decline in the energetics of mitochondria i.e. production of ATP as well as an 
increase in production of oxidants and oxidative stress are characteristic of ageing 
and age related neurodegeneration (Mattson and Magnus, 2006, Navarro and 
Boveris, 2007, Boveris and Navarro, 2008, Rebrin et al., 2003, Butterfield et al., 
1999, Calabrese et al., 2006).  
 
In addition, a pro-oxidizing shift in glutathione status has been associated with ageing 
in humans and rodents (Rebrin et al., 2003, Jones et al., 2002). Longitudinal studies 
on humans aged 19-85 have demonstrated a chronic increase in oxidative stress 
throughout adulthood (Jones et al., 2002). Indeed, studies have shown a decrease in 
GSH levels and an increase in GSSG levels in AD patients (Calabrese et al., 2006), 
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which was also reflected by increased glutathionylation of proteins in AD brains 
(Newman et al., 2007).  
 
It has been suggested that an age related decline in energy metabolism and the 
redox status of the cell should be viewed as interdependent (Yap et al., 2009). This is 
reflected in the ‘so called’ mitochondria energy – redox axis. The energy component 
includes the entry of glycolytic substrates into the TCA cycle and generation of 
reducing equivalents (NADH, FADH2). The redox component includes mitochondrial 
redox indicators such as glutathione (GSH/GSSG), thioredoxin (Trx(-SH)/Trx-SS), 
glutaredoxin (Grx) and peroxiredoxins (Prx) and therefore mechanisms dependent on 
flux of NADPH. NADPH is generated by a reduction of NADP+ by NADH in 
mitochondria as well as during pentose phosphate pathway when NADP+ is reduced 
to NADPH. A decrease in energy production in the mitochondria would impact redox 
balance in the cell and vice versa.  In addition, altered redox status in the cell could 
lead to post-translational modifications of proteins involved in metabolism (Yap et al., 
2009). 
 
4.1.2.1 Oxidative Phosphorylation 
 
During oxidative phosphorylation NADH produced in TCA cycle is oxidized by the 
mitochondrial electron transport chain (ETC). It has been estimated that the terminal 
electron acceptor, cytochrome oxidase, uses up 95% of oxygen consumed by 
mammalian cells (Yap et al., 2009). As electrons flow through complexes of ETC, 
protons are transported across the inner mitochondrial membrane generating energy. 
The protons then flow back through ATP synthase (complex V), which uses the 
energy to generate ATP from ADP (Nicholls, 2002, Navarro and Boveris, 2007).  
 
The effects of ageing on respiration are more pronounced in tissues composed of 
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post-mitotic cells such as brain, heart and skeletal muscles. Most tissues have a 
constant requirement for ATP, however muscles and neurons have very high and 
variable demand for ATP (Nicholls, 2002). It has been shown that activities of 
complexes I, III and IV decrease with age in mitochondria isolated from brain tissue 
(Navarro and Boveris, 2007). Decrease in activities of these complexes is further 
associated with morphological changes in mitochondria. This ultimately leads to 
neurons being unable to produce ATP during increased energy demand (Navarro 
and Boveris, 2004) 
 
4.1.2.2 TCA cycle 
 
The tricarboxylic acid cycle (TCA) in its most simple form involves a series of 
reactions in which the products of glycolysis are oxidized to generate reducing 
equivalents, NADH and FADH2 (Nelson and Cox, 2005). NADH donates electrons for 
complex I during oxidative phosphorylation and is also important in the generation of 
NADPH, by reduction of NADP+ by either NADP+ dehydrogenase or NADP+ 
transhydrogenase. NADPH is the only electron source for regeneration of glutathione 
and thioredoxin (Rydstrom, 2006). 
 
The activities of several enzymes essential for the TCA cycle and NADH production 
have been shown to be decreased in ageing and AD. Activities of aconitase, α-
ketoglutarate dehydrogenase (αKGDH) and pyruvate dehydrogenase have all been 
shown to decrease in ageing (Zhou et al., 2009).  In addition, a decline in activities of 
α-ketoglutarate dehydrogenase (αKGDH) and pyruvate dehydrogenase (PDH) have 
been associated with AD (Gibson et al., 2000). It has been previously shown that 
aconitase and αKGDH are susceptible to H2O2 levels. In the presence of H2O2 the E2 
subunit of αKGDH has been shown to be glutathionylated which leads to decreased 
activity (Nulton-Persson et al., 2003, Applegate et al., 2008). A reduction in αKGDH 
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activity is associated with a decrease in the production of NADH during oxidative 
stress due to inability to utilize glutamate in TCA cycle (Tretter and Adam-Vizi, 2000). 
Any changes in the activity of TCA enzymes could lead to a decrease in NADH levels 
which results in decreased oxidative phosphorylation as well as a reduction in the 
NADPH pool (Yap et al., 2009). 
 
Succinyl-CoA: 3-oxoacid Co-A transferase (SCOT) a mitochondrial matrix enzyme 
important for ketolysis is also reduced during ageing. Ketone bodies are the only 
alternative source of energy for the brain during hypoglycaemia. As such, a decrease 
in SCOT activity during ageing further increases brain sensitivity to energy deficits 
(Yap et al., 2009).  
 
An overall decline in the activities of enzymes involved in acetyl-CoA production 
(PDH and SCOT) as well as TCA cycle enzymes such as αKGDH can lead to a 
decrease in ATP production as well as affecting the redox balance within the cell 
(Yap et al., 2009). 
 
4.1.3 ROS and antioxidants 
 
Reactive oxygen species (ROS) are generated constantly during oxidative 
phosphorylation (Dringen et al., 2000). They include inorganic molecules such as 
superoxide radical anion, H2O2 and hydroxyl radicals but also organic molecules 
such as alkoxyl and peroxyl radicals. ROS can cause damage to the cell such as 
DNA strand breaks, lipid peroxidation and protein modification. To avoid such 
damage cells have developed mechanisms to prevent generation of ROS or to limit 
the effect of its damage (Dringen et al., 1993a). These include thiol/disulfide redox 
buffers and the H2O2 removal system.   
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The thiol/disulfide exchange involves glutathione, thioredoxin and related enzymes 
and is important in maintaining redox status of the cell as well as the NADPH pool 
(Yap et al., 2009). 
 
Glutathione (GSH) is synthesized in the cytosol by the consecutive action of two 
enzymes, γ-glutamylcysteine (γGluCys) and glutathione synthetase. The former 
enzyme uses glutamate and cysteine as substrates and produces the dipeptide 
γGluCys, the latter enzyme combines γGluCys with glycine to produce GSH (Dringen 
et al., 2000). GSH is present at high levels (~5-10mM) in most cell compartments 
and it has been found to quickly equilibrate between the mitochondria and cytosol 
although the exact mechanism of its transport is not well known (Hurd et al., 2005). 
GSH plays an important role in the removal of H202 generated during oxidative 
phosphorylation. GSH is oxidized to GSSG via a direct reaction of thiol group with 
H202. GSSG is then reduced back to GSH by action of glutathione reductase, an 
enzyme which requires NADPH (Han et al., 2006, Dalle-Donne et al., 2008). Under 
normal conditions GSSG levels are very low, at about 1/100th of the total GSH pool 
(Schafer and Buettner, 2001) (Fig. 4.1).  
 
One of the consequences of altered GSH/GSSG redox status is the formation of 
protein mixed disulfides (glutathionylation). However, cells possess enzymes which 
are able to reduce protein disulfides or glutathionylated proteins such as glutaredoxin 
(Grx2) (Dalle-Donne et al., 2008).  
 
4.1.3.1 ROS formation  
 
As mentioned in section 4.1.2.1 and 4.1.2.2, several enzymes involved in TCA cycle 
and oxidative phosphorylation have been found to have decreased activities in AD 
brain. These include αKGDH and PDH (Gibson et al., 2000). As these enzymes are 
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involved in reduction of molecular oxygen, their decreased activity would increase 
production of ROS, specifically superoxide (Zhu et al., 2005). 
 
 
 
 
 
 
 
Figure 4.1 Schematic diagram showing removal of H202 by GPx and recycling of 
GSH from GSSG by GR.  
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Superoxide is normally converted to H2O2 via the action of Superoxide Dismutase 1 
(SOD1) or 2 (SOD2). Indeed, levels of SOD1 have been found to be elevated in AD 
brains (Serra et al., 2001, Ozcankaya and Delibas, 2002), which together with 
increased O2- levels lead to an increase in concentration of H2O2 (Braidy et al., 2008). 
 
Oxidants produced in mitochondria as a consequence of oxidative phosphorylation 
(O2- and H2O2) have been found to play an important role in signalling pathways (Han 
et al., 2009). Many metabolic pathways are regulated by H2O2 through either 
activation/inhibition of redox-sensitive proteins such as glycogen synthase kinase 
(GSK), protein kinase B (Akt) and c-Jun N-terminal kinase (JNK), or through post-
translational modifications of proteins such as aconitase or PDH. O2- and H2O2 can 
both coordinate responses between cytoplasm and mitochondria. However, during 
ageing and AD ROS production is significantly increased. The increased production 
of O2- and H2O2 has been shown to dysregulate signalling cascades and cause 
damage to lipids, proteins and DNA (Yap et al., 2009). 
 
O2- is a precursor for H2O2 and is converted by Mn-SOD (SOD-2) in the mitochondrial 
matrix or Cu/Zn-SOD (SOD-1) in the cytoplasm (Fernandez-Fernandez et al., 2012). 
However, O2- generated at complex III is released both into the matrix and 
intermembrane space (IMS) where it can modify proteins residing there (Han et al., 
2003b, Han et al., 2001, Han et al., 2003a, Inarrea et al., 2005). 
 
Levels of H2O2 generated in the mitochondria increase with age and changes in 
mitochondria bioenergetics (i.e. NADPH production) may contribute to that increase. 
Glutathionylation of proteins which is a sign of increased ROS production, results in 
an increase in the production of O2- as seen in complex I of liver mitochondria (Taylor 
et al., 2003). Additionally, glutathionylation increases with age and in AD (Dalle-
Donne et al., 2008) and has been associated with further increases in the generation 
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of O2- and H2O2 (Yap et al., 2009). 
 
H2O2 diffusion to the cytoplasm may act as a signal for many processes, which are 
regulated through the activation of cytosolic kinases (Cadenas, 2004). Many 
phosphatases and cytosolic kinases such as members of the insulin pathway, 
glycogen synthase kinase (GSK3β), Akt and JNK as well as members of MAP kinase 
family have been found to localize to mitochondria (Horbinski and Chu, 2005). One of 
the examples is translocation of JNK to mitochondria in response to increased H2O2. 
JNK can further regulate metabolism (Zhou et al., 2008, Nemoto et al., 2000) by 
phosphorylation of proteins in the mitochondrial matrix, as well as membranes such 
as pyruvate dehydrogenase E1 subunit (Schroeter et al., 2003). Phosphorylation of 
PDH leads to a decrease in ATP levels (Zhou et al., 2008) and a decrease in PDH 
activity which is an early event in AD and has been associated with cognitive decline 
(Zhou et al., 2008). 
 
In AD, the increase in ROS has also been suggested to be caused by insertion of 
Aβ(1-42) into neuronal and glial membrane (Butterfield, 1997, Varadarajan et al., 
2000). Additionally, the reduction of metal ions such as Fe2+ in the presence of H2O2 
can result in the production of highly reactive HO which in turn could cause 
significant damage to the cell (Huang et al., 1999). Normally accumulation of metals 
such as Fe2+ is prevented by ferritin and transferrin which bind to them with high 
affinity (Miranda et al., 2000). However, these mechanisms are limited in the brain 
leading to accumulation of Fe2+, thus increasing the risk of metal-induced damage 
(Miranda et al., 2000). Dysfunction of metal homeostasis has been implicated in AD 
(Liu et al., 2006) and elevated levels of Fe2+ have been found in hippocampal 
neurons of AD patients (Smith et al., 1997). 
 
In summary, changes in GSH redox status lead to glutathionylation of proteins such 
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as complex I and the oxidation of proteins. This further increases levels of O2- and 
H2O2, ultimately leading to dysregulation of signaling cascades such as JNK (Navarro 
and Boveris, 2007).    
 
4.1.4 NAD+/NADH and NADP+/NADPH 
 
NAD+, reduced nicotinamide adenine dinucleotide (NADH), nicotinamide adenine 
dinucleotide phosphate (NADP+) and reduced nicotinamide adenine dinucleotide 
phosphate (NADPH) have long been known to play important roles in energy 
metabolism, reductive biosynthesis and antioxidant activity (Belenky et al., 2007, 
Berger et al., 2004, Pollak et al., 2007). NAD+ and NADH are mainly used by 
enzymes to catalyze oxidation, while NADP+ and NADPH to catalyze reduction 
(Pollak et al., 2007). In recent years numerous studies have shown that pyridine 
nucleotides have numerous functions (Belenky et al., 2007, Berger et al., 2004, 
Pollak et al., 2007). They appear to have a role in ageing via NAD+ -dependent 
histone deacetylase i.e. sirtuins (Blander and Guarente, 2004), oxidative cell death 
via poly (ADP-ribose) polymerase-1 (PARP) (Virag and Szabo, 2002, Ying, 2006), 
mobilization of intracellular calcium stores via cyclic ADP-ribose and nicotinic acid 
adenine dinucleotide phosphate (NAADP)  (Lee, 2001) and generation of ROS via 
NADPH oxidase (Bedard and Krause, 2007).  
 
NADPH is formed in mitochondria via three pathways involving NADP+ isocitrate 
dehydrogenase, malic enzymes and nicotinamide nucleotide transhydrogenase 
(NNT) (Ying, 2008). NNT catalyzes the reaction in mitochondria, which includes 
reduction of NADP+ from NADH. This provides an important link between 
bioenergetics and defence against reactive oxygen species (Yap et al., 2009). 
Additionally NNT activity depends on membrane potential of the mitochondria (Yap et 
al., 2009).  
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NADPH is required for regeneration of GSH in mitochondria and therefore is a 
limiting factor of this system (Rydstrom, 2006, Zhang et al., 2007a). In addition, 
decreases in mitochondrial membrane potential caused by a loss of electron flow 
through ETC as well as decreased availability of NADH might affect the conversion of 
NADP+ to NADPH. 
 
4.1.4.1 NAD+ and PARP-1 
 
Low levels of reactive oxygen species are a part of normal metabolism in the cell 
(Ogino and Wang, 2007) and normally they do not exert any harmful effects due to 
the action of antioxidants. However, an increase in oxidative stress such as that seen 
in AD (Mhatre et al., 2004, Moreira et al., 2005, Zhu et al., 2004) and an imbalance 
between production of ROS and antioxidant mechanisms may lead to cell damage. 
An increase in DNA damage induced by oxidative stress is a major factor associated 
with ageing and AD (Nunomura et al., 1999, Braidy et al., 2008). Therefore, it is 
important for the cell to have efficient repair mechanisms (Braidy et al., 2008). NAD+ 
has been shown to have an important role in DNA repair as well as gene signalling 
pathways (Erdelyi et al., 2005, Malanga and Althaus, 2005).  
 
NAD+ was previously identified as a parent compound in the pyridine family (NADH, 
NADP+ and NADPH), which is involved in several metabolic reactions. NAD+ is also 
an electron transporter in oxidative phosphorylation and ATP production, and is 
involved in glutathione and thioredoxin antioxidant systems via NADPH (Braidy et al., 
2008). Recent studies have also shown evidence that NAD+ is important in DNA 
repair and gene silencing (Rafaeloff-Phail et al., 2004). 
 
NAD+ acts as a substrate for the enzyme poly (ADP-ribose) polymerase (PARP). 
PARP-1 is a DNA binding enzyme, which is activated by breaks in DNA caused by 
	  
	  
157	  
ROS and is critical in the base excision repair (BER) process (Bouchard et al., 2003). 
PARP cleaves NAD+ into adenosine 5’- diphosphoribose (ADPR) and nicotinamide 
and then attaches polymers of ADP-ribose to histones and other nuclear proteins (de 
Murcia et al., 1997). 
 
In addition to its role in PARP activation, NAD+ also acts as a substrate for the sirtuin 
family of enzymes (silent information regulators of gene function) (Sauve et al., 
2006). These enzymes has been implicated in cell survival under conditions of stress 
and toxicity as well as longevity (Yang and Sauve, 2006).  
 
During oxidative stress and increased ROS production, rapid NAD+ depletion caused 
by PARP activation can induce a cellular energy ‘crisis’ by reducing ATP synthesis, 
ultimately leading to cell death (Pacher and Szabo, 2007, Pillai et al., 2005, Alano et 
al., 2004, Wang et al., 2003). Excessive activation of PARP can also lead to a 
decreased SIRT1 deacetylase activity through NAD+ depletion. This in turn leads to 
accumulation of acetylated p53 and cell death (Furukawa et al., 2007). It has been 
shown that PARP-1 activation leads to translocation of the mitochondrial permeability 
transition pore (MPTP) (Alano et al., 2004) and apoptosis-inducing factor (AIF) (Yu et 
al., 2002). Multiple protein kinases have been shown to contribute to PARP-1 
mediated cell death including JNK1, which appears to activate PARP-1 by a direct 
phosphorylation (Zhang et al., 2007b) and therefore is implicated in mitochondrial 
impairment and cell death induced by PARP-1. 
 
These studies have been supported by the positive effect of pyruvate 
supplementation after PARP-1 activation. During hypoglycaemia induced by PARP-1 
activation, the cells are unable to use glucose even when it is restored to normal 
levels. This happens due to absence of NAD+ required for glycolysis. However, the 
cells are able to metabolise pyruvate in the absence of NAD+ and therefore pyruvate 
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supplementation has been found to reduce energy metabolism impairments and cell 
death as well as improving neuronal survival both in vitro as well as in brain slices 
and animal models (Suh et al., 2005, Ying et al., 2002). 
 
Depletion of NAD+ associated with PARP activity has been implicated in AD (Love et 
al., 1999) and Aβ-induced neuronal death (Fonfria et al., 2005). An increase in the 
concentration of poly(ADP-ribose) polymers concentration in the temporal and frontal 
lobes of AD individuals has been shown (Love et al., 1999) suggesting 
overexpression or increased activity of PARP. It has also been shown that oxidative 
damage to DNA has negative effects on metabolism of carbohydrates, which may be 
caused by NAD+ depletion induced by PARP (Braidy et al., 2008).  
 
PARP-1 has been found to interact with cell cycle regulators such as p53 (Braidy et 
al., 2008). p53 induced by oxidative stress has been shown to regulate expression of 
several genes that can induce cell cycle arrest in G1 or prevent DNA replication 
before damage repair or induce apoptotic death (Malanga et al., 1998). Increased 
expression of PARP-1 and p53 have been found in neurons of AD patients as well as 
in cultured neurons treated with Aβ(1-42) (de la Monte et al., 1998, Culmsee et al., 
2001). PARP-1 appears to activate DNA dependent protein kinase which then 
phosphorylate p53. 
 
The combination of sirtuins and caloric restriction has been found to play an 
important role in cell survival during oxidative stress (Sauve et al., 2006). SIRT1 acts 
primarily by deacetylating lysine residues in targeted proteins in the presence of 
NAD+ and therefore releases nicotinamide, acetyl ADP ribose (AADPR) and 
deacetylated substrates (Sauve et al., 2006). Caloric restriction appears to increase 
the NAD+ pool and therefore activates SIRT1 (Sauve et al., 2006). An increase in 
NAD+ levels may be associated with an increased life span as well as the 
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transcriptional silencing of telomeres and ribosomal DNA. Such silencing is seen as a 
way of measuring SIRT1 activity (Anderson et al., 2002). 
 
NAD+ depletion also affects gene expression (Bedalov and Simon, 2004). Indeed, 
increased SIRT1 has been shown to regulate gene expression by targeting 
transcription factors such as p53 (Luo et al., 2001), forkhead-box (FOXO) 
transcription family (Brunet et al., 2004) and NF-κB (Yeung et al., 2004). Depletion of 
NAD+ due to PARP activity would impair SIRT1 and therefore promote p53, FOXO 
and Bax activities, which can trigger apoptosis (Pillai et al., 2005). However, 
enhanced NAD+ levels could induce protective factors (Pallas et al., 2008).  
 
Another factor that could affect NAD+ levels is NADH dehydrogenase which is a part 
of complex I within mitochondria. NADH dehydrogenase oxidizes NADH to NAD+ and 
has been found to have reduced activity in AD brains (Lin and Guarente, 2003). This 
suggests that regulation of NAD+/NADH ratio is further impaired in AD (Braidy et al., 
2008, Lin and Guarente, 2003).  
 
As NAD+ has an essential role in the production of energy, DNA repair and other cell 
functions, depletion of NAD+ caused by oxidative stress in AD, can be an important 
step in development and progression of the disease (Braidy et al., 2008). In addition, 
NAD+ deficit may provide an important target for treatments in AD (Belenky et al., 
2007). 
 
4.1.5 Supplementation 
 
Studies on the use of metabolites to overcome the energy deficit have shown that 
mitochondrial energy substrates such as pyruvate, can have a neuroprotective role 
against oxidative stress (Wang et al., 2007) as well as Aβ toxicity (Alvarez et al., 
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2003). Treatment of neurons under oxidative stress with pyruvate decreased 
mitochondrial membrane depolarization, production of O2- and prevented caspase 3 
release following Aβ treatment (Alvarez et al., 2003, Wang et al., 2007). Pyruvate 
directly affects mitochondria through the regulation of NADP+ redox status (Alvarez et 
al., 2003). Another promising approach is supplementation of glucose with ketone 
bodies (Henderson, 2008). These are normally produced from fat stores when 
glucose levels decrease. Although glucose is the primary source of energy in the 
brain, cells can metabolize ketones during prolonged fasting (Greene et al., 2003). 
Ketone bodies include acetoacetate and β-hydroxybutyrate and are derived from 
fatty acids in the liver. They are then transported into the brain through the blood-
brain barrier via monocarboxylic transporters (MCTs) (Pellerin et al., 1998). Ketones 
can meet up to ~60% of brain energy requirements (Cahill, 2006). The metabolism of 
ketones in the brain involves conversion of β-hydroxybutyrate to acetoacetate, 
acetoacetate to acetoacetyl CoA, and acetoacetyl CoA to CoA (Cunnane et al., 
2011). Interestingly ABAD has been found to be blocked by Aβ, facilitate the 
utilization of ketone bodies both in vitro and in vivo (Du Yan et al., 2000). 
Unfortunately, ketone bodies cannot completely substitute for glucose as it is 
essential for lactate production (Cunnane et al., 2011). 
 
However, as mentioned above, the activity of the SCOT enzyme is decreased in AD 
which suggests ketolysis is also affected, leading to further reduction in energy 
production in AD (Yap et al., 2009). 
 
4.1.6 Glucose transport 
 
Glucose transport is facilitated by glucose transporters (GLUTs), of which several 
isoforms has been described. GLUT1 is localized on the membrane of blood-brain 
barrier endothelial cells, whilst GLUT3 is localized on neurons and GLUT2 is 
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expressed in astrocytes (Dwyer et al., 2002). Additionally, two more, insulin sensitive 
transporters were have been found to be expressed in neurons – GLUT4 and 
GLUTx1 (Watson and Craft, 2004).  
 
Decreased levels of GLUT1 and GLUT3 have been found in AD brains in several 
regions including the frontal, parietal, occipital and temporal cortical areas as well as 
the caudate nucleus and hippocampus. This suggests that glucose transport may be 
in part responsible for the hypoglycaemia seen in AD patients (Liu et al., 2008). 
 
Insulin sensitive transporters GLUTx1 and GLUT4 are expressed mainly in the 
hippocampus and hypothalamus. A significant overlapping distribution of insulin-
sensitive glucose transporters, insulin receptors and insulin have been found in 
specific regions of the brain which support memory (Apelt et al., 1999). Additionally, 
changes in insulin levels modulate GLUT4 expression in the brain (Vannucci et al., 
1998) suggesting a possible role of insulin in hypoglycaemia and AD (see section 
4.1.8). 
 
4.1.7 Glutamate 
 
L-glutamate is the most common neurotransmitter in the mammalian CNS. Upon 
presynaptic depolarization, glutamate is released from vesicles into the synapse, 
increasing the glutamate concentration almost 1000-fold (Walton and Dodd, 2007). 
Glutamate then binds to postsynaptic receptors, triggering an influx of cations and 
cellular depolarization. Glutamate is then quickly removed from the synaptic cleft by 
high-affinity transporters on astrocytes (Walton and Dodd, 2007). This prevents over-
stimulation and excitotoxicity. In the astrocytes, glutamate is converted into glutamine 
by glutamine synthase. Glutamine is then released from astrocytes and taken up by 
neurons, which convert it back to glutamate by phosphate-activated glutaminase. 
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Glutamate is further packed into vesicles (Walton and Dodd, 2007).  
 
Any changes in glutamate neurotransmission and recycling can have severe 
consequences. Prolonged increases in glutamate levels leads to sustained neuronal 
depolarization, which in turn results in Na+ and Ca2+ influx and further release of 
glutamate. Ca2+ can lead to delayed necrosis and to lesser extent apoptosis (Walton 
and Dodd, 2007). Continuous release of glutamate and the spreading of the process 
is called excitotoxicity, a process that has been previously found to be associated 
with Alzheimer’s Disease (Hynd et al., 2004). 
 
NMDA receptors can be activated by L-glutamate and glycine and are thought to be 
involved in synaptic plasticity and long-term potentiation (LTP). It has been previously 
shown that the density of NMDA receptors decreases with age (Segovia et al., 2001) 
and that a decrease in NMDA function can contribute to neurodegeneration (Olney et 
al., 1998). However, an FDA approved drug for treatment of moderate to severe AD, 
memantine, is a low affinity, non-competitive NMDA receptor antagonist. It competes 
with Mg2+ for binding to ion channel of the NMDA receptor and reduces NMDA 
activation. It has been suggested that memantine may reduce the pathophysiological 
activation of NMDA receptors but still allow physiological activation. Previous studies 
have shown that activation of NMDA leads to dissociation of PP-2A from NMDA 
complex and therefore leads to hyperphosphorylation of tau (Chan and Sucher, 
2001). Treatment of organotypic hippocampal cultures with memantine restores tau 
phosphorylation to physiological levels (Li et al., 2004). 
 
Additionally, studies have shown a decrease in GluR1 and GluR2 subunits of AMPA 
receptors in AD (Armstrong and Ikonomovic, 1996), as well as co-localization of APP 
with GluR2/3 (Thorns et al., 1997). Aβ-treated rat hippocampal neurons have shown 
increased Ca2+ levels and this effect was partially blocked by non-NMDA receptor 
	  
	  
163	  
antagonists (Brorson et al., 1999), suggesting AMPA receptors play a role in Aβ 
induced neurodegeneration. 
 
Numerous studies have also shown a direct interaction of Aβ with NMDA receptors. 
Aβ has been found to bind to NMDA receptors triggering neuronal damage through 
NMDA induced Ca2+ influx (De Felice et al., 2007). Aβ exposure led to an increase in 
intracellular Ca2+ and mitochondrial Ca2+ overload, oxidative stress, depolarization of 
mitochondrial membrane and cell death in rat cortical and hippocampal neurons 
through NMDA and AMPA receptor mechanisms (Alberdi et al., 2010). Neurons from 
transgenic mouse models of AD have also been found to express lower levels of 
NMDA. Despite the decrease in NMDA receptors they have been shown to be over 
reactive in AD (Ferreira et al., 2010). The loss or inactivation of NMDA receptors 
during AD progression has been suggested to be neuroprotective (Walton and Dodd, 
2007).   
 
In addition to glutamate receptors, glutamate transporters have also been found to be 
affected in AD (Walton and Dodd, 2007). Glutamate transporters are essential for the 
maintenance of glutamate levels in mammalian brain. High-affinity uptake is the only 
way to remove glutamate from the synaptic cleft and halt activation of its receptors 
(Logan and Snyder, 1972). Glutamate transport has been found to be significantly 
reduced in temporal, frontal, parietal and hippocampal cortices of AD brains (Masliah 
et al., 1996a). This decrease was associated with an increase in markers of neuronal 
death and decrease in the neuronal marker synaptophysin (Masliah et al., 1996a). 
Additionally, free radicals have been shown to inhibit glutamate uptake. ROS can act 
on transporters directly or through oxidative by-products such as 4-hydroxynonenal 
(HNE) (Volterra et al., 1994). Peroxidation of lipids in the membrane has been shown 
to lead to HNE formation and inactivation of GLT-1 (EAAT2) (Lauderback et al., 
2001). 
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Glutamine synthase (GS) is an enzyme that uses ATP to convert glutamate and 
ammonium to glutamine. In the brain this reaction takes place in astrocytes and is 
essential for glutamate homeostasis (Walton and Dodd, 2007). 
 
Previous studies have shown that GS activity declines with age. This decrease in 
activity is significantly increased in patients with AD (Smith et al., 1991). GS is very 
sensitive to oxidation and increased ROS can lead to conformational change that 
alters its activity (Butterfield et al., 1997). As mRNA changes have not been found 
this suggest that changes occur at protein level (Le Prince et al., 1995). Furthermore, 
a decrease in GS activity may lead to accumulation of glutamate inside the cell and 
therefore a reversal of glutamate transport which would contribute to 
excitotoxicity (Nicholls and Attwell, 1990). GS is normally found in astrocytes in all 
cortical layers. Astrocytic processes that surround capillaries demonstrate intense 
staining for GS. However, in AD GS is significantly reduced in vascular end-feet 
(Robinson, 2001). A decrease in GS activity could be due to a lack of substrate. As 
the activity of the transporters has been shown to be reduced in AD, this may also 
affect the level of glutamate that is taken up by astrocytes (Walton and Dodd, 2007). 
Another important enzyme in glutamate-glutamine cycle is phosphate-activated 
glutaminase (PAG), which in neurons converts glutamine into glutamate (Walton and 
Dodd, 2007). Immunocytochemical staining of AD brains demonstrated a decrease in 
levels of PAG (Akiyama et al., 1989). 
 
Even small disturbances in glutamate homeostasis can have adverse effects. 
Increased levels of glutamate can lead to increased energy requirements (chapter 3), 
ROS production, receptor overstimulation and reduction of excitatory signals 
(Danbolt, 2001). These effects can lead to excitotoxicity and neuronal cell death. AD 
individuals demonstrate a decreased ability to take up and store glutamate.  In 
addition, glutamate transporters have been found to be more sensitive to oxidative 
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stress in AD patients (Begni et al., 2004). 
 
4.1.8 Insulin 
 
Normal healthy individuals demonstrate a tightly controlled relationship between 
glucose metabolism and insulin. Disruption in this relationship can lead to diseases 
such as diabetes mellitus, which is characterized by hyperinsulinaemia and insulin 
resistance. Numerous studies have demonstrated cognitive impairments in 
individuals with type 2 diabetes (T2D) (Ryan and Geckle, 2000).  In addition, T2D 
increases risk of developing vascular dementia and may increase the risk of 
developing AD (Messier, 2003). As such attention has been focussed on the  
possible effects of insulin on neurodegeneration in AD (Watson and Craft, 2004). 
Insulin is a hormone, which is almost exclusively synthesized and secreted by 
pancreatic β cells. Its main role is in regulation of glucose metabolism in peripheral 
tissue (Correia et al., 2012). A large number of studies have shown that insulin is 
transported from the periphery into the brain via blood-brain barrier (BBB) by a 
saturable transport mechanism (Banks, 2004, Woods et al., 2003).  However, whilst 
some evidence supports local synthesis of insulin (Schechter et al., 1994) it is widely 
accepted that little or no insulin is produced in the brain (Woods et al., 2003).  
 
Insulin has an important effect on brain function such as cognition, memory and 
synaptic plasticity as well as processes such as homeostasis or neuronal survival 
(Zhao and Alkon, 2001). Insulin acts through the insulin receptor (IR) with the highest 
insulin binding in specific brain regions, which include olfactory bulb, cerebral cortex, 
hippocampus, hypothalamus, amygdala and septum (Unger et al., 1991). Insulin 
binding to its receptor activates two major signalling pathways: the mitogen-activated 
protein kinase (MAPK) and the phosphoinositide 3-kinase (PI3-K)/Akt (Cardoso et al., 
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2009). It has also been shown that insulin promotes expression of NMDA receptors 
(Skeberdis et al., 2001), which are important in long-term potentiation (LTP).  
It has been proposed that neurodegeneration seen in AD could be caused, at least in 
part, by disruption in insulin signalling (de la Monte and Wands, 2005). This 
hypothesis has been supported by evidence showing reduced insulin levels and 
insulin receptor expression in brains of AD patients (Frolich et al., 1998). In addition, 
progression through AD Braak stages was associated with a decrease in expression 
of IGF-1, IGF-2 and their receptors (Rivera et al., 2005). It has also been shown that 
individuals with AD have increased fasting plasma insulin levels and decreased 
cerebrospinal fluid (CSF) insulin levels (Watson and Craft, 2004) although other 
studies failed to show increase in fasting plasma insulin levels (Umegaki et al., 2002). 
In support of these findings it has been shown that administration of glucose and 
insulin has a beneficial effect on memory in AD patients (Manning et al., 1993). 
 
4.1.8.1 Insulin and Aβ 
 
The effect of insulin on Aβ is somewhat controversial. 
The hormone has been found to modulate Aβ processing in CNS (Watson and Craft, 
2004). One particular study has shown that subjects over 70 years old had increased 
levels of Aβ (1-42) in CSF after administration of insulin and the greatest increase of 
Aβ was associated with reduced memory (Watson and Craft, 2004). It has been 
suggested that the effect of insulin could include modulation of Aβ release and 
clearance (Gasparini et al., 2001). 
 
It has previously been shown that insulin increases Aβ levels by enhancing trafficking 
from ER and trans-Golgi network to the plasma membrane (Gasparini et al., 2001). 
Additionally, insulin can also competitively inhibit insulin-degrading enzyme (IDE), 
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which is a major enzyme that can degrade Aβ (Qiu and Folstein, 2006). As type 2 
diabetes (T2D) is associated with increased levels of insulin in the CSF (Watson et 
al., 2003), this could explain higher incidence of AD in individuals diagnosed with 
T2D (Correia et al., 2012). Interestingly, increased activity of IDE in IDE/APP double 
transgenic mice resulted in decreased levels of Aβ in the brain (Leissring et al., 
2003). 
 
However, insulin signalling has been shown to have beneficial effects on APP and its 
processing by acting on IR and GSK3 activity suppression. This leads to an increase 
in the secretion of sAPPα (Solano et al., 2000). Other reports have also shown that 
inhibition of GSK3β expression or activity prevents Aβ induced neurodegeneration 
(Takashima et al., 1993, Alvarez et al., 1999). Additionally, GSK3α modulates APP 
processing thus increasing secretion of Aβ (Phiel et al., 2003).  
 
4.1.8.2 Insulin in AD 
 
A decrease in the concentration of insulin in the CSF of individuals with AD has been 
suggested to result from the so called “insulin-resistant brain state”.  This includes 
downregulation of blood-brain barrier (BBB) function and IR activity and consequently 
a decrease in insulin transport.  Insulin resistance in the brain results in decreased 
activity of IDE and could lead to a decrease in the degradation of Aβ (Correia et al., 
2012). 
 
The presence of both insulin resistance and insulin deficiency has been proposed to 
be responsible for neurodegeneration in AD (Kroner, 2009). Under normal conditions 
insulin binding to the receptor activates PI3-K/Akt signaling pathway. PI3-Akt in turn 
phosphorylates and therefore inhibits glycogen synthase kinase-3β (GSK-3β). GSK-
3β inhibition results in a reduction of tau phosphorylation, which promotes its binding 
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to microtubules (Hong and Lee, 1997). Insulin resistance in the brain could lead to 
decreased activation of PI3-K/Akt signaling pathway and therefore an increase in 
levels of phosphorylated tau (Schubert et al., 2004). It has been shown that insulin 
resistance potentiates Aβ deposition and hyperphosphorylation of tau leading to 
neuronal dysfunction and death and ultimately cognitive decline (Jolivalt et al., 2008). 
 
4.1.8.3 Insulin and glucose administration and memory 
 
It has previously been shown that acute hyperglycaemia can facilitate memory 
whereas chronic hyperglycemia (such as associated with T2D) may disrupt memory. 
Studies in rodents have demonstrated beneficial effects of glucose on memory (Lee 
et al., 1988, Hughes, 2003) but the effect was most beneficial when glucose was 
administered prior or just after training (Lee et al., 1988, Messier, 1997) as opposed 
to extended periods of time. This suggests that glucose is important in consolidation 
rather than retrieval of information. The positive effect of glucose on memory has 
been suggested to be caused by changes in cholinergic activity in hippocampus 
(Stone et al., 1988, Okaichi and Okaichi, 2000). 
 
Studies on healthy humans have shown that glucose changes can affect memory. 
Severe hypoglycaemia can impair higher cortical functions leading to disruptions of 
memory (Sommerfield et al., 2003). On the other hand acute hyperglycaemia can 
facilitate memory and other cognitive functions (Craft et al., 1992, Sunram-Lea et al., 
2002).  
 
Clinical studies have also shown that treatment with insulin while maintaining 
euglycaemic conditions facilitates memory in patients with AD as well as healthy 
control (Craft et al., 1996, Craft et al., 2003).  
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4.1.9 (β-site APP cleaving enzyme-1) BACE 
 
Previous studies have shown that synaptic activity and brain metabolism have an 
effect on BACE enzyme expression, which is essential in the production of Aβ 
(Struble et al., 2010). Based on this evidence, Struble et al. (2010) suggested a 
hypothesis for the metabolic cause of the AD. 
 
BACE1 protein levels and activity are increased in sporadic AD (Fukumoto et al., 
2002). In addition, BACE expression is also up-regulated as a result of decreased 
metabolism (Yan et al., 2007). Some in vivo studies have used unilateral naris 
closure to block stimuli from reaching olfactory receptors and therefore suppress 
synaptic and metabolic activity in the olfactory bulb. This results in a decline in the 
activity of mitochondrial enzymes such as cytochrome c oxidase and succinic 
dehydrogenase, as well as upregulation of BACE and an increase in production of c-
terminal fragments of AβPP and the Aβ (Yan et al., 2007). Additionally, in mice where 
BACE has been knocked out, unilateral closure also results in a decrease in activity 
of mitochondrial enzymes but without an increase in BACE and Aβ, suggesting that 
metabolic deficits are the initial response to a decline in synaptic activity (Yan et al., 
2007).  
 
Evidence for the role of BACE and Aβ in normal functioning of the brain is limited. It 
has been hypothesized that Aβ modulates neuroplasticity by a concentration-
dependent mechanism (Puzzo et al., 2008). In addition, BACE also has been found 
to modulate synaptic plasticity and synaptogenesis by regulating axonal growth 
(Zhang et al., 2009). 
 
Brain metabolic activity and mitochondrial function begin to decline at around 30 
years of age (De Santi et al., 1995, Petit-Taboue et al., 1998). This decline may 
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result in increases in BACE expression and further lead to increases in Aβ production 
(Struble et al., 2010). As a result Aβ accumulation could further affect mitochondrial 
function and energy metabolism (Uemura and Greenlee, 2001, Atamna and Frey, 
2007) and therefore cause increases in ROS production and a decrease in synaptic 
activity. This may result in a vicious cycle where initial suppression of metabolic 
activity would lead to increases in Aβ production that further affects 
metabolism (Struble et al., 2010). This hypothesis could also account for the 
manifestation of familial AD. As metabolic activity starts to decline at 30 years of age, 
up-regulation of BACE and an increase in Aβ in individuals carrying mutations may 
occur. This would accelerate the onset of the disease, which may not be observed 
earlier, when high metabolism in the brain suppresses BACE activity (Struble et al., 
2010).  
 
4.1.10 Aims and objectives of the study 
 
Within view of the large body of evidence suggesting impaired metabolism in AD, it is 
important to study metabolic changes in a relevant human model. To date most of 
the studies on hypometabolism in AD have used transgenic animals or imaging 
studies of human brain. The aim of this chapter therefore, was to investigate the 
effects of Aβ on metabolism in terms of changes in glucose, glycogen, glutamate and 
lactate metabolism as well as oxidative stress and calcium signalling using a human 
stem cell derived culture of neurons and astrocytes. 
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4.2 Materials and Methods 
4.2.1 Cells 
 
4.2.1.1 Primary cultures 
Mixed cortical neuronal and glial cultures were prepared from Wistar rat pups 2-3 
days post-partum. The pups were killed by cervical dislocation. The cortex was 
dissected and placed in ice-cold Gey’s salt solution (Sigma-Aldrich, UK) containing 
20µg/ml gentamycin (Life Technologies, UK). The tissue was then minced using a 
scalpel and placed in Ca2+-free and Mg2+-free Hanks’ buffered saline solution (Life 
Technologies, UK), containing 0.1 % trypsin (Life Technologies, UK) for 30 min at 
37°C. The trypsin was inactivated by adding Neurobasal medium (Life Technologies, 
UK) containing B27 (Life Technologies, UK), 100 units/ml penicillin and 100 µg/ml 
streptomycin and 10% horse serum (Life Technologies, UK). Cells were then 
centrifuged at 1200rpm (258 x g) for 5 min and then medium was replaced with 5ml 
of fresh Neurobasal medium. Cells were dissociated by trituration with a glass 
Pasteur pipette with a flame-rounded tip and passed through 70µm filter (BD 
Biosciences, UK). Cells were then counted using a haemocytometer and plated onto 
poly-D-lysine coated 12 well plates at a final concentration of 5 x 105 cells/ml. Cells 
were maintained at 37˚C and 5% CO2 and fed twice a week and were used after 5 
days. 
 
Plates for primary cultures were coated with poly-D-lysine (Sigma-Aldrich, UK) at 
concentration of 50µg/ml. Briefly, poly-D-lysine was resuspended in sterile H2O and 
filtered through 0.22µm filter, the wells were coated with 2ml of the solution and 
incubated at 37˚C overnight. The poly-D-lysine was aspirated and plates were rinsed 
with sterile H2O and dried. 
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4.2.2 Immunohistochemistry: GFAP / β-tubulin-III staining  
 
Primary cultures were stained according to protocol described in section 3.2.2.1. 
 
4.2.3. Treatment of NT2.N/A, NT2.A and primary cultures with Aβ(1-42) 
 
NT2/D1 derived co-cultures and pure astrocytes were prepared as described in 
section 3.2.1.1 and primary cultures were prepared according to the protocol outlined 
in section 4.2.1.1. Cultures plated on 12-well plates were treated with 20, 2 and 
0.2µM of oligomeric Aβ(1-42) prepared in HEPES (as described in section 2.2.1.1) 
Subsequently plates were incubated for 6, 24, 48, 72 and 96 hours. Following the 
treatment various assays were performed. 
 
4.2.4 Viability assay 
 
The viability of the cultures following treatment with Aß(1-42) was determined using 
the Cell-titre BlueTM assay (Promega, UK). Following experimental treatment, 
medium was removed from the wells of the 12-well cell-culture plate.  Subsequently 
the plate was washed with 500µl phenol red-free DMEM media, supplemented with 
10% heat inactivated FBS (NT2.N/A, NT2.A) or 10% horse serum (primary cultures), 
100 units/ml penicillin and 100 µg/ml streptomycin and 2mM L-glutamine.  1ml of 
Cell-titre BlueTM reagent was mixed with 10mls of the DMEM medium. 500µl of this 
solution was added to each well of the plate.  The plate was incubated for 3 hours at 
37°C. Following incubation medium was transferred to a 96-well plate and the 
absorbance was measured at 590nm using a Thermo Multiscan EX 96-well plate 
reader (Thermofisher, UK). 
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4.2.5 Gene expression 
 
Changes in gene expression following exposure to Aβ were investigated using 
qRTPCR. Changes in genes associated with AD were monitored using the Human 
Alzheimer’s Disease RT² Profiler™ PCR Array (Qiagen, UK). 
 
The Human Alzheimer’s Disease RT² Profiler™ PCR Array (Qiagen, UK), 
investigated changes in gene expression following treatment of NT2.N/A co-cultures 
with 2µM Aβ for 48h. This array profiles the expression of 84 genes that are 
important in the onset, development, and progression of Alzheimer’s disease such as 
genes contributing to Aβ generation, clearance, and degradation or genes involved in 
Aβ signal transduction leading to neuronal toxicity and inflammation.  
 
In order to determine changes in genes associated with ANLS, oxidative stress and 
cell death following treatment of NT2.N/A co-cultures with 0.2, 2 and 20µM Aβ for 48, 
72 and 96h primers were obtained from PrimerDesign, UK. This method has been 
described in section 3.2.3.2. Primers for GLUT1, GLUT3, MCT2, MCT4, MCT1, GLT-
1, GLAST, GLUL, GPX1, SOD2, CASP3, INSR and HIF1A were used. 
 
4.2.5.1 RNA extraction 
 
RNA was isolated from NT2.N/A cultures following treatment with Aβ(1-42) and 
untreated controls according to protocol described in section 3.2.3.1 
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4.2.5.2 Real-time RT-PCR (Human Alzheimer’s Disease RT² Profiler™ PCR 
Array) 
 
First-strand cDNA synthesis. 1µg of total RNA was reverse transcribed using the RT2 
First strand kit (Qiagen, UK) according to the manufacturer’s instructions. cDNA was 
diluted to 100µl by adding DEPC treated RNase-free water and placed on ice. The 
PCR was carried out using a Stratagene MX3000P Real-time PCR machine.  For 
one 96-well plate of the Alzheimer’s Disease PCR Array (Qiagen, UK), a 2450µl PCR 
master mix (Qiagen, UK) containing RT2 PCR master mix and 98µl of diluted cDNA 
was prepared, and an aliquot of 25 µl was added to each well. For quality control the 
RT² Profiler™ PCR Arrays include built-in positive control elements for the proper 
normalization of the data, for the detection of genomic DNA contamination, for the 
quality of the RNA samples, and for general PCR.  The cycling conditions for the 
PCR reaction were: 10 min at 95 °C, 15 s at 95 °C, 1 min at 60 °C for 40 cycles were 
used. Three replicates were run for each differentiated sample and controls. Genes 
measured in this assay are listed in Appendix 8. 
 
4.2.5.3 Data normalization and analysis (Human Alzheimer’s Disease RT² 
Profiler™ PCR Array) 
 
Five endogenous control genes; Beta-2-Microglobulin (B2M), hypoxanthine 
phosphoribosyltransferase (HPRT1), ribosomal protein L13a (RPL13A), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and β- actin (ACTB) — 
present on the PCR Array were used for normalization. Each replicate cycle 
threshold (CT) was normalized to the average CT of 5 endogenous controls on a per 
plate basis. The comparative CT method was used to calculate the relative 
quantification of gene expression. The following formula was used to calculate the 
relative amount of the transcripts in the chemical treated samples (treat) and the 
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vehicle-treated samples (control), both of which were normalized to the endogenous 
controls. ΔΔCT = ΔCT (treat) – ΔCT (control) for biological RNA samples or ΔΔCT = 
ΔCT (Human Brain Reference RNA, HBRR) – ΔCT (Universal Human Reference 
RNA, UHRR) for reference RNA samples. ΔCT is the difference in CT between the 
target gene and endogenous controls by subtracting the average CT of controls from 
each replicate. The fold change for each treated sample (relative to the control 
sample (or UHRR) = 2–ΔΔCT. 
 
4.2.5.4 Sensitivity detection and identification of differentially expressed genes 
(Human Alzheimer’s Disease RT² Profiler™ PCR Array) 
 
PCR Array quantification was based on the CT number. A gene was considered not 
detectable when CT >32. CT was defined as 35 for the ΔCT calculation when the 
signal was under detectable limits. A list of differentially expressed genes was 
identified using a 2-tailed t-test. The criteria were a p value less than 0.05 and a 
mean difference equal to or greater than 2-fold. The statistical calculation was based 
on ΔCT values. 
 
4.2.6 Determination of glucose levels 
 
Glucose levels were measured using Glucose (HK) Assay Kit (Sigma-Aldrich, UK). 
The assay is based on enzymatic reaction where glucose undergoes phosphorylation 
by hexokinase in the presence of ATP. The next step involves oxidation of glucose 6-
phosphate to gluconate-6-phosphate by glucose-6-phosphate dehydrogenase. 
During the oxidation an equimolar amount of NAD+ is reduced to NADH. The 
increase in absorbance is then read on a spectrophotometer at 340nm. 
	  
	  
176	  
 
 
4.2.6.1 Sample preparation 
 
NT2.N/A and NT2.A were prepared as described in section 3.2.1.1 and primary 
cultures as described in section 4.2.1.1. Cultures plated on 12-well plates were then 
exposed to a range of concentrations of Aβ(1-42). Aβ(1-42) was prepared using 
protocol from section 2.2.1.1 and then diluted to 20, 2 and 0.2µM in DMEM Glutamax 
high glucose, with pyruvate (Life Technologies, UK) containing 10% inactivated foetal 
bovine serum (Life Technologies, UK), 100 units/ml penicillin and 100 µg/ml 
streptomycin (for NT2.N/A and NT2.A cultures) or Neurobasal with B27 (Life 
Technologies, UK) with 10% horse serum (Life Technologies, UK) and 100 units/ml 
penicillin and 100 µg/ml streptomycin (for primary cultures). Next plates were 
incubated for 6, 24, 48, 72 and 96 hours. Following the treatment cell culture medium 
was collected and used for the glucose assay. 
 
4.2.6.2 Protocol  
 
The assay was adapted to a 96-well microplate. Briefly, 200 µl Glucose (HK) Assay 
Reagent was added to 40 µl of sample in each well. Standards were prepared using 
a solution of glucose (1 mg/ml) and 1:2 serially diluted using dH2O giving 
concentrations of 500, 250, 125, 62.5, 31.25, 15.625, 7.813 and 3.906 µg/ml. The 
reaction was incubated for 15 minutes at room temperature and absorbance was 
measured at 340nm using a Thermo Multiscan EX 96-well plate reader 
(Thermofisher, UK). All readings were corrected for background and glucose 
concentration was expressed in µg/ml. 
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4.2.7 Determination of glycogen levels 
 
Glycogen levels were measured according to method described in section 3.2.5. 
 
4.2.7.1 Sample preparation 
 
Samples were prepared as described in section 4.2.6.1 
 
4.2.7.2 Determination of protein levels 
 
Protein levels were measured according to protocol described in section 3.2.5.3. 
 
4.2.8 Determination of glucose and glucose-6-phosphate levels 
 
Glucose and glucose-6-phosphate levels inside the cells were measured using 
method described in section 3.2.5. 
 
4.2.8.1 Sample preparation 
 
Samples were prepared as described in section 4.2.6.1 
 
4.2.8.2 Determination of protein levels 
 
Protein levels were measured according to protocol described in section 3.2.5.3. 
 
4.2.9 Determination of lactate levels 
 
Lactate levels were measured according to method described in section 3.2.6. 
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4.2.9.1 Sample preparation 
 
Samples were prepared as described in section 4.2.6.1 
 
4.2.10 Determination of pyruvate levels 
 
A Pyruvate Assay Kit was used to measure pyruvate levels (Abcam, UK). The 
method is based on the oxidation of pyruvate by pyruvate oxidase. The product then 
interacts with pyruvate probe to produce colour (λ= 570 nm) and fluorescence (at 
Ex/Em = 535/587 nm). 
 
4.2.10.1 Sample preparation  
 
Samples were prepared as described in section 4.2.6.1 
 
4.2.10.2 Protocol  
 
Pyruvate levels were measured in accordance with the manufacturer’s instructions. 
Briefly, the assay was set up in a 96-well microplate. 50µl of media samples were 
used per well and mixed with 50µl reaction mix containing 46µl Pyruvate Assay 
Buffer, 2µl Pyruvate Probe and 2µl Enzyme Mix. 50µl reaction mix was also added to 
pyruvate standards that were prepared at 0, 2, 4, 6, 8 and 10 nmol/well. The reaction 
was incubated at room temperature for 30 minutes, protected from light and then 
read at 570nm using a Thermo Multiscan EX 96-well plate reader (Thermofisher, 
UK). All readings were corrected for background and pyruvate concentration was 
expressed in µM. 
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4.2.11 Determination of glutamate levels 
 
Glutamate levels were measured using Amplex® Red Glutamic Acid/Glutamate 
Oxidase Assay kit (Life Technologies, UK). It provides a sensitive method for a 
continuous detection of glutamic acid. In the assay L-glutamic acid undergoes 
oxidation by glutamate oxidase to produce α-ketoglutarate, NH3 and H2O2. L-glutamic 
acid can be regenerated using L-alanine and L-glutamate-pyruvate transaminase by 
transamination of α-ketoglutarate. This creates multiple cycles of the initial reaction, 
thus increasing H2O2 levels. In a reaction catalysed by horseradish peroxidase, H2O2 
reacts with 10-acetyl-3,7-dihydroxyphenoxazine in a 1:1 stoichiometry. This reaction 
generates resorufin which is highly fluorescent.  
 
4.2.11.1 Sample preparation 
 
Samples were prepared as described in section 4.2.6.1 
 
4.2.11.2 Protocol 
 
Glutamate levels were measured in media samples according to manufacturer’s 
instructions. Briefly 50 µl of media samples were used for each reaction. L-glutamic 
acid standards were prepared in 1x reaction buffer at concentrations ranging from 0 
to 20 µM. 1x reaction buffer was used as a negative control and 10 µM H2O2 as 
positive control. Next 50 µl of working solutions of 100 µM Amplex® Red reagent 
containing 0.25 U/ml HRP, 0.08 U/ml L-glutamate oxidase, 0.5 U/ml L-glutamate-
pyruvate transaminase, and 200 µM L-alanine was added to each well. The reaction 
was incubated for 30 minutes at 37°C protected from light. Then the fluorescence 
was read using SpectraMAX GeminiXS microplate luminometer (Molecular Devices, 
UK) and SoftMaxPro software (excitation: 540nm, emission: 590nm). All readings 
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were corrected for background and glutamate concentrations are expressed in µM or 
as a percentage of glutamate in normal full media. 
 
4.2.12 Determination of glutamine levels 
 
Glutamine levels were measured using Glutamine determination Kit (Sigma-Aldrich, 
UK). The method is based on two step reaction. First involves enzymatic deamination 
of L-glutamine by glutaminase that produces L-glutamate. In the second reaction L-
glutamate undergoes dehydrogenation by L-glutamate dehydrogenase to produce α-
ketoglutarate. This step is accompanied by reduction of NAD+ to NADH that results in 
an increase in absorbance at 340nm. In the samples containing both L-glutamine and 
L-glutamate, the endogenous L-glutamate must also be measured. 
 
 
4.2.12.1 Sample preparation 
 
Samples were prepared as described in section 4.2.6.1 
 
4.2.12.2 Protocol 
 
The assay was adapted to a 96-well microplate. To measure L-glutamine levels in 
samples containing both L-glutamate and L-glutamine two 25µl media aliquots were 
examined. To the first aliquot 20µl of Acetate buffer, 10µl of glutaminase and 45µl of 
H2O were added. To the second aliquot 20µl of Acetate buffer and 55µl of H2O were 
added. Standards were prepared as follows. 20µl of Acetate buffer and 10µl of 
glutaminase were added to varying amounts of 2mM glutamine standards and H2O to 
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give standards at concentrations of 1.0, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2 and 0.1 
mmoles/L. All samples were later incubated for 1 hour at 37°C. After incubation 100µl 
of Tris-EDTA-Hydrazine buffer, 10µl of NAD+ solution, 1µl of ADP solution and 39µl 
H2O were added to each sample. Absorbance was read using a Thermo Multiscan 
EX 96-well plate reader (Thermofisher, UK) at 340nm to obtain background reading. 
Then 2µl of L-glutamic dehydrogenase was added the each well and samples were 
incubated at room temperature for 40 minutes. After incubation absorbance was read 
at 340nm. The readings were corrected for background and L-glutamine levels were 
measured by subtracting endogenous L-glutamate concentration from total L-
glutamate concentration (derived from both L-glutamine and L-glutamate). The 
results were expressed as mmoles/L. 
 
4.2.13 Determination of total glutathione levels 
 
The method to investigate levels of total glutathione (GSH+GSSG) was first 
described by Owens and Belcher (1965). The sensitivity of the assay was then 
improved by Tietze (1969) and it was later adapted to a microplate method  (Clarke 
et al., 1996). This assay is based on enzymatic reaction involving oxidation of GSH 
by 5,5’-dithiobis(2-nitrobenzoic) (DTNB), to produce chromophore TNB which results 
in increases in absorbance at 410nm. The sensitivity is increased by recycling GSH 
by glutathione reductase (GSR) and NADPH. 
 
4.2.13.1 Sample preparation  
 
Samples were prepared as described in section 4.2.6.1. Following the treatment cells 
were washed three times with PBS and then scraped in 1ml of PBS. Samples were 
then centrifuged at 6600g for 2.5 minutes. Next the supernatant was removed and 
the pellet was resuspended in 3.3µl of 100% sulphosalicylic acid (SSA) to precipitate 
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protein. Samples were centrifuged at 13000g for 90 seconds. Next 96.6 µl of stock 
buffer (125mM sodium phosphate, 6.3mM disodium EDTA, pH 7.5) was added to the 
samples and they were centrifuged at 13000g for 90 seconds. Supernatant was then 
used in the total glutathione assay and the pellet for protein determination.   
 
4.2.13.2 Protocol 
 
The assay was designed in a 96-well microplate. Standards were prepared by 
diluting 100mM GSH in H20 and SSA to generate 0, 20, 40, 60 and 80 µM samples. 
150 µl of a 0.35mM NADPH in stock buffer and 50 µl of a 6mM DTNB in stock buffer 
was added to each well. Next 25 µl of samples (from section 4.2.13.1) or standards 
were added to each well and incubated at 30°C for 5 minutes. The absorbance was 
then read using a Thermo Multiscan EX 96-well plate reader (Thermofisher, UK) at 
410nm to obtain background readings. Subsequently 25 µl of GSR (4U/ml) was 
added to each sample and absorbance was read immediately. The absorbance 
readings were taken over a period of 10 minutes. The glutathione levels were 
calculated using standard curve and were corrected for background and expressed 
as nmoles per mg of protein. 
 
4.2.13.3 Determination of protein levels 
 
The pellet from section 4.2.13.1 was used to determine protein levels. The protein 
content was determined using the DC protein assay reagent kit (Bio-Rad, UK), 
according to the manufacturer’s instructions. Briefly, 127µl working reagent A’ was 
added to the protein pellet. The pellet was then vortexed until solubilised. 127µl of 
working reagent A’ was also added to 100µl of BSA standards (125-2000µg/ml) or 
water which acted as a BSA-free control and vortexed. Then 100µl of water was 
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added to the solubilised pellet to correct for volume difference between samples and 
standard curve. The samples and standard solutions were then transferred to a test-
tube and 1ml of reagent B was added. Tubes were then vortexed and incubated at 
room temperature for 15min. The solution was transferred to a 96-well plate and the 
absorbance was measured at 750nm using Multiskan Go microplate 
spectrophotometer (Thermo Scientific, UK) 
 
4.2.14 Determination of NAD+/NADH ratio 
 
A NAD+/NADH Quantification Kit was used to measure NAD+ and NADH levels 
(Abcam, UK). This method allows detection of the intracellular nucleotides: NADH, 
NAD+ as well as their ratio. The method includes NAD cycling enzyme as the cycling 
reaction increases the detection and specificity of the assay. 
 
4.2.14.1 Sample preparation  
 
NT2.N/A were prepared as described in section 3.2.1.1. Cultures plated on 12-well 
plates were then exposed to 2µM Aβ(1-42) (section 2.2.1.1) and then diluted in 
DMEM Glutamax high glucose, with pyruvate (Life Technologies, UK) containing 
10% inactivated foetal bovine serum (Life Technologies, UK), 100 units/ml penicillin 
and 100 µg/ml streptomycin. Next plates were incubated for 6, 24, 48, 72 and 96 
hours. 
 
Following the treatment cells were washed with cold PBS and scraped. Cells were 
then centrifuged at 2000rpm (400g) for 5 min and PBS was removed. 400 µl of 
NADH/NAD+ Extraction Buffer was added to the pellet. NADH and NAD+ were 
extracted by two freeze and thaw cycles (20min on dry-ice and 10min at room 
temperature). Following the extraction, the lystate was vortexed for 10 sec and 
	  
	  
184	  
centrifuged at 12000rpm (13,800g) for 5 min. The supernatant containing extracted 
NADH and NAD+ was transferred to a new tube and used in the assay. 
 
4.2.14.2 Protocol 
 
NAD+ and NADH levels were measured in accordance with the manufacturer’s 
instructions. Briefly, to detect NADt (NADH and NAD+) 50 µl of the extract was 
transferred into 96-well plate in duplicates. To detect NADH, NAD+ is firstly 
decomposed. This was done by aliquoting 200 µl of the extract into microcentrifuge 
tubes and heating at 60˚C for 30min on a heating block. Samples were then cooled 
on ice and 50 µl of the NADH samples were transferred into 96-well plate in 
duplicates. Samples were then mixed with 100 µl of the NAD Cycling Mix that was 
prepared by adding 2 µl of NAD cycling enzymes mix to 100 µl NAD cycling buffer. 
The cycling mix was also added to NADH standards that were prepared at 0, 20, 40, 
60, 80 and 100 pmol/well. Plate was then incubated at room temperature for 5 min to 
convert NAD+ to NADH. 10 µl of NADH developer was added to each well and the 
plate was incubated at room temperature for 1 to 4 hours. The plate was then read at 
450nm using a Thermo Multiscan EX 96-well plate reader (Thermofisher, UK). All 
readings were corrected for background and protein content. NAD+ levels were 
calculated by subtracting NADH readings from NADt. Results were expressed as 
NAD+/NADH ratio. 
 
4.2.14.3 Determination of protein levels 
 
The protein concentration of sample was determined using the Bradford assay 
reagent kit from BioRad in accordance with the manufacturer’s instructions. Briefly 
800µl of diluted sample, BSA standard (ranging from 2-12 µg/ml) or NAD/NADH 
Extraction Buffer which acted as a BSA-free control were added to a microcentrifuge 
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tube with the 200µl of dye reagent concentrate. Each sample was vortex and 
incubated at room temperature for 5 min. The samples and standards were then 
transferred into a 96-well plate and read at 590nm using a Thermo Multiscan EX 96-
well plate reader (Thermofisher, UK). 
 
4.2.15 Determination of ATP levels 
 
The CellTiter-Glo® Luminescent Cell Viability Assay was used to measure ATP 
levels in cell lysate (Promega, UK). This method relies on mono-oxygenation of 
luciferin which is catalyzed by luciferase in the presence of Mg2+, ATP and oxygen. 
 
4.2.15.1 Sample preparation  
 
NT2.N/A were prepared as described in section 3.2.1.1. Cultures plated on 12-well 
plates were then exposed to 2µM Aβ(1-42) which was prepared using protocol from 
section 2.2.1.1 and then diluted in DMEM Glutamax high glucose, with pyruvate (Life 
Technologies, UK) containing 10% inactivated foetal bovine serum (Life 
Technologies, UK), 100 units/ml penicillin and 100 µg/ml streptomycin. Next plates 
were incubated for 6, 24, 48, 72 and 96 hours. 
 
4.2.15.2 Protocol 
 
ATP levels were measured in accordance with the manufacturer’s instructions (see 
Appendix 7). Briefly, following the treatment cells were scraped in 400µl of cell media 
and transferred into a microcentrifuge tube. 400µl of CellTiter-Glo® Reagent was 
added to the cells as well as ATP standards (ranging from 10 – 1000 nM) and the 
tubes were mixed for 2 minutes on a shaker to induce cell lysis. Then the tubes were 
left on a bench for 10min to equilibrate. The luminescence was recorded using 
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SpectraMAX GeminiXS microplate luminometer (Molecular Devices, UK) and 
SoftMaxPro software.  
 
4.2.15.3 Determination of protein levels 
 
Protein levels were measured according to protocol described in section 3.2.5.3. 
 
4.2.16 Enzyme-linked Immunoabsorbant Assay (ELISA) 
4.2.16.1 Sample preparation  
 
For all ELISAs samples were prepared as described in section 4.2.6.1 
 
4.2.16.1 IL-6 ELISA (Bender MedSystems) 
 
An ELISA to detect IL-6 was used in accordance with the manufacturer’s instructions. 
A Maxi-sorp immune-plate (NUNC) was coated by transferring 100µl of coating 
antibody (2.5µg/ml) to each well. The plate was sealed with an adhesive film and 
stored at 4˚C overnight. The next day each well was washed 3 times with 0.05% 
Tween 20 in PBS. The plate was then blocked using 250µl assay buffer (0.5% BSA, 
0.05% Tween 20 in PBS) and incubated for 2 hours at room temperature. After 
blocking the wells were washed twice as previously described. 100µl of standards 
prepared in assay buffer (100, 50, 25, 12.5, 6.25, 3.125, 1.56 pg/ml) were then added 
in duplicates to the plate. 50µl of samples were added per well together with 50µl of 
assay buffer. Biotin-conjugate anti-human IL-6 monoclonal antibody was diluted 
1:1000 in assay buffer and 50µl was added to each well. Plate was then covered with 
adhesive film and incubated at room temperature for two hours. The plate was then 
washed four times as described previously. 100µl Streptavidin-HRP diluted 1:5000 in 
assay buffer was then added to each well. The plate was then sealed and incubated 
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at room temperature for 1 hour. Following incubation the plate was washed four 
times as described above. 100µl of tetramethylbenzidine (TMB) solution was then 
added to each well. The plate was then incubated at room temperature, protected 
from light, until a suitable colour had developed. The reaction was stopped with 50µl 
of 0.5M H2SO4 per well. The absorbance was then read using a Thermo Multiscan 
EX 96-well plate reader (Thermofisher, UK) at 450nm. The results were corrected for 
background. 
 
4.2.16.2 IL-1β ELISA (eBioscience) 
 
An ELISA to detect IL-1β was used in accordance with the manufacturer’s 
instructions. A Maxi-sorp immune-plate (NUNC) was coated by transferring 100µl of 
anti-human IL1-β capture antibody (1:250 dilution in Coating buffer) to each well. The 
plate was sealed with an adhesive film and stored at 4˚C overnight. The next day 
each well was washed 5 times with 0.05% Tween 20 in PBS. The plate was then 
blocked using 200µl 1X Assay Diluent and incubated for 1 hours at room 
temperature. After blocking the wells were washed five times as previously 
described. 100µl of human IL-1β standard protein prepared in 1X Assay Diluent (500, 
250, 125, 62.5, 31.25, 15.625, 7.813, 3.906 pg/ml) and samples were added in 
duplicated to the plate. Plate was then covered with adhesive film and incubated at 
room temperature for two hours. The plate was then washed five times as described 
previously. 100µl of Biotin-conjugate anti-human IL-1β diluted 1:250 in 1X Assay 
Diluent was then added to each well and plated was sealed and incubated for 1 hour 
at room temperature.  The plate was then washed five times as described above. 
Next 100µl of Avidin-HRP diluted 1:250 in 1X Assay Diluent was added to each well 
and plate was covered with adhesive film and incubated for 30 minutes at room 
temperature. The plate was then washed seven times as described previously, 
allowing the wells to soak in Wash buffer for 1-2 minutes. 100µl of 1X TMB solution 
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was added to each well and the plate was incubated at room temperature for 15 
minutes. The reaction was stopped with 50µl of 0.5M H2SO4 per well. The 
absorbance was then read using a Thermo Multiscan EX 96-well plate reader 
(Thermofisher, UK) at 450nm. The results were corrected for background. 
 
4.2.16.3 TNF-α ELISA (R&D Systems) 
 
An ELISA to detect TNF-α was used in accordance with the manufacturer’s 
instructions. A Maxi-sorp immune-plate (NUNC) was coated by transferring 100µl of 
mouse anti-human TNF-α coating antibody (4µg/ml) to each well. The plate was 
sealed with an adhesive film and incubated overnight at room temperature. The next 
day each well was washed 3 times with 0.05% Tween 20 in PBS. The plate was then 
blocked using 300µl Reagent Diluent (1% BSA in PBS) and incubated for 1 hour at 
room temperature. After blocking the wells were washed three times as previously 
described. 100µl of TNF-α protein standards prepared in Reagent Diluent (1000, 500, 
250, 125, 62.5, 31.25 and 15.625 pg/ml) and samples were then added in duplicates 
to the wells. The plate was covered with adhesive film and incubated at room 
temperature for 2 hours. Following incubation each well was washed three times as 
described previously. Biotinylated goat anti-human TNF-α antibody was diluted in 
Reagent Diluent to concentration of 350 ng/ml and 100 µl was added to each well. 
The plate was sealed and incubated for 2 hour at room temperature. Each well was 
then washed three times as described above. Next 100µl of Streptavidin-HRP (1:200 
dilution in Reagent Diluent) was added to each well and plate was covered with 
adhesive film and incubated for 20 minutes at room temperature, protected from light. 
The plate was then washed three times as described previously. 100µl of TMB 
solution was added to each well and the plate was incubated at room temperature for 
20 minutes, protected from light. The reaction was stopped with 50µl of 0.5M H2SO4 
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per well. The absorbance was then read using a Thermo Multiscan EX 96-well plate 
reader (Thermofisher, UK) at 450nm. The results were corrected for background. 
 
4.2.16.4 β-NGF ELISA (R&D Systems) 
 
An ELISA to detect β-NGF was used in accordance with the manufacturer’s 
instructions. A Maxi-sorp immune-plate (NUNC) was coated by transferring 100µl of 
mouse anti-human β-NGF coating antibody (2µg/ml) to each well. The plate was 
sealed with an adhesive film and incubated overnight at room temperature. The next 
day each well was washed 3 times with 0.05% Tween 20 in PBS. The plate was then 
blocked using 300µl Reagent Diluent (1% BSA in PBS) and incubated for 1 hour at 
room temperature. After blocking the wells were washed three times as previously 
described. 100µl of β-NGF protein standards prepared in Reagent Diluent (2000, 
1000, 500, 250, 125, 61.25 and 31.25 pg/ml) and samples were then added in 
duplicates to the wells. The plate was covered with adhesive film and incubated at 
room temperature for 2 hours. Following incubation each well was washed three 
times as described previously. Biotinylated goat anti-human β-NGF antibody was 
diluted in Reagent Diluent to concentration of 50 ng/ml and 100 µl was added to each 
well. The plate was sealed and incubated for 2 hour at room temperature. Each well 
was then washed three times as described above. Next 100µl of Streptavidin-HRP 
(1:200 dilution in Reagent Diluent) was added to each well and plate was covered 
with adhesive film and incubated for 20 minutes at room temperature, protected from 
light. The plate was then washed three times as described previously. 100µl of TMB 
solution was added to each well and the plate was incubated at room temperature for 
20 minutes, protected from light. The reaction was stopped with 50µl of 0.5M H2SO4 
per well. The absorbance was then read using a Thermo Multiscan EX 96-well plate 
reader (Thermofisher, UK) at 450nm. The results were corrected for background. 
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4.2.16.5 BDNF ELISA (R&D Systems) 
 
An ELISA to detect BDNF was used in accordance with the manufacturer’s 
instructions. A Maxi-sorp immune-plate (NUNC) was coated by transferring 100µl of 
mouse anti-human BDNF coating antibody (2µg/ml) to each well. The plate was 
sealed with an adhesive film and incubated overnight at room temperature. The next 
day each well was washed 3 times with 0.05% Tween 20 in PBS. The plate was then 
blocked using 300µl Reagent Diluent (1% BSA in PBS) and incubated for 1 hour at 
room temperature. After blocking the wells were washed three times as previously 
described. 100µl of BDNF protein standards prepared in Reagent Diluent (1500, 750, 
375, 187.5, 93.75, 46.875 and 23.437 pg/ml) and samples were then added in 
duplicates to the wells. The plate was covered with adhesive film and incubated at 
room temperature for 2 hours. Following incubation each well was washed three 
times as described previously. Biotinylated mouse anti-human BDNF antibody was 
diluted in Reagent Diluent to concentration of 25 ng/ml and 100 µl was added to each 
well. The plate was sealed and incubated for 2 hour at room temperature. Each well 
was then washed three times as described above. Next 100µl of Streptavidin-HRP 
(1:200 dilution in Reagent Diluent) was added to each well and plate was covered 
with adhesive film and incubated for 20 minutes at room temperature, protected from 
light. The plate was then washed three times as described previously. 100µl of TMB 
solution was added to each well and the plate was incubated at room temperature for 
20 minutes, protected from light. The reaction was stopped with 50µl of 0.5M H2SO4 
per well. The absorbance was then read using a Thermo Multiscan EX 96-well plate 
reader (Thermofisher, UK) at 450nm. The results were corrected for background. 
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4.2.17 Calcium  
 
NT2.N/A cultures following treatment with 2µM Aβ for 48h as well as controls were 
loaded with Fluo-4 (Life Technologies, UK). The staining was carried out by 
incubating for 60min at 37oC with 5µM of Fluo-4 and 0.01% pluronic acid. The 
recording chamber was mounted on a motorized moveable bridge (Luigs and 
Neumann, Germany) and fluorescence dye was excited using an Optoscan 
monochromator system (Cairn, UK) at excitation wavelength 488nm and emission 
wavelength 516nm, fitted to a Nikon FN1 upright microscope; filter cubes were 
obtained from Chroma (Chroma VT, USA). Images of areas of 444µm x 341µm were 
routinely acquired every 5s for 15 min with a x20 objective lens (NA=0.8) using an 
ORCA ER CCD camera (Hamamatsu) and analysed using Simple PCI software 
(Compix Hamamatsu, Digital Pixel, UK). Statistical analysis was performed using 
GraphPad Prism Software. 
 
4.2.18 Statistics 
 
Results were expressed as the mean of three samples ± standard error of the mean 
(SEM).  Comparisons between treatments were performed using analysis of variance 
(ANOVA) followed by Dunnett’s or Tukeys post-test or Students T-test using 
GraphPad Prism Software.  Differences were considered significant for p values 
<0.05. 
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4.3 Results 
 
The study presented in chapter 3 provided evidence for functional metabolic coupling 
of NT2 derived neurons and astrocytes that is consistent with the ANLS model. 
Based on these results, NT2.N/A and NT2.A cultures were used to investigate 
changes in metabolism caused by treatment with Aβ(1-42). The methods used 
covered a range of biochemical assays that measured extracellular or intracellular 
levels of metabolites such as glucose, glycogen or lactate as well as ATP or reducing 
agents such as NADH. In addition, cells were investigated for signs of oxidative 
stress and calcium changes. The results obtained from NT2 derived cultures were 
compared to commonly used in vitro model, namely rat primary cortical cultures.   
 
4.3.1 Preparation of primary cultures 
 
The primary mixed glial and neuronal cultures were prepared from cortices of Wistar 
rat pups. Initially the cultures were maintained in two different types of media: 
Neurobasal and DMEM F12. Five days after plating the cultures were stained for β-
Tubulin and GFAP and analysed to establish which media combination resulted in 
cultures with highest confluence and cell growth similar to NT2.N/A cultures. As seen 
in Fig. 4.2A and 4.2B the cultures grown in F12 media were sparse in comparison to 
cultures maintained in Neurobasal media. Both cultures displayed typical neuronal 
and astrocytic morphology, with neurons extending axons and dendrites together 
with astrocytes. Cultures grown in neurobasal media in Fig. 4.2C and 4.2D produced 
a large number of astrocytes and networks of neurons with fine processes (Fig. 
4.2B). As these cultures were considered to be most similar to NT2 networks in terms 
of the ratio of neurons to astrocytes these culture conditions were chosen to produce 
cultures for treatment with Aβ. An example of such culture is shown in Fig. 4.3. 
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4.3.2 Viability studies 
 
NT2.N/A co-cultures, NT2.A cultures and mixed rat glial and neuronal cultures were 
treated with different concentrations of Aβ(1-42) (20, 2, 0.2µM) for 6, 24, 48, 72 and 
96h. Following the treatment, viability of the cells was measured using Cell-titre 
BlueTM assay (Promega, UK).  
 
In the co-cultures the only significant change was seen at the highest concentration 
of Aβ(1-42) (Fig. 4.4A). 20µM Aβ caused an increase in viability at 6h (111.84 ± 
4.17%, p<0.05) and a decrease in viability at 48h (88.69 ± 4.29%, p<0.05). In the 
pure astrocytic cultures there was a significant increase in the viability of the cells 
treated with 0.2µM Aβ for 72h (106.07 ± 2.11%, p<0.05) (Fig. 4.4B). Similarly the 
primary cultures did not show any significant cell death over time (Fig. 4.4C). After 
24h treatment with 20µM and 0.2µM the cultures showed an increase in viability 
(20µM: 106.88 ± 1.67, p<0.05; 0.2µM: 107.91 ± 1.25%, p<0.05). The same increase 
in viability was seen after 72h treatment with the highest concentration of Aβ (105.46 
± 0.99%, p<0.05). 
 
4.3.3 Glucose studies 
 
Glucose uptake from the medium was measured using Glucose (HK) Assay Kit 
(Sigma-Aldrich, UK). NT2.N/A, NT2.A and primary cultures all showed a significant 
decrease in glucose uptake following treatment with 2µM and 0.2µM Aβ at all time 
points. Glucose levels in the medium from co-cultures were significantly increased 
(p<0.001) at all time points (Fig. 4.5A). Similar increases in glucose levels were seen 
in primary cultures (p<0.001) at all time points except for 2µM Aβ treatment at 6h 
(p<0.01) (Fig. 4.5C). Astrocytic cultures also demonstrated a decrease in glucose 
uptake although to a lesser extent than neuronal and astrocytic cultures (Fig. 4.5B). 
	  
	  
194	  
At 24h the glucose levels in the media were significantly increased following the 
treatment with Aβ (control: 1829.14 ± 52.73µg/ml; 2µM: 2222.39 ± 16.89µg/ml, 
p<0.001; 0.2µM: 2257.82 ± 44.35µg/ml, p<0.001). Decrease in glucose uptake 
became less significant over time in astrocytes. At 72h the increase in glucose is at 
p<0.05 for both concentrations and at 96h only 0.2µM Aβ treatment cause any 
substantial impact (p<0.05). 
 
The glucose uptake over time differed between the cultures. In all cases the starting 
concentration of glucose in the medium was 4500µg/ml. The NT2.N/A cultures used 
up over 50% of the available glucose in the first 6h (control: 1814.84 ± 34.02 µg/ml) 
(Fig. 4.5A). Pure astrocytic cultures took up less glucose than co-cultures (control: 
2064.3 ± 65.7 µg/ml) whilst uptake in primary cultures was even slower (control: 
2955.77 ± 55.08 µg/ml) (Fig. 4.5B and 4.5C).  
 
The primary cultures were also more sensitive to Aβ treatment and glucose uptake 
was blocked to a greater extent than in NT2.N/A or NT2.A cultures. After 96h primary 
cultures treated with 0.2µM Aβ used up 57.72 ± 1.98% of the glucose from the media 
(control: 98.64 ± 0.25%) while NT2.N/A used up 92.8 ± 0.28% (control: 96.05 ± 
0.05%) and NT2.A 87.54 ± 0.34% (control: 89.1 ± 0.17%). 
 
4.3.4 Glycogen studies 
 
Following the treatment of the cultures with Aβ glycogen levels inside the cells were 
measured at 6, 24, 48, 72 and 96h. NT2.N/A co-cultures showed an initial decrease 
in glycogen levels at 6h (0.2µM: 96.05 ± 0.47%, p<0.001; 2µM: 96.59 ± 0.15%, 
p<0.001) (Fig. 4.6A). Glycogen levels increased, to control levels at 24h, with 
significant (p<0.001) increases at 72hr to 129.3 ± 5.57% when treated with 2µM Aβ 
and 123.35 ± 3.94% with 0.2µM Aβ. At 96h the differences were less apparent with 
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only 0.2µM Aβ having a significant effect (113.24 ± 4.32%, p<0.05) (Fig. 4.6A). 
Primary cultures demonstrated a similar pattern, with glycogen levels increasing at 
48h. However, the increase in glycogen was much more significant and at 96h levels 
of glycogen reached 277.06 ± 16.47% (p<0.001) after treatment with 2µM Aβ and 
258.75 ± 19.97% (p<0.001) when treated with 0.2µM Aβ (Fig. 4.6C). Additionally, 
from 48h there was a decrease in glycogen levels in cells treated with 20µM Aβ 
which was significant at 48h (p<0.001) and 72h (p<0.001).  
 
Pure astrocytes also demonstrated an increase in glycogen levels from 6h (2µM: 
129.99 ± 7.13, p<0.01) (Fig. 4.6B). Increases were observed at all time points, but 
were only significant at 24 and 96h. 
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Figure 4.2 Immunofluorescent images of primary cortical mixed neuronal and 
glial cultures. Images showing (A) GFAP positive astrocytes and (B) β-tubulin 
positive neurons grown in F12 medium and (C) GFAP positive astrocytes and (D) β-
Tubulin positive neurons grown in Neurobasal medium. Scale bar 150µM. 
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Figure 4.3 Immunofluorescent images of primary cortical mixed neuronal and 
glial cultures. Images showing (A) β-tubulin positive neurons (green), (B) GFAP (red) 
positive astrocytes, (C) nuclei stained with Hoechst and (D) an overlay. Scale bar 
24.9µM. 
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Figure 4.4 Viability results following treatment with 20µM, 2µM, 0.2µM Aβ 
measured by CellTitre BlueTM assay. (A) NT2.N/A, (B) NT2.A and (C) primary 
cultures. Viability was measured after 6, 24, 48, 72 and 96h. Results are expressed 
as percentage of non-treated control ± SEM, n=3. p<0.05 (*), p<0.01 (**), p<0.001 
(***). 
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Figure 4.5 Glucose levels in the media following treatment with 20µM, 2µM, 
0.2µM Aβ. (A) NT2.N/A, (B) NT2.A and (C) primary cultures. Glucose was measured 
after 6, 24, 48, 72 and 96h. Results are expressed as µg/ml ± SEM, n=3. p<0.05 (*), 
p<0.01 (**), p<0.001 (***). 
 
 
 
 
 
 
 
 
	  
	  
200	  
4.3.5 Glucose and glucose-6-phosphate 
 
Glucose and glucose-6-phosphate levels inside the cells were measured after the 
treatment with Aβ. As in previous experiments the effect was restricted to two lower 
concentrations of Aβ, 2µM and 0.2µM. The NT2.N/A co-cultures showed an 
accumulation of glucose and glucose-6-phosphate at all time points (Fig. 4.7A). The 
increase was most significant at 6h (control: 116.29 ± 5.61 nmol/mg protein; 0.2µM: 
171.71 ± 9.06 nmol/mg protein, p<0.01) and 24h time point (control: 84.84 ± 3.93 
nmol/mg protein; 0.2µM: 139.34 ± 14.07 nmol/mg protein, p<0.01). The accumulation 
of glucose and glucose-6-phosphate was more significant and reached higher levels 
in astrocytes than in co-cultures, with 6h (control: 110.01 ± 8.41 nmol/mg protein; 
0.2µM: 213.76 ± 13.95 nmol/mg protein, p<0.001) and 24h time points (control: 142.8 
± 8.58 nmol/mg protein; 0.2µM: 211.36 ± 6.32 nmol/mg protein, p<0.001) showing 
the largest increase (Fig. 4.7B). Similarly primary cultures also showed a very 
significant (p<0.001) accumulation of glucose and glucose-6-phosphate at all time 
points (Fig. 4.7C).  
 
In addition to the effect of Aβ, there was a significant difference in the levels glucose 
and glucose-6-phosphate between control of NT2–derived cultures (N/A and A) and 
primary cultures. In controls primary cultures, levels of glucose and glucose-6-
phosphate decreased with time, reaching very low levels at 96h time point (0.44 ± 
0.29 nmol/mg protein), while in NT2-derived control cultures levels of glucose and 
glucose-6-phosphate decreased more slowly. 
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Figure 4.6 Glycogen levels inside the cells following treatment with 20µM, 2µM, 
0.2µM Aβ. (A) NT2.N/A, (B) NT2.A and (C) primary cultures. Glycogen was 
measured after 6, 24, 48, 72 and 96h. Results are expressed as percentage of non-
treated control ± SEM, n=3. p<0.05 (*), p<0.01 (**), p<0.001 (***). 
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Figure 4.7 Glucose and Glucose-6-phosphate levels inside the cells following 
treatment with 20µM, 2µM, 0.2µM Aβ. (A) NT2.N/A, (B) NT2.A and (C) primary 
cultures. Glucose and Glucose-6-phosphate were measured after 6, 24, 48, 72 and 
96h. Results are expressed as nmol/mg protein ± SEM, n=3. p<0.05 (*), p<0.01 (**), 
p<0.001 (***). 
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4.3.6 Lactate studies 
 
Lactate levels in the cell conditioned media following treatment with Aβ were found to 
be significantly decreased in NT2.N/A co-cultures. At 6h there was no significant 
change in lactate levels.  
 
However, after 24h the levels were decreased following treatment with both 0.2µM 
and 2µM Aβ treatments (control: 13.59 ± 0.26mM; 2µM: 10.63 ± 0.11mM, p<0.01; 
0.2µM: 9.47 ± 0.6mM, p<0.001) (Fig. 4.8A). The decrease was also seen at 48h and 
72h, however, at 96h levels of lactate were similar to control levels (control: 19.95 ± 
0.18mM; 2µM: 19.89 ± 0.78mM; 0.2µM: 21.31 ± 0.33mM). Pure astrocytes did not 
demonstrate any change following the treatment with Aβ.  Interestingly, levels of 
lactate in pure astrocyte cultures were much lower than in co-cultures (Fig. 4.8B). In 
primary cultures, the decrease in lactate was very significant and was seen from 6h 
(control: 5.23 ± 0.41mM; 2µM: 3.75 ± 0.10mM, p<0.01; 0.2µM: 3.81 ± 0.10mM, 
p<0.01) through to 96h (control: 19.41 ± 0.97mM; 2µM: 13.30 ± 0.87mM, p<0.001; 
0.2µM: 10.16 ± 1.08mM, p<0.001) (Fig. 4.8C). 
 
Lactate was found to accumulate over time in all cultures. In NT2.N/A cultures and 
primary cultures the lactate levels were much higher than in pure astrocytes. 
Additionally, in NT2.N/A co-cultures the accumulation was slower than in primary 
cultures. NT2.N/A reached 19.95 ± 0.18mM levels at 96h while primary cultures 
reached 20.59 ± 0.84mM levels at 48h after which time the levels remained stable. 
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4.3.7 Pyruvate studies 
 
The levels of pyruvate level in the medium were measured following the treatment 
with Aβ. The initial pyruvate concentration in NT2.N/A and NT2.A medium supplied 
was 1mM while in primary cultures medium the concentration was 200µM. 
 
All cultures demonstrated a significant reduction in pyruvate levels over time 
regardless of treatment. In NT2.N/A cultures treated with both 0.2µM and 2µM Aβ, 
the levels of pyruvate were higher than in control. The most significant increase was 
seen at 24h (control: 397.55 ± 7.7µM; 2µM: 446.48 ± 15.89µM, p<0.05; 0.2µM: 
460.75 ± 8.34µM, p<0.01) and 48h (control: 326.78 ± 8.71µM; 2µM: 364.02 ± 7.6µM, 
p<0.05; 0.2µM: 379.62 ± 6.97µM, p<0.01) (Fig. 4.9A). However, at 96h the level of 
pyruvate dropped significantly in comparison to control. In pure astrocytes there was 
no change in the concentration of pyruvate after the treatment with Aβ (Fig. 4.9B). 
Primary cultures demonstrated a similar pattern to NT2.N/A co-cultures, with an 
increase in pyruvate concentration that became more significant after 6h (Fig. 4.9C). 
Conversely to NT2.N/A co-cultures there was no decrease at 96h in primary culture 
(control: 4.19 ± 0.44µM; 2µM: 19.62 ± 0.89µM, p<0.001; 0.2µM: 21.0 ± 0.91µM, 
p<0.001). 
 
4.3.8 Glutamate studies 
 
Treatment with Aβ was also found to have an effect on glutamate levels in the media. 
In NT2.N/A co-cultures there was a significant decrease in glutamate levels from 24h 
with the largest decrease at 72h and 96h (control: 22.31 ± 1.19µM; 2µM: 13.33 ± 
0.41µM, p<0.001; 0.2µM: 13.05 ± 1.52µM, p<0.001) (Fig. 4.10A). This decrease 
became more significant with time, as the control and 20µM Aβ treated cells 
accumulated more glutamate in the media. In pure astrocytes, the decrease was also 
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present but to a lesser extent (Fig. 4.10B). Overall the levels of glutamate in the 
media samples were much lower in pure astrocytic cultures than co-cultures of 
neurons and astrocytes. Primary cells also showed a significant decrease in 
glutamate levels after treatment with 2µM and 0.2µM Aβ. The decrease was 
significant from 24h and most significant at 96h (control: 9.08 ± 0.34µM; 2µM: 5.51 ± 
0.37µM, p<0.001; 0.2µM: 5.35 ± 0.43µM, p<0.001) (Fig. 4.10C). 
Additionally when 0.5mM glutamate was added to the NT2.N/A co-cultures in the 
presence of 2µM Aβ, the uptake of glutamate was significantly decreased in 
comparison to controls at both 6h and 48h (Fig. 4.11). 
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Figure 4.8 Lactate levels in the media following treatment with 20µM, 2µM, 
0.2µM Aβ. (A) NT2.N/A, (B) NT2.A and (C) primary cultures. Lactate was measured 
after 6, 24, 48, 72 and 96h. Results are expressed as mM ± SEM, n=3. p<0.05 (*), 
p<0.01 (**), p<0.001 (***). 
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Figure 4.9 Pyruvate levels in the media following treatment with 20µM, 2µM, 
0.2µM Aβ. (A) NT2.N/A, (B) NT2.A and (C) primary cultures. Pyruvate was measured 
after 6, 24, 48, 72 and 96h. Results are expressed as mM ± SEM, n=3. p<0.05 (*), 
p<0.01 (**), p<0.001 (***). 
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Figure 4.10 Glutamate levels in the media following treatment with 20µM, 2µM, 
0.2µM Aβ. (A) NT2.N/A, (B) NT2.A and (C) primary cultures. Glutamate was 
measured after 6, 24, 48, 72 and 96h. Results are expressed as µM ± SEM, n=3. 
p<0.05 (*), p<0.01 (**), p<0.001 (***). 
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Figure 4.11 Glutamate levels in the media following treatment of NT2.N/A co-
cultures with 2µM Aβ and 0.5mM glutamate. Glutamate was measured after 6 and 
48h. Results are expressed as µM ± SEM, n=3. p<0.05 (*), p<0.01 (**), p<0.001 (***). 
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4.3.9 Glutamine studies 
 
Glutamine levels in the media samples demonstrated a small increase, which was 
only significant in NT2.N/A co-cultures treated with both 0.2µM and 2µM Aβ for 72h 
(control: 28.51 ± 1.22mM; 0.2µM: 34.33 ± 0.56mM; 2µM: 33.42 ± 0.53mM p<0.05) 
(Fig. 4.12A). Pure astrocytic cultures did not show significant changes except for 72h 
treatment with 0.2µM Aβ (control: 27.95 ± 0.96mM; 0.2µM: 32.13 ± 0.76mM, p<0.05) 
(Fig. 4.12B). Primary cultures showed no increase in glutamine following the 
treatment with Aβ. However, the primary cultures accumulated more glutamine than 
NT2.N/A and NT2.A cultures, with higher levels seen already at 6h (NT2.N/A: 9.33 ± 
1.76mM: NT2.A: 8.67 ± 1.76mM; primary cells: 20.56 ± 1.86mM). 
 
4.3.10 GSH/GSSG ratio 
 
NT2.N/A co-cultures treated with all concentrations of Aβ showed a significant 
decrease in GSH/GSSG ratio at 6 and 24h (Fig. 4.13A). The trend remained similar 
at 48h, 72h and 96h, however, the decrease was not significant. Pure astrocytes also 
showed a decrease in GSH/GSSG ratio from 6h time point (Fig. 4.13B). This 
decrease was significant up to 48h time point. After 72h the GSH/GSSG ratio 
increased to control levels (control: 18.44 ± 1.67; 20µM: 18.65 ± 1.8; 2µM: 23.1 ± 1.8; 
0.2µM: 21.77 ± 1.22). At 96h there was a further increase in the ratio which was 
significant at all three concentrations (p<0.05). 
 
4.3.11 NAD+/NADH and ATP 
 
NAD+/NADH ratios and ATP levels were measured in NT2.N/A co-cultures following 
treatment with 2µM Aβ. The NAD+/NADH ratio followed a bell shaped trend, with an 
increase in the ratio at 24h and then a steady decrease at 48, 72 and 96h (Fig. 
	  
	  
211	  
4.14A). Both Aβ-treated and control cells follow this trend. There was an initial 
increase in NAD+/NADH ratio following the treatment with Aβ was for 24h (control: 
0.66 ± 0.06; 2µM: 0.91 ± 0.02, p<0.05). However, after this time point the ratio was 
much lower following the Aβ treatment and became more significant with time 
reaching its highest levels at 96h (control: 0.52 ± 0.03; 2µM: 0.18 ± 0.01, p<0.001). 
This decrease in ratio was due to a decrease in NAD+ levels (see Appendix 5 and 6). 
At 96h NAD+ levels in control were 819.6 ± 17.5 pmol/mg of protein, whilst after 
treatments with 2µM Aβ 347.5 ± 20.2 pmol/mg of protein.  ATP levels following 
treatment with 2µM Aβ decreased from 6h, becoming significant at 24h (Fig. 4.14B). 
ATP levels reached their lowest levels at 72h and 96h (control: 8.34 ± 0.86nmol/mg 
protein; 2µM: 3.29 ± 0.20nmol/mg protein, p<0.01). 
 
4.3.12 ELISA determinations 
 
Five different types of ELISA were used to analyse samples from NT2.N/A and 
NT2.A cultures, including IL-6, IL-1β, TNF-α, β-NGF and BDNF. No changes were 
found following the treatment with Aβ(1-42) (data not shown). NT2.N/A cultures 
released low levels of IL-6 (48h: 6.07±1.23 pg/ml), however, IL-1β, TNF-α, β-NGF 
and BDNF were not detected by ELISAs. 
 
4.3.13 Calcium imaging studies 
 
As changes in calcium signalling have previously been shown in astrocytes following 
Aβ treatment (Abramov et al., 2003), calcium changes in stem cell derived astrocytes 
were determined following Aβ treatment. Calcium responses were recorded following 
exposure of NT2.N/A co-cultures to 2µM Aβ as well as in controls. The excitability of 
astrocytes which is defined by variations in intracellular calcium (Volterra and 
Meldolesi, 2005) was investigated by fluorescent calcium imaging. 
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Figure 4.12 Glutamine levels in the media following treatment with 20µM, 2µM, 
0.2µM Aβ. (A) NT2.N/A, (B) NT2.A and (C) primary cultures. Glutamate was 
measured after 6, 24, 48, 72 and 96h. Results are expressed as mmoles/L ± SEM, 
n=3. p<0.05 (*), p<0.01 (**), p<0.001 (***). 
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Figure 4.13 GSH/GSSG ratio inside the cells following treatment with 20µM, 2µM, 
0.2µM Aβ. (A) NT2.N/A and (B) NT2.A. Glutamate was measured after 6, 24, 48, 72 
and 96h. Results are expressed as ratio ± SEM, n=3. p<0.05 (*), p<0.01 (**), p<0.001 
(***). 
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Figure 4.14 NAD+, NADH and ATP levels inside the cells following treatment of 
NT2.N/A with 2µM Aβ. (A) NAD+, NADH and (B) ATP were measured after 6, 24, 48, 
72 and 96h. Results are expressed as ratio ± SEM (A) and nmol/mg protein ± SEM 
(B), n=3. p<0.05 (*), p<0.01 (**), p<0.001 (***). 
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Following loading of the cells with the cell permeable calcium indicator fluo-4, the 
activity was recorded over time. 
 
Fig. 4.15 shows a control culture with spontaneously active cells (A) and a graphical 
representation of calcium oscillations in 3 representative astrocytes (B). In control 
cells only 32.29 ± 7.6% of cells demonstrated calcium oscillations (Fig. 4.16A) with 
low oscillation frequency (control: 0.22 ± 0.02 per min; Fig. 4.16B). Following 
treatment with Aβ there was a significant increase in the number of astrocytes 
displaying calcium oscillations (69.55 ± 3.09%; p<0.05; Fig. 4.16A). A representative 
culture treated with Aβ is presented in Fig. 4.15C and D. Additionally, the frequency 
of oscillation in the astrocytes was significantly increased (Aβ: 0.31 ± 0.03 per min; 
p<0.05; Fig. 4.16B) 
 
4.3.14 Gene expression determinations 
 
Changes in gene expression following the treatment with Aβ were investigated. The 
Human Alzheimer’s Disease RT² Profiler™ PCR Array (SABiosciences) was used to 
determine changes in AD associated genes whilst additional qRT-PCR was 
performed to determine changes in genes associated with astrocyte-neuron lactate 
shuttle, oxidative stress and cell death.  
 
Gene arrays were run using samples from control and NT2.N/A co-cultures treated 
with 2µM Aβ for 48h. The results showed significant up-regulation of the following 
genes: A2M (α2-macroglobulin), APBB2 (β-amyloid precursor protein-binding family B 
member 2), BACE1 (β-site APP-cleaving enzyme 1), CASP4 (caspase-4), GAP43 
(growth-associated calmodulin-binding phosphoprotein), GNG8 (guanine nucleotide 
binding protein (G protein), gamma 8), GSK3β (glycogen synthase kinase-type 3, 
isozyme β), IDE (insulin-degrading enzyme), LPL (lipoprotein lipase), SNCA (α-
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synuclein) and downregulation of BCHE (butyrylcholinesterase) (Fig. 4.18). The 
highest fold change was seen in the upregulated genes: GAP43 (10.13), CASP4 
(4.76) and LPL (3.54).  
 
qRT-PCR experiments to determine changes in genes associated with the lactate 
shuttle, oxidative stress and cell death were carried out using RNA samples from 
NT2.N/A co-cultures treated with 20, 2, 0.2µM Aβ for 48, 72 and 96h as well as 
appropriate controls. The results demonstrated no significant changes in any of the 
genes analysed (see Appendix 9, 10 and 11).  
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Figure 4.15 Calcium oscillations in NT2.N/A co-cultures. (A) Image of NT2.N/A 
control co-culture. Yellow circles indicate spontaneously active astrocytes. Scale bar 
100µm. (B) Representative fluorescence time course from 3 different astrocytes from 
image (A). (C) Image of NT2.N/A co-culture treated with 2µM Aβ for 48h. Yellow 
circles indicate active astrocytes. Scale bar 100µm. (B) Representative fluorescence 
time course from 3 different astrocytes from image (A). 
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Figure 4.16 Quantified changes in calcium oscillations in response to 2µM Aβ. (A) 
Bar graph displaying the number of astrocytes responding with calcium elevations to 
2µM Aβ and control. (B) Bar graph displaying frequency of calcium oscillations in 
response to 2µM Aβ and control. Results are expressed as percentage ± SEM (A) 
and oscillation per minute ± SEM (B), n=3. p<0.05 (*), p<0.01 (**), p<0.001 (***). 
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Symbol Well 
Fold Difference t-test 
Fold Up- or 
Down- 
regulation 
Test Sample / 
Control Sample P value 
Test Sample / 
Control Sample 
A2M A01 2.29 0.0319 2.29 
APBB2 A08 3.50 0.0306 3.50 
BACE1 B04 2.32 0.0318 2.32 
BCHE B06 0.30 0.0487 -3.29 
CASP4 B09 4.76 0.0222 4.76 
GAP43 C10 10.13 0.0433 10.13 
GNG8 D11 2.27 0.0184 2.27 
GSK3B E03 3.41 0.0458 3.41 
IDE E05 3.23 0.0038 3.23 
LPL E09 3.54 0.0454 3.54 
SNCA G08 2.13 0.0165 2.13 
 
Figure 4.17 Changes in the expression of genes associated with Alzheimer’s 
Disease following treatment of NT2.N/A cultures with 2µM Aβ.The table shows the 
fold change in gene expression and p value from a t-test. The change in gene 
expression was considered significant at p<0.05 and fold change ≥ 2. For full list of 
genes and p values see Appendix 8. 
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4.4 Discussion 
 
Multiple studies have demonstrated disturbances in glucose uptake and utilization in 
the brains of Alzheimer’s disease patients. This chapter also demonstrates for the 
first time, similar disturbances in neurons and astrocyte cultures derived from human 
stem cells following exposure to Aβ. 
 
 Change 
 NT2.N/A NT2.A primary 
viability no change no change no change 
extracellular glucose é é éé 
intracellular glycogen é é éé 
intracellular glucose / glucose-6-
phosphate é é é 
extracellular lactate ê no change êê 
extracellular pyruvate é no change éé 
extracellular glutamate êê ê êê 
extracellular glutamine no change no change no change 
intracellular GSH/GSSG ratio ê ê ✕ 
intracellular NAD+/NADH ratio ê ✕ ✕ 
intracellular ATP ê ✕ ✕ 
intracellular calcium é ✕ ✕ 
 
Figure 4.18 Summary table of chapter 4 results. é = moderate increase; éé = 
high increase; ê = moderate decrease; êê = high decrease; ✕ = no data 
available. 
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4.4.1 Comparison of NT2.N/A cocultures and primary cultures 
 
The results shown in this thesis reveal distinct differences in the severity of response 
from rat primary co-cultures and human NT2 derived co-cultures. Primary cultures 
appear more vulnerable to perturbation by Aβ and the changes in the metabolism are 
also more enhanced. One possible explanation is the use of human Aβ(1-42), which 
could be more toxic to rat cultures than human cells. However, another, more 
plausible explanation could be differences in the cells present in both cultures. 
Astrocytes in particular have been shown to be distinctly different in terms of glial 
function and diversity in humans when compared with rodents (Verkhratsky and Butt, 
2013).  
It has been suggested that increases in the complexity of the mammalian brain and 
intellectual power, are accompanied by an increase in the number and complexity of 
glial cells (Oberheim et al., 2006).  This difference is particularly apparent in human 
brains (Oberheim et al., 2009). Human astrocytes are larger and more complex than 
those found in rodent brains (Verkhratsky and Butt, 2013). The average diameter of a 
human protoplasmic astrocyte is 2.5% larger than an equivalent rat astrocyte 
(Verkhratsky and Butt, 2013). Similarly fibrous astrocytes in white matter are ~2.2 
times larger in human brain than rodent brain (Verkhratsky and Butt, 2013). In 
addition, human protoplasmic astrocytes have ~ 10 times more processes than 
rodent astrocytes and as a result human protoplasmic astrocytes contact ~2 million 
synapses whereas rodent astrocytes only contact ~20,000 – 120,000 synapses 
(Oberheim et al., 2009, Bushong et al., 2002). Primate’s brains also include astroglial 
subtypes that are not found in other vertebrates such as interlaminal astrocytes 
(Colombo and Reisin, 2004, Colombo et al., 1995). Additionally the possibility of 
primary cultures containing microglial cells cannot be ruled out. As microglial cells 
have both positive and negative effects in Alzheimer’s disease (Hanisch and 
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Kettenmann, 2007, Wyss-Coray, 2006), it is possible that they contribute to the 
response seen following Aβ(1-42) treatment. 
In the light of the different effects of Aβ(1-42) on rodent and human NT2 co-cultures it 
will be  necessary to characterize both cell preparations in more detail before any 
conclusions can be drawn. However, these results strongly suggest that human stem 
cell derived neurons and astrocytes could be used to determine the interactions 
between human brain cells in disease. 
 
4.4.2 No change in viability of the cultures 
 
Following treatment with Aβ(1-42) none of the cultures showed any changes in 
viability. Occasional increase or decrease that has been shown to be statistically 
significant, is not necessarly biologically significant. Additionally the nature of the 
Cell-titre BlueTM viability assay should be considered. This assay uses a dye, 
resazurin, which is actively reduced in mitochondria to give a fluorescent resorufin. 
This reaction uses diaphorase as enzymes and requires presence of NAD(P)H 
(Candeias et al., 1998). This assay can be therefore used to study mitochondrial 
metabolic activity. As Aβ(1-42) has been shown to affect metabolism and 
mitochondrial function, other methods should be used to investigate cell death such 
TUNEL assay to look at DNA fragmentation or caspase assay to look at apoptosis.  
 
4.4.2 Decrease in glucose uptake and utilization 
 
The studies described in this chapter have revealed increased levels of glucose in 
media samples from stem cell derived and primary cultures following treatment with 
Aβ. Increased levels of glucose suggest a decrease in uptake and/or utilization. 
These results support previous research including PET studies on patients with 
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Alzheimer’s disease as well as in vivo and in vitro studies using animal models 
(described in detail in chapter 4.1). The mechanisms of glucose uptake inhibition and 
decrease in glucose utilization have been extensively investigated and several 
possible causes have been proposed. A study by Uemura and Greenlee (2001) has 
shown that SNARE complex-mediated docking and fusion of GLUT3 vesicles is 
inhibited by Aβ thus decreasing glucose uptake. Other studies have suggested that a 
decrease in glucose uptake could be due to a decrease in amount of glucose 
transporters in the brain. Studies on AD brains has shown that the amounts of 
GLUT1 and GLUT3, as measured by immunoblotting analysis, were significantly 
decreased in comparison to aged-matched controls (Simpson et al., 1994). However, 
the decrease has also been shown to be associated with translational or post-
translational changes, as mRNA levels of GLUT1 have not been shown to be 
reduced in AD brains (Mooradian et al., 1997). Additionally, deficits in the 
upregulation of GLUT3 protein in response to energy requirements in old rat neurons 
when compared to young rats suggest that age-related changes in glucose transport 
occur during ageing (Patel and Brewer, 2003). In the data presented in this chapter 
gene expression analysis of samples collected from co-cultures of neurons and 
astrocytes did not show any significant changes in expression of either GLUT1 or 
GLUT3.  
 
Conversely, not all published reports have demonstrated a decrease in glucose 
uptake. A recent study by Allaman et al. (2010) demonstrated an increase in glucose 
uptake and various downstream pathways such as glycolysis, TCA cycle and 
pentose phosphate shunt in response to Aβ. Discrepancies between the results from 
this chapter and previous reports could stem from the use of different cell types. In 
their study Allaman et al. (2010) used pure primary astrocytes and pure neuronal 
cultures from mice. Additionally, the protocol for preparation of Aβ differed from the 
one used here, as Allaman et al. (2010) solubilized Aβ in DMSO or sterile deionized 
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water. As shown in Chapter 1, DMSO causes a very rapid aggregation of Aβ which 
could explain differences in results obtained in this study and in paper by Allaman et 
al. (2010). 
 
In this study, a decrease in glucose uptake upon treatment with 2µM and 0.2µM 
Aβ(1-42) could be explained by an accumulation of glucose and glucose-6-
phosphate inside the cells. Previous studies by DiNuzzo et al. (2010) have shown 
that a rapid increase in intracellular glucose-6-phosphate leads to a 40% decrease in 
glucose flow through the hexokinase pathway in astrocytes. This could potentially 
leads to a decrease in glucose phosphorylation in astrocytes and might therefore 
increase the amount of free glucose that is available to neurons in the brain. 
Accumulation of glucose/glucose-6-phosphate inside the cells shown in this thesis 
suggests a block in glucose phosphorylation or pathways downstream glucose 
phosphorylation stage, including glycolysis, the pentose phosphate pathway or 
glycogenesis.  
 
4.4.3 Increase in glycogen load in the cells 
 
An increase in glycogen levels following the treatment with 2µM and 0.2µM Aβ(1-42) 
could be explained by accumulation of glucose-6-phosphate which instead of passing 
through glycolysis is directed through glycogen synthesis pathways.  
 
The metabolism of glycogen is tightly regulated through kinases and phosphorylases.  
One specific phosphatase, protein phosphatase 1 (PP-1) plays an important role in 
the regulation of glycogen metabolism (section 3.1.3.6). Glycogen synthase is 
activated by PP-1 via dephosphorylation. At the same time PP-1 dephosphorylates 
glycogen phosphorylase, thus inactivating it.  An interesting study by Knobloch et al. 
(2007) has shown that impairment of LTP by Aβ(1-42) involves PP-1 and that LTP 
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impairment can be fully reversed by PP1 inhibition in vitro and in vivo. Inhibition of 
PP1 has also been shown to stimulate secretion of sAPP through nonamyloidogenic 
processing. A similar effect has been obtained by treatment of cells with phorbol 
esters via protein kinase C-mediated phosphorylation (da Cruz e Silva et al., 1995). 
These studies therefore suggest a beneficial effect of protein kinases and a 
detrimental effect of protein phosphatases in AD. However, it has been shown that in 
AD brains levels of protein phosphatases such as PP1, PP2A or PP5 are decreased 
while protein kinase levels such as GSK3β or Cdk5 are increased (Chung, 2009). 
GSK3β has been also shown to be responsible for phosphorylation of tau protein and 
formation of tangles as well as has been implicated in Aβ(1-42) toxicity and 
interaction with PS1 (Lucas et al., 2001, Hooper et al., 2008). Interestingly, NT2.NA 
co-cultures treated with 2µM Aβ(1-42) demonstrate an increase in GSK3β 
expression, which is to be expected considering the involvement of GSK3β in AD. 
However, this kinase has the opposite effect to PP-1 as it phosphorylates glycogen 
synthase and therefore inactivates it. Under normal conditions GSK3β inhibits 
glycogen synthesis and glucose uptake, as well as altering the expression of genes 
regulated by insulin (Jope and Johnson, 2004). However, in this chapter, co-cultures, 
pure astrocytes and rat primary cultures demonstrated an increase in glycogen load. 
As phosphorylation of GSK3β influence its activity, an increase in the level of 
expression may not translate to changes in activity. Additionally, glycogen synthase 
(GS) must be pre-phosphorylated by casein kinase II (CKII) for GSK3 to 
phosphorylate GS efficiently and down-regulate its activity (Jope and Johnson, 
2004). Many substrates of GSK3β have been shown to require pre-phosphorylation 
(priming) before phosphorylation by GSK3β. This means that the activity of such 
priming kinases may be a limiting factor in the activity of GSK3β (Hooper et al., 
2008). It is possible that that the expression of GSK3β is increased, however, the 
kinase itself is inactive, or that casein kinase II that is involved in the phosphorylation 
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of glycogen synthase is inactive. Further experiments will aim to determine the 
phosphorylation state of GSK3β following treatment with Aβ in these cultures. 
In addition to an increase in glycogen levels in the cultures, the results also showed a 
small decrease in NT2.N/A cocultures at 6h. This initial decrease in glycogen load in 
cocultures, even though statistically significant, may not reflect biological 
significance. 
 
4.4.4 Changes in glutamate levels 
 
In this chapter glutamate production as well as glutamate uptake was shown to be 
affected by treatments with Aβ(1-42). Glutamate levels in the media were much lower 
when cells were exposed to 2µM and 0.2µM Aβ(1-42). Similar results were also 
obtained from rat cortical cultures. Overall glutamate levels in pure astrocytic cultures 
were lower than in co-cultures. This is not unexpected as the majority of glutamate is 
produced by neurons whilst astrocytes take up the glutamate released by neurons 
and convert it to glutamine. However, it should be noted that astrocytes have been 
shown to produce and release glutamate as well as other gliotransmitters such as 
ATP (Parpura and Zorec, 2010).  
 
Previous studies of AD brains have demonstrated a marked decrease in phosphate-
activated glutaminase (Akiyama et al., 1989) an enzyme which converts glutamine to 
glutamate in neurons. As neurons are unable to synthesise glutamate through 
intermediary metabolism (Waagepetersen et al., 2005), glutaminase is the only 
enzyme which can ensure glutamate production in neurons. In addition, previous 
studies have shown a decrease in glutamine synthase (GS) in AD brain (Smith et al., 
1991, Le Prince et al., 1995, Butterfield et al., 1997). This enzyme converts 
glutamate taken up by astrocytes into glutamine which is then released and taken up 
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by neurons. The reduction in both enzymes would lead to disturbances in glutamate 
production in the AD brain. 
 
Stem cell derived co-cultures in this thesis also demonstrated a decrease in the 
uptake/production of glutamate. When treated with 2µM Aβ(1-42) in the presence of 
0.5mM glutamate, cultures contained higher levels of glutamate in their media than 
cells not exposed to Aβ(1-42). These results are supported by previous studies which 
have shown that Aβ treatment inhibits glutamate uptake in hippocampal astrocytes 
(Harris et al., 1995, Harris et al., 1996, Parpura-Gill et al., 1997).  However, the 
mechanisms causing the inhibition of glutamate transport are not well understood. It 
has been previously suggested that Aβ(1-42) could inhibit glutamate uptake through 
generation of oxygen-dependent free radicals (Harris et al., 1995, Harris et al., 1996). 
Other studies have shown that inhibition of glycolysis blocks glutamate uptake 
(Swanson, 1992a).  Furthermore, the inhibition of glucose uptake by Aβ(25-35)  have 
been found to affect glutamate transport (Parpura-Gill et al., 1997). The decrease in 
the uptake of glucose seen in NT2 co-cultures, pure astrocytes and rat primary 
cultures could be responsible for the decrease in glutamate uptake. However, gene 
expression analysis of the NT2 co-cultures treated with Aβ did not demonstrate any 
changes in the expression of glutamate transporters. 
 
Numerous studies have linked excitotoxicity to the development of AD (Parihar and 
Brewer, 2007). In addition, an increase in NMDA receptor activation by Aβ, a 
downregulation of glutamate transporters in AD brain, inhibition of the glutamate 
uptake by Aβ and increase in hyperphosphorylation of tau following activation of 
NMDA receptors have been reported (Parihar and Brewer, 2007). The efficiency of 
memantine (NMDA receptor antagonist) used in the treatment of AD also supports 
the active role of glutamate and excitotoxicity in AD (Lipton, 2006).  
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In neurodegenerative diseases, uptake of glutamate can be disturbed due to a 
decline in energy metabolism (Parihar and Brewer, 2007). Studies on the use of 
creatine to improve energy metabolism have shown that neurons preloaded with 
creatine were protected from glutamate and Aβ(1-42) toxicity (Brewer and 
Wallimann, 2000). This group hypothesized that long-term energy deficiency can 
lead to a failure in the reduction of intracellular calcium and therefore over-activation 
of NMDA receptors. 
 
Other studies have linked NMDA receptors activation to ROS production (Lafon-
Cazal et al., 1993). Indeed Schulz et al. (2000) have shown that excitotoxicity leads 
to ROS production and depletion of glutathione. It has also been suggested that 
glutamate toxicity may lead to ETC complex defects and mitochondrial dysregulation 
and therefore an increase in the production of free radicals (Halliwell, 1992).  
 
4.4.5 Changes in lactate production and pyruvate uptake  
 
Following exposure to Aβ(1-42) lactate levels were significantly decreased in co-
cultures (both stem cell derived and primary). Under physiological conditions the rate 
of glucose utilization is higher in astrocytes than neurons (Magistretti and Pellerin, 
1996). Glucose taken up by astrocytes is metabolized into lactate, which is then 
released to be taken up by neurons and can sustain synaptic activity (Bittar et al., 
1996). The results shown in this thesis strongly suggest that Aβ(1-42) leads to 
inhibition of the glycolytic pathway which results in the accumulation of glucose-6-
phosphate, decreased uptake of glucose and therefore lactate production. 
Interestingly, this effect is not seen in pure astrocytes. According to the ANLS 
hypothesis, lactate is produced by astrocytes in response to glutamate release from 
neurons and subsequent uptake by astrocytes (Pellerin and Magistretti, 2012). The 
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absence of neurons and low glutamate levels may explain the very low lactate levels 
in the media and thus limit the effect of Aβ(1-42) on lactate production.  
 
Pyruvate is another important energy source in the brain (Nicklas et al., 1971). The 
transport of lactate and pyruvate across the blood-brain barrier is limited and thus it 
cannot substitute for glucose to maintain brain function (Pardridge and Oldendorf, 
1977). However, when produced inside the brain, pyruvate and lactate are useful 
energy sources for neurons (Ide et al., 1969). Media used to grow and maintain both 
stem cell derived co-cultures and primary cultures in the experiments presented here 
contained high levels of pyruvate. However, following treatment with low levels of 
Aβ(1-42) the uptake of pyruvate was decreased in NT2.N/A co-cultures and primary 
cultures, further limiting availability of substrates for TCA cycle. 
 
4.4.6 Aβ(1-42) treatment affects the cellular NAD+/NADH ratio in NT2.N/A co-
cultures 
 
NAD+ is a coenzyme and a parent compound to NADH, NADP+ and NADPH. It is 
involved in many crucial processes for cell survival as a cofactor for enzyme-
catalyzed oxidation (Berger et al., 2004), a donor of electrons for ETC during 
oxidative phosphorylation (Araki et al., 2004) and as a contributor for ATP production. 
NAD+ is mainly located in mitochondrial matrix and together with NADP+ is important 
in signal transduction, DNA repair, glutathione metabolism and recycling and the 
thioredoxin system (Ziegler and Schulz, 2000). 
 
As the treatment of the cells with Aβ leads to a decrease of substrates available for 
entry into the TCA cycle, it was necessary to investigate changes in NAD+/NADH 
ratio. Co-cultures demonstrated an initial increase in NAD+/NADH ratio in both control 
and Aβ treated cells and this was followed by a significant decrease, particularly in 
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Aβ treated cells. Increases in the NAD+/NADH ratio seen in the control is possibly a 
result of increased glycolysis and subsequent production of lactate following feeding 
of the cells. During this process NAD+ is reduced to NADH. However, in order to 
allow aerobic glycolysis to continue in astrocytes NADH must be oxidised back to 
NAD+ via the production of lactate by lactate dehydrogenase As Aβ treatment 
partially blocks glucose uptake, this could lead to a decrease in the NAD+/NADH ratio 
in comparison to control. 
 
A decrease in the availability of substrates (glucose, pyruvate) and an increase in the 
requirement for NAD+ can lead to NAD+ depletion. This scenario is typical of both 
acute and chronic neurodegenerative diseases (Parihar and Brewer, 2007). The level 
of NAD+ in mitochondria can be affected by different factors such as ROS and Ca2+ 
via permeability transition pore (PTP) opening (Di Lisa et al., 2001). PTP opening can 
result in release of NAD+ to the cytoplasm where it is rapidly consumed by enzymes 
which are abundant in the cytoplasm e.g. glycohydrolases which hydrolyse NAD+ into 
ADP-ribose and nicotinamide. Glycohydrolases could also catalyze formation of 
cADP-ribose which triggers release of Ca2+ from sarcoplasmic reticulum causing 
further opening of PTP and subsequent release of NAD+ (Dodoni et al., 2004). 
However, these mechanisms as well as their association with AD and ageing are 
poorly understood (Parihar and Brewer, 2007).  
 
Another enzyme which relies heavily upon accessibility of NAD+ is PARP. PARP-1 
activity has been found in neuronal and also non-neuronal cells in CNS. In addition, 
excessive PARP-1 activity has been shown to have detrimental effects in cells due to 
a reduction in NAD+ (Ha, 2004). As described in section 4.1.4.1, PARP has been 
previously detected in frontal and temporal cortex of AD patients which suggests an 
increase in the consumption of NAD+ (Love et al., 1999). PARP-associated depletion 
of NAD+ has been found in conditions linked to increased ROS and DNA damage 
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(Schraufstatter et al., 1986). A decrease in NAD+ stores, leads to a heavy demand on 
ATP stores for synthesis of new NAD+ (Pieper et al., 1999). This can lead to an 
energy crisis in the cell which can cause further cell death via necrosis (Ha and 
Snyder, 1999).  
 
NAD+ is also required for Sir2 activity which has been found to increase life span in 
C. elegans and S. cerevisiae (Kaeberlein et al., 1999). In humans SIRT1 is involved 
in chromatin remodeling and regulation of transcription factors such as p53 (Luo et 
al., 2001). However, SIRT1 and the Sir2 family as well as PARP require NAD+ for 
their nuclear activities. An increase in NAD+ synthesis and activation of SIRT1 has 
been previously found to protect against axonal degeneration (Araki et al., 2004). As 
such a decrease in NAD+ could lead to neurodegeneration.   
 
NAD+ is a precursor for NADH and it is converted into NADH mainly during the TCA 
cycle. This NADH is then required for the phosphorylation of ADP by ATP synthase 
during oxidative phosphorylation. As such there is a relationship between the rate of 
ATP production and the ratio of NADH to NAD+ (redox ratio) whereby a decline in 
NAD+ can limit ATP synthesis through the TCA cycle.  
 
It has been shown that in 24 month old rats there is an age related decline in 
NAD(P)H (Parihar and Brewer, 2007). Additionally, exposure to glutamate causes an 
influx of Ca2+ which results in a much faster decline of NAD(P)H in old neurons in 
comparison to middle aged or embryonic neurons.  This has been suggested to be a 
result of complex I activity attempting to meet the requirement for electrons which 
power proton gradient and ATP production (Parihar and Brewer, 2007). As such low 
NAD(P)H levels in aged neurons could explain the vulnerability of cells to metabolic 
stress (Brewer, 1998).  
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Another factor that could influence NADH to NAD+ ratio is NADH dehydrogenase 
(part of complex I). In AD it has been shown that there are changes in expression of 
mitochondrial and nuclear genes encoding NADH dehydrogenase, specifically a 
down-regulation of mitochondrial genes in temporal cortex of AD (Manczak et al., 
2004). Additionally, activity of NADH dehydrogenase was also shown to be impaired 
in homogenates of plaques (Mattson, 2000). 
 
4.4.7 Effect of Aβ on ATP production 
 
Experiments in this chapter have demonstrated changes in glycolysis as well as the 
availability of substrates for entry into the TCA cycle and the ratio of NAD+/NADH. As 
such it was important to establish whether there was a subsequent effect on 
production of ATP. NT2 derived co-cultures treated with Aβ demonstrated a 
decrease in ATP from 6h, which became most significant at 72 and 96h. This 
demonstrates a detrimental effect of Aβ on the metabolism of the cells and is in line 
with previous studies. Studies of AD brains have shown a reduction in the activities of 
enzymes involved in glycolysis such as hexokinase (Liguri et al., 1990) and 
phosphofructokinase (Sims et al., 1987) but also in mitochondrial components such 
as pyruvate dehydrogenase complex (PDHC), α-ketoglutarate dehydrogenase 
complex (KGDHC) and cytochrome oxidase c (COX). A reduction in the activity of 
key enzymes of the TCA cycle, KGDHC and PDHC, has long been associated with 
neurodegeneration and AD (Sorbi et al., 1983, Blass, 2000). The reduction in 
KGDHC could be responsible for a general decline in brain metabolism and its 
activity has been found to have a higher correlation with cognitive decline than 
amyloid plaques or neurofibrillary tangles (Gibson et al., 1999). Some studies of AD 
brains have also demonstrated that decreased activity of PDHC is not only found not 
only in damaged regions of the brain but also in those showing no neuropathological 
changes (Butterworth and Besnard, 1990). COX has also been shown to have 
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abnormal kinetics but its activity is also decreased in AD brain and peripheral tissue. 
Additionally, it has been shown that the localization of such decreases in COX levels 
correspond to pre-mortem decreases in glucose metabolism (Rapoport et al., 1991). 
Decreases in COX activity have also been linked to a decrease in neuronal firing, a 
decrease in Na+/K+-ATPase activity and therefore a decrease in utilization and 
demand for ATP (Wong-Riley, 1989). 
 
The decrease in ATP levels following exposure to low concentrations of Aβ 
presented in this thesis is also supported by previous studies on mitochondria 
isolated from rat brains. These studies show a direct effect of micromolar levels of Aβ 
on mitochondrial respiration (Canevari et al., 1999), ATP synthesis (Moreira et al., 
2003) as well as the activities of various enzymes associated with energy transfer 
(Shoffner, 1997, Casley et al., 2002). It has been suggested that Aβ can interact 
directly with mitochondrial membranes causing changes in mitochondrial function 
(Parihar and Brewer, 2007) but also the inhibition of COX activity that is seen in AD 
(Canevari et al., 1999). Indeed, other studies have also shown a concentration-
dependent decrease in ATP/O ratio (moles of ATP produced per g-atom of oxygen 
consumed), ETC inhibition, increase in production of ROS and COX release in 
response to Aβ (Aleardi et al., 2005). 
 
4.4.8 Antioxidant defence and ROS production 
 
The brain is very susceptible to oxidative damage particularly due to its high 
metabolic rate, high levels of unsaturated lipid levels and a limited ability to 
regenerate (Andersen, 2004).  In addition, oxidative stress and damage have been 
previously linked to AD (Perry et al., 1998, Butterfield, 2002). 
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For normal functioning of the brain it is essential to maintain the balance between 
generation of ROS and antioxidant defence mechanisms. Endogenous antioxidants, 
which protect from ROS damage include enzymatic systems and cellular molecules 
(Aliev et al., 2008). Three primary enzymes include SOD, catalyse and glutathione 
peroxidase (GPx), but there are also secondary enzymes involved such as 
glutathione reductase (GR), glucose-6-phosphate dehydrogenase, and cytosolic GST 
(Aliev et al., 2008). The function of these enzymes is to decrease peroxide levels or 
to maintain supply of intermediates such as glutathione (GSH) or NADPH	  
(Vendemiale et al., 1999). GSH reacts directly with free radicals in a nonenzymatic 
reactions and is also an electron donor in the process of reduction of peroxides 
catalyzed by GPx. The product of this reaction is GSSG which is subsequently 
converted back into GSH by the action of glutathione GR which uses NADPH as a 
cofactor (Scott et al., 1963). In a healthy cell, GSSG levels rarely exceed 10% of total 
cellular GSH (Aliev et al., 2008). The ratio of GSH/GSSG has been therefore used as 
an indicator for oxidative stress in vivo (Asensi et al., 1999). 
 
In the work presented here NT2.N/A and NT2.A cultures were investigated for 
changes in GSH and GSSG following treatment with Aβ. Pure astrocytic cultures 
demonstrated a decrease in total GSH levels and an increase in GSSG levels which 
translated into a decrease in GSH/GSSG ratio. After 48h the ratio increased 
suggesting a recovery from the initial insult. A similar decrease in the GSH/GSSG 
ratio was seen in co-cultures at 6 and 24h. After 24h there still appears to be a 
decrease in GSH/GSSG ratio, however, it is not significant at any of the later time 
points. Nevertheless, we can conclude that treatment with Aβ leads to a decrease in 
GSH and an increase in GSSG levels. This suggests increased oxidative stress and 
is in line with previous studies. It has been shown that GSH levels decrease in red 
blood cells during normal ageing as well as in AD (Liu et al., 2004) and that GSSG 
levels are increased in AD (Benzi and Moretti, 1995). A study by Abramov et al. 
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(2003) performed on rat mixed hippocampal neuronal and glial cultures as well as 
pure cortical astrocytes linked sporadic [Ca2+]c signals caused by Aβ to GSH 
depletion. These sporadic fluctuations of [Ca2+]c were only seen in astrocytes and led 
to a decrease in GSH in those cells. As astrocytes supply neighbouring neurons with 
precursors for GSH (Sagara et al., 1993), a reduction in GSH levels in astrocytes 
could cause a decrease in GSH levels in neurons. This could further impair neuronal 
viability as neurons become vulnerable to oxidative stress (Abramov et al., 2003). 
 
A decrease in GSH has also been associated with downregulation of glutamate 
cysteine ligase (GCL), which is the first enzyme involved in de novo synthesis of 
GSH (Liu et al., 2004). This group have also demonstrated age-related decreases in 
the activity and mRNA content of glutathione synthase (GS), the second enzyme 
involved in the synthesis of glutathione (Liu et al., 2004). In addition they were also 
able to show that a decrease in GSH levels in red blood cells from male AD patients 
was linked to decrease in GCL and GS activity (Liu et al., 2004). 
 
In this chapter, gene expression analysis did not show any significant changes in 
antioxidant enzymes, such as GPx or SOD following treatment of NT2.N/A cells with 
Aβ. Further analysis of the expression and activity of enzymes associated with GSH 
synthesis is required before conclusions can be drawn on the impact of Aβ on the 
oxidative status of the cultures. 
 
Increases in GSSG levels following treatment with Aβ in this study suggest an 
increase in ROS production. Mitochondria are a major source of ROS, which at low 
levels are beneficial to the cell (Gericke, 2006) but can cause cell damage and lead 
to cell death at higher levels (Parihar and Brewer, 2007). It has been shown that 
during ageing, ROS levels increase as well as antioxidant activity which suggests 
upregulation of self-protective mechanisms (Pratico and Delanty, 2000).  Evidence 
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from experiments on isolated mitochondria supports the hypothesis of oxidative 
stress in ageing (section 1.7). As ageing is the major risk factor in AD, it has been 
suggested that increases in ROS production associated with ageing is a major 
contributor to the development of the disease (Parihar and Brewer, 2007). 
 
An increase in Aβ has been found to induce oxidative stress in AD transgenic mice 
(Matsuoka et al., 2001) and also leads to an increase in production of H2O2 in 
cultured cells (Behl et al., 1994). Together these studies demonstrate an association 
between oxidative stress and Aβ production, however it is not possible to determine 
which process occurs first in the development of the disease (Parihar and Brewer, 
2007). 
 
Results from post-mortem tissue of AD patients have shown markers for lipid 
peroxidation and protein nitration in the cortex and hippocampus (Butterfield and 
Lauderback, 2002). They have also demonstrated increases in the levels of protein 
carbonyls in AD compared to age matched controls (Smith et al., 2000). In addition, 
markers for oxidative damage of DNA (8-hydroxy-2’-deoxyguanosine) have been 
found in the CSF of AD patients. The accumulation of ROS could have a significant 
effect not only on nuclear DNA but also on mtDNA. mtDNA damage has been 
implicated in AD and could lead to mitochondrial dysfunction and a decline in ATP 
production (Parihar and Brewer, 2007). Additionally, free radicals may increase levels 
of oxidized proteins (section 4.1.3), which could lead to altered conformation and 
activity of enzymes involved in oxidative phosphorylation and the ETC such as 
cytochrome oxidase c (section 4.1.3). Oxidative stress can also lead to a reduction in 
the expression of metabolic enzymes by signalling pathways involving redox 
sensitive transcription factors, kinases and phosphatases (Thannickal and Fanburg, 
2000). These changes associated with ROS production could lead to further 
mitochondrial dysfunction (Parihar and Brewer, 2007).  
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4.4.9 Calcium changes 
 
Calcium release in cells has a very significant effect on cellular functioning, including 
mitochondrial energy metabolism. It can activate mitochondrial matrix 
dehydrogenases which produce more NADH and therefore donate electrons through 
ETC as well as affecting ATP production (McCormack et al., 1990). Calcium influxes 
can depolarize mitochondrial membrane potential (Vergun, 2007) but they also 
activate neurotransmitter release after action potential firing in neurons (Khvotchev et 
al., 2000). In addition, increases in calcium levels can affect enzymes such as protein 
kinases and phospholipases (Clapham, 2007), integrity of the cytoskeleton 
(Schlaepfer and Zimmerman, 1985) as well as play important role in excitotoxicity 
which is a major feature of neurodegenerative diseases (Parihar and Brewer, 2007). 
 
Dysregulation of intracellular calcium signalling in AD has been intensively studied 
(Mattson, 2004). Increases in intracellular calcium has been found to cause 
accumulation of Aβ and hyperphosphorylation of tau and can lead to neuronal death 
(LaFerla, 2002). Presenillin 1 has also been linked to calcium homeostasis and it has 
been shown that mutations in PS1 can cause changes in inositol triphosphate-
coupled intracellular calcium stores and calcium pathways (Yoo et al., 2000). 
Dysregulation of calcium homeostasis has been confirmed in both fibroblast and 
neurons from AD patients and transgenic mice with PS1 mutations (Huang et al., 
2005).  
 
The effects of Aβ on [Ca2+]c signalling has been extensively studied. However, the 
results of these studies are controversial, as Aβ has been found to increase and 
decrease [Ca2+]c, modulate Ca2+ channel activity or alter the dynamic of [Ca2+]c 
signals. In this thesis, Aβ increased calcium oscillations as well as the number of 
activated astrocytes. Abramov et al. (2003) demonstrated that in mixed neuronal and 
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astrocytic co-cultures Aβ had no effect on [Ca2+]c in neurons but triggered complex 
and sporadic [Ca2+]c fluctuations in astrocytes (Abramov et al., 2003). In addition, 
they demonstrated that the calcium changes were dependent on extracellular 
calcium and independent of the ER calcium stores. This suggests that Aβ causes 
Ca2+ influx selectively into astrocytes (Abramov et al., 2003). This supports the 
suggestion that Aβ can form pores in cell membranes that allow influx of Ca2+ (Lin et 
al., 2001). Additionally, the same study found that Aβ induces ROS generation in 
astrocytes and that this leads to GSH depletion in both neurons and astrocytes, in a 
calcium-dependent manner (Abramov et al., 2003). 
 
ROS production was found to be dependent upon activation of NADPH oxidase 
which generates oxidative stress and depletion of GSH (Abramov et al., 2004). 
Astrocytes can withstand this insult and are resistant to cell death, whilst neurons 
have been found to die within 24h after exposure (Abramov et al., 2003). As GSH 
depletion was blocked by glutathione precursors and NADPH oxidase inhibitors, it 
was suggested that neuronal death is a result of oxidative stress (Abramov et al., 
2004). In a recent study, neuronal death was shown to be mediated by overactivation 
of PARP-1 in response to oxidative stress, NAD+ depletion and loss of mitochondrial 
membrane potential Abeti et al. (Abeti et al., 2011). 
 
Increases in calcium oscillations and the number of cells that were activated in this 
study as well as decrease in NAD+/NADH and GSH/GSSG ratio are in agreement 
with studies done by Abramov et al. (2003,2004,2011). In addition, this study 
provides a link between Aβ and oxidative stress and changes observed in cellular 
metabolism. 
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4.4.10 Gene expression changes 
 
Changes in gene expression following exposure to 2µM Aβ(1-42) were investigated 
using the Human Alzheimer’s Disease RT² Profiler™ PCR Array (QIAGEN, UK). This 
array profiles the expression of 84 genes that are important in the onset, 
development, and progression of Alzheimer’s disease such as genes contributing to 
Aβ generation, clearance, and degradation or genes involved in Aβ signal 
transduction leading to neuronal toxicity and inflammation.  
 
Analysis showed significant upregulation and downregulation of several genes which 
have been previously shown to be associated with AD. However as the gene 
expression analysis was only performed on NT2.N/A co-cultures, it is impossible to 
determine whether the changes affected only one specific cell type or both. As such 
further investigation of pure cultures is required. 
 
4.4.10.1 Upregulation of A2M 
 
A2M is a gene that encodes α2-macroglobulin (α2M) which is a 718 kDa glycoprotein 
of a similar structure and function to a group of proteins called α-macroglobulins 
(Kovacs, 2000). It is found at high levels in the serum and cerebrospinal fluid (CSF) 
(Borth, 1992). It is also produced in the brain where it binds different extracellular 
ligands which are internalized by neurons and astrocytes (Kovacs, 2000). The most 
well characterised function of α2M is its pan-protease inhibitory activity (Barrett and 
Starkey, 1973). α2M binds to proteases and entraps them (Borth, 1992). The 
proteases are unable to dissociate from α2M, however they are still active and able to 
cleave small substrates (Lauer et al., 2001). 
 
In AD, α2M has been found to be associated with amyloid plaques (Kovacs, 2000)  as 
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well as binding to soluble Aβ (Hughes et al., 1998). Binding of α2M to Aβ has been 
shown to inhibit Aβ fibril formation and neurotoxicity (Hughes et al., 1998) as well as 
promoting its degradation by proteases already bound to α2M (Lauer et al., 2001). 
Additionally, α2M/Aβ complexes can undergo LPR-mediated endocytosis and 
lysosomal degradation (Narita et al., 1997). However, large amounts of α2M can be 
neurotoxic (Kovacs, 2000) and it has also been found to be a risk factor for late onset 
AD genes such as APOE. A DNA polymorphism in A2M gene has been associated 
with AD and increases in amyloid plaque formation in AD brains (Blacker et al., 
1998). However, subsequent studies have not consistently confirmed this positive 
association (Wavrant-DeVrieze et al., 1999, Myllykangas et al., 1999). The 
connection of A2M polymorphism to late onset AD is still controversial. 
 
Gene expression analysis following exposure of NT2.N/A cells to Aβ show that A2M 
is significantly upregulated. This is in line with previous studies that have shown an 
increase of α2M in cortical and hippocampal senile plaques as well as intracellular 
staining of hippocampal neurons (Bauer et al., 1991). 
 
4.4.10.2 Upregulation of APBB2 
 
Gene expression analysis demonstrated an increase in expression of APBB2 gene. 
This gene codes for β-amyloid precursor protein-binding family B member 2 which is 
an adaptor protein that can bind the cytoplasmic domain of βAPP (Golanska et al., 
2008). It is believed to be involved in the βAPP processing. Previous experiments 
have shown that overexpression of APBB2 increases γ-secretase processing of 
βAPP thus promoting Aβ production (Chang et al., 2003). 
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4.4.10.3 Upregulation of BACE1 
 
Gene expression analysis of NT2.N/A cells exposed to Aβ demonstrated an 
upregulation of BACE1. This gene codes for the β-site APP-cleaving enzyme 1 
(Sinha et al., 1999), a type 1 transmembrane aspartic protease. BACE1 is highly 
expressed in neurons (Sinha et al., 1999), and it is involved in APP processing and 
production of Aβ (described in detail in section 1.4.1). It has previously been shown 
that overexpression of BACE1 leads to an increase in Aβ production whilst BACE1 
knockdown abolishes Aβ production (Vassar et al., 1999). BACE1 has been found to 
cleave APP with the Swedish familial mutation ~10-fold to 100-fold more efficiently 
than normal APP (Sinha et al., 1999, Vassar et al., 1999). Interestingly, it has been 
proposed that hypometabolism can affect BACE1 expression (section 4.1.9). 
 
Recent studies have shown that BACE1 can also affect metabolism in the SH-SY5Y 
cell line. Stable overexpression of BACE1 has led to impairment of utilization of 
glucose and lactate as well as reduction in activities of hexokinase and pyruvate 
dehydrogenase (Prof. M. Ashford: personal communication). 
 
Results discussed above suggest that hypometabolism seen in NT2.N/A, NT2.A and 
primary cultures treated with Aβ could lead to increases in expression of BACE1.  
This could lead to further increases in Aβ production as well as hypometabolism 
seen in the cells. However, this link requires further investigation. 
 
4.4.10.4 Downregulation of BCHE 
 
BCHE gene encodes butyrylcholinesterase (BChE) which together with 
acetylcholinesterase (AChE) is a part of cholinesterases (ChEs) family. AChE is a 
key component of the cholinergic brain synapses and its function is to terminate 
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nerve impulses by rapid hydrolysis of acetylocholine (ACh) (Ul-Haq et al., 2010). In 
the human brain, BChE plays a secondary role in hydrolysis of ACh as AChE is the 
more active enzyme (Greig et al., 2002). According to the cholinergic hypothesis, 
sporadic AD is caused by a deficiency in cholinergic function. Levels of ACh have 
been found to be very low in the hippocampi and cortexes of AD patients (Terry and 
Buccafusco, 2003). Additionally, many of the available treatments focus on improving 
ACh levels either by replacement of ACh precursors (choline or lecithin) or the use of 
AChE inhibitors (physostigmine). Other treatments include specific M1 muscarinic or 
nicotinic agonists, M2 muscarinic antagonists. 
 
The function of BChE is not fully known but it appears to be involved in regulation of 
cell proliferation and differentiation during early neuronal development but also acts 
as a scavenger in the detoxification of certain chemicals, and is involved in 
lipoprotein (very-low-density lipoprotein; VLDL) metabolism (Ul-Haq et al., 2010). 
Some neurons also demonstrate BChE activity in the hydrolysis of ACh (Wright et al., 
1993). Studies on AChE and BChE activity in the AD brain have shown that, with 
progression of the disease, the activity of AChE decreases while BChE levels 
increase (Perry et al., 1978, Arendt et al., 1992). This suggests that BChE might be 
compensating for decrease in AChE activity (Giacobini, 2003). 
 
However, the gene expression analysis presented in this study showed a decrease in 
expression of BChE. Differences may stem from a relatively short exposure to Aβ in 
comparison to development and progression of disease in AD brains. 
 
4.4.10.5 Upregulation of CASP4 
 
CASP4 gene encodes human caspase-4 which is an inflammatory caspase. It is 
located in the ER and is activated by proteolytic cleavage when cells are exposed to 
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ER stress-inducing reagents (Hitomi et al., 2004). Activation of caspase-4 has been 
shown to trigger either apoptosis or an inflammatory response (Salminen et al., 2009) 
and may be associated with neuronal stress in AD (Katayama et al., 2004). It has 
also been shown that mutations in PS2 mutation can trigger cleavage and activation 
of caspase-4 and subsequently activation of caspases 3 and 9 (Yukioka et al., 2008). 
Additionally, some studies have shown that exposure of cells to Aβ activates both 
caspase-4 and 12 (Katayama et al., 2004). In AD, the amyloidogenic cleaving of APP 
has been associated with a negative feedback on caspase-4 activation. The release 
of AICD and its interacting partner, FE65 transcription factor, leads to its 
translocation to the nucleus where the AICD-FE65 complex can bind to the promoter 
region of caspase-4 thus blocking its action (Kajiwara et al., 2009). In the gene 
expression analysis CASP4 gene was significantly upregulated suggesting an initial 
ER stress-related response to Aβ treatment. 
 
4.4.10.6 Upregulation of GAP43 
 
GAP43 encodes a 43 kDa growth-associated calmodulin-binding phosphoprotein 
(GAP-43, neuromodulin, B50). GAP-43 is mainly found in neurons (Basi et al., 1987), 
and is particularly concentrated in growth cones (Nelson et al., 1989). GAP-43 has 
been shown to be involved in axonal growth and is often used as a marker of 
synaptogenesis (Benowitz and Routtenberg, 1997).  
 
It is regulated by phosphorylation via protein kinase C (PKC) and there appears to be 
a correlation between GAP-43 phosphorylation state and enhancement of LTP 
(Gianotti et al., 1992) as well as behavioural learning (Young et al., 2002).  
 
GAP-43 has been shown to be affected in AD, although the nature of these changes 
remains controversial. An early study has suggested a “trend” towards an increase in 
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GAP-43 levels in hippocampus of AD brains. The authors of this study suggested 
that it was a sign of neuritic sprouting (Masliah et al., 1991). More recent studies 
have shown a decrease in GAP-43 in the cortex and hippocampus (Bogdanovic et 
al., 2000). These results were in line with other studies that have shown aberrant 
localization and a decrease in GAP-43 levels in different areas of AD brains (de la 
Monte et al., 1995). Another study which tried to address controversy around GAP-43 
analysed hippocampal samples within short post-mortem times (Rekart et al., 2004). 
The authors of this study demonstrated an increase in GAP-43 in AD patients and 
again suggested that it may represent a sign of axonal sprouting. 
 
In the study presented here gene expression analysis showed a significant increase 
in GAP-43 expression following exposure to Aβ.  
 
4.4.10.7 Upregulation of GSK3Β 
 
GSK3β gene encodes glycogen synthase kinase-type 3, isozyme β (GSK3β). GSK3 
was initially described as a regulator of glycogen metabolism. It phosphorylates 
glycogen synthase and therefore inhibits its activity and glycogen synthesis (Embi et 
al., 1980). The effects of GSK3β on metabolism and glycogen turnover were 
discussed in details in sections 4.4.2 and 4.1.8. 
 
GSK3β is localized in neuronal and astrocytic compartments, in rough endoplasmic 
reticulum, free ribosomes, mitochondria and within post-synaptic densities in 
dendritic spines (Perez-Costas et al., 2010). This kinase has been associated with 
NMDA-dependent long-term potentiation (LTP) and long-term depression (LTD). The 
signaling cascade involved in regulation of LTP and LTD includes PI3K/AKT/GSK3 
mechanisms, which lead to phosphorylation of GSK3β and inhibition of its activity. 
This pathway has been shown to be critical for LTD or LTP formation (Hooper et al., 
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2007). GSK3β also plays a role in NMDA receptor trafficking (Chen et al., 2007) and 
pre-synaptic functions in developing and mature nerve terminals (Smillie and Cousin, 
2011). 
 
GSK3β has been previously shown to play an important role in development of AD. 
and has been identified as a key kinase which is able to phosphorylate tau both in 
vitro and in vivo (Ishiguro et al., 1993, Terwel et al., 2008). GSK3β transgenic mice 
have been shown to display hyper-phosphorylation of tau and neurodegeneration 
(Lucas et al., 2001). 
 
The upregulation of GSK3β following the treatment with Aβ is consistent with 
previous studies. 
 
4.4.10.8 Upregulation of IDE 
 
The IDE gene codes for insulin-degrading enzyme (IDE, insulysin), a 110kDa thiol 
zinc-metalloendopeptidase. It is located in cytosol, peroxisomes, endosomes and 
also on the cell membrane (Duckworth et al., 1998). IDE cleaves small proteins 
which share one characteristic, i.e. formation of β-pleated sheet-rich amyloid fibrils. 
These proteins include amyloid β-protein (Aβ), insulin, glucagon, amylin, atrial 
natriuretic factor, and calcitonin (Kurochkin, 2001). As IDE is a major enzyme that 
can degrade Aβ (Qiu and Folstein, 2006) in both neuronal and microglial cultures 
(Qiu et al., 1997, Vekrellis et al., 2000), it can thus eliminate its neurotoxic effects 
(Mukherjee et al., 2000). The link between insulin, IDE, AD and diabetes has been 
described in detail in section 4.1.8 The upregulation of IDE following exposure of NT2 
co-cultures to Aβ suggests an activation of a protective mechanism in these cells.  
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4.4.10.9 Upregulation of LPL 
 
The LPL gene encodes lipoprotein lipase, an enzyme which catalyzes the hydrolysis 
of triacylglycerol, but also mediates uptake of lipoproteins by acting as a bridging 
molecule between lipoproteins and sulphated glycosaminoglycans (GAGs) (Williams 
et al., 1992). It has previously been shown that LPL is highly expressed in the brain 
(Goldberg et al., 1989). In AD it has been shown that LPL accumulates in amyloid 
plaques (Rebeck et al., 1995). Additionally, SNPs in the LPL gene have been found 
to be associated with an increased risk of AD (Blain et al., 2006). A recent study by 
Nishitsuji et al. (2011) has shown that LPL forms a complex with Aβ, leading to an 
increase in uptake and lysosomal degradation of Aβ in astrocytes. The upregulation 
of LPL gene after exposure to Aβ in NT2 co-cultures suggests that multiple 
mechanisms of Aβ clearance may be active in these cells. 
 
4.4.10.10 Upregulation of SNCA 
 
The SNCA gene encodes α-synuclein, a 18-20 kDa peptide (Spillantini et al., 1995). 
Synucleins are highly expressed in the central nervous system as well as, skeletal 
muscles and spleen (Hong et al., 1998). In the brain, they are localized in the 
neocortex, hippocampus, and substantia nigra (Suh and Checler, 2002). α-Synuclein 
has been shown to be a key molecule involved in Parkinson's disease (PD) and 
dementia with Lewy bodies (DLB). Whilst very rare, inherited cases of PD appear to 
be associated with mutations in α-synuclein gene (Kruger et al., 1998). In AD α-
synuclein is associated with amyloid plaques. Apart from amyloid β-peptides, the 
plaques are also composed of a component known as non-Abeta component (NAC) 
(Masliah et al., 1996b). NAC has been shown to be derived from a precursor protein, 
which was later determined to be α-synuclein (Ueda et al., 1993). The expression of 
α-synuclein in the brain appears to correlate with the severity of AD cases (Iwai et al., 
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1996). It has also been shown that aged transgenic mice overexpressing APP have 
amyloid plaques, which were immunoreactive to α-synuclein (Yang et al., 2000). 
However, the specific role of α-synuclein in AD still remains to be determined. The 
upregulation of SNCA gene in NT2 cultures shows that Aβ treatment alone is 
sufficient to trigger an increase in the expression of α-synuclein and suggests an 
important role of this protein in AD. 
 
4.5 Conclusion 
 
Data presented in this chapter provides evidence for a detrimental effect of Aβ on 
cellular metabolism. Cultures treated with low concentrations of Aβ showed a clear 
hypometabolism, particularly with regards to changes in glucose, lactate, pyruvate 
and glycogen metabolism. Interference with metabolic pathways led to a deficit in 
ATP production as well as NAD+/NADH ratio. This effect would have serious 
implications in the brain which has a high energy demand, especially in terms of 
memory formation and antioxidant mechanisms. An increase in calcium responses 
as well as a decrease in GSH/GSSG ratio, all point towards Aβ-induced metabolic 
and oxidative stress. In addition, gene expression analysis suggests an increase in 
factors involved in the clearance and degradation of Aβ.  
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Chapter 5: Conclusions and future experimental approaches 
 
As numerous cell types interact during the progression of Alzheimer’s disease, it is 
important that any in vitro model of the disease reflects this arrangement. The model 
described here has previously been used in our laboratory to model neurotoxicity and 
has demonstrated the importance of including astrocytes to realistically model toxic 
effects. During the course of this project this model was utilised in order to study the 
response of neurons and astrocytes to Aβ(1-42). 
 
Previous studies in our laboratory have demonstrated that NT2.D1-derived neurons 
and astrocytes are functional and can generate action potentials (neurons) as well as 
spontaneous and induced calcium oscillations (astrocytes) (Hill et al., 2012). This 
human model of functional neurones and astrocytes therefore offers a unique 
opportunity to investigate functional changes in response to toxic Aβ(1-42). In 
addition, changes in biochemical endpoints such as metabolites, cellular viability and 
calcium responses can also be demonstrated. Such an advanced and relevant model 
has not thus far been applied to the study of the aetiology of Alzheimer’s Disease.  
 
This study has demonstrated for the first time metabolic coupling between neurons 
and astrocytes derived from human stem cells. The ANLS hypothesis proposes that 
during neuronal activity, glutamate released into the synaptic cleft is taken up by 
astrocytes and triggers glucose uptake, which is converted into lactate and released 
via monocarboxylate transporters for neuronal use. Using NT2 derived co-culture it 
was possible to successfully model this in vitro. 
 
In this study, mixed cultures of NT2.N/A cells were utilised to investigate the 
metabolic properties of these cells and measured the response of the astrocytic 
network to well characterised neuromodulators. Using expression analysis and 
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metabolic approaches it was shown that NT2.N/A cells express the main tenets of 
the ANLS model and display functional characteristics consistent with their neuron-
astrocyte metabolic coupling. This study shows that NT2.N/A cultures modulate their 
glucose uptake in response to glutamate, an effect that was blocked by cytochalasin 
B and ouabain. Additionally, the experiments presented that in response to increased 
neuronal activity and under hypoglycaemic conditions, co-cultures modulate 
glycogen turnover and increase lactate production. Similar results were also shown 
following treatment with glutamate, potassium, isoproterenol and dbcAMP.  Together 
these results demonstrate that NT2 human stem cell derived co-culture model is 
metabolically competent and demonstrates a functional astrocyte neuron lactate 
shuttle (ANLS). This study therefore lays the foundation for further development of 
stem cell derived neurons and astrocytes to better understand the metabolic coupling 
between neurons and astrocytes and its relationship to plasticity and 
neurodegeneration. 
 
Changes in metabolism of the brain during ageing and Alzheimer’s Disease has been 
extensively studied.  It is now widely accepted that AD is accompanied by brain 
hypometabolism that varies between different regions of the brain. 
 
Analysis of the effects of Aβ(1-42) on co-cultures of neurons and astrocytes revealed 
a significant changes in the metabolism of cells that is analogous to that seen both in 
human studies and animal models. A major feature of this cellular response is a clear 
hypometabolism particularly with regards to glucose as well as changes in the 
metabolism of pyruvate, lactate and glycogen, which can act as alternate sources of 
fuel during hypoglycaemia. These changes lead to a reduction in ATP production 
which suggests a significant energy deficit in the cultures (Fig. 5.1A). This has 
serious implications in the brain which has a very high energy demand, particularly 
with regard to memory formation and protection from oxidative stress in neurons. 
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A) 
 
B) 
 
Figure 5.1 Summary conclusion figure showing Aβ(1-42) induced metabolic 
changes (A) and oxidative stress (B). Figure A) shows changes in ANLS, glycolysis 
in astrocytes and oxidative phosphorylation in neurons. Figure B) represents 
changes in the pentose phosphate shunt pathway in neurons and astrocytes as well 
as antioxidant defence (GSH/GSSG recycling pathway). 
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Indeed, Aβ(1-42) has also been shown to increase oxidative stress, trigger calcium 
responses and decrease NAD+ availability (Fig. 5.1B). This would not only affect the 
antioxidant defence of the cells but also the ability to produce ATP and repair DNA 
via PARP. As the effect was less pronounced in pure astrocytic cultures this study 
suggests that the astrocytes are able to cope with the Aβ(1-42) insult, whilst in the 
presence of neurons which require protection, astrocytes are put under higher 
metabolic and antioxidant demands.  
 
At present, models of AD fail to recapitulate all of the major features of the disease.  
This may also be reflected in the fact that many of the new therapies for the 
treatment of AD have failed to have a significant impact on the development of the 
disease.  Human stem cell derived models of the brain are increasingly proving to 
provide useful tools in the study of human disease. 
 
Overall, this project presents a unique departure from standard experimental models 
of the brain. It provides a realistic model of basic human neuronal and astrocytic 
interactions which can be used to simulate human neurodegeneration in vitro. 
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5.1 Future experimental approaches 
 
The ability to control the aggregation state of Aβ(1-42) is a crucial step, as 
monomers, oligomers and fibrils have different toxicity profiles. In the study 
presented here Aβ(1-42) and Aβ(1-40) were monitored using two experimental 
techniques – western blotting and ThT assay. However, more studies should be 
performed to ensure a replicable process of Aβ(1-42) aggregation such as Atomic 
Force Microscope (AFM) which has been previously used (Dahlgren et al., 2002). An 
additional advantage for future studies on effects of Aβ(1-42) would be the use of 
natural peptide as opposed to a synthetic one This could be achieved by 
overexpression human APP or expressing human APP with Swedish mutation in a 
cell line e.g. SY5Y or NT2. As natural forms of Aβ(1-42) are more toxic than 
synthetically derived peptides this would ensure an appropriate modelling of the 
disease (Lambert et al., 1998).  
 
To fully understand how Aβ(1-42) causes metabolic changes in NT2.N/A cultures, it 
is necessary to investigate changes in enzyme expression and activity e.g. 
hexokinase or pyruvate dehydrogenase. These enzymes have been found to 
decrease in AD (Gibson et al., 1998) and it is essential that it is confirmed whether a 
similar effect is seen in NT2.N/A cultures. Additionally, more advanced method could 
be used to investigate metabolic trafficking between neurons and astrocytes. One of 
such methods is in vitro 13C-NMR spectroscopy. As it does not require isolation of 
metabolites due to incorporation of the label into specific carbon positions, it provides 
information about many different metabolites and metabolic pathways. The use of 
this method would allow investigation of the fate of the glucose and glutamate, not 
only in terms of ANLS but also glutamate-glutamine cycling. It would be 
advantageous to study metabolic changes following the treatment with Aβ(1-42) in 
real-time. This could be achieved by the use of specialized equipment such as 
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Seahorse Bioscience XF Extracellular Flux analyser. This system measures the 
oxygen consumption rate (a measure of mitochondrial respiration) as well as 
extracellular acidification rate (a measure of glycolysis) and fatty acid oxidation.  
Additionally it is able to measure mitochondrial stress (by determining basal 
respiration, ATP turnover, proton leak, and maximal respiration) and glycolysis stress 
(by determining glycolysis, glycolytic capacity, and glycolytic reserve).  
 
It is probably important to mention that the experiments presented in this thesis 
should also be performed on pure neuronal and astrocytic cultures. Studying the cells 
in isolation as well as in co-culture would allow to determine how each cell type is 
affected by Aβ(1-42) treatments. 
 
In addition, more focus should be directed to mitochondrial function. This could be 
done by determining mitochondrial membrane potential, using lipophylic cationic dye 
such as JC-1.  
 
An interesting hypothesis linking hypometabolism and Aβ production has been 
previously described (Struble et al., 2010). It proposes a possible impact of 
hypometabolism on BACE1 expression. Creation of NT2.N/A cultures overexpressing 
APP or mutated APP would allow investigation into the effects of APP processing on 
metabolic endpoints in these cells. In addition, RNAi or shRNA could be used to 
silence particular genes in order determine their involvement in response to Aβ. As 
changes in glycogen metabolism have not been described in vivo it would be useful 
to determine, glycogen load in transgenic mice during the disease progression. 
 
Further functional studies of neurons and astrocytes should also be carried out. The 
stimulation and recording of electrical activity from cultures following exposure to 
Aβ(1-42) using multi-electrode array (MEA)  analysis would be of great value. 
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The results obtained in this thesis on NT2.D1 derived cultures of neurons and 
astrocytes provide a good foundation for future experiments on more patient-specific 
platforms such as iPS cells. The progress in reprogramming and differentiation of iPS 
cells makes them an ideal candidate for studies on metabolic coupling between 
neurons and astrocytes in Alzheimer’s Disease. As iPS cells are derived from patient, 
they therefore express factors associated with AD at physiological levels that cannot 
be carried simulated overexpression studies or via the application of exogenous Aβ. 
 
Patient specific models of AD could be generated from fibroblasts taken from patients 
with APP/presenillin mutations as well as controls (Wray et al., 2012). iPS cells could 
be differentiated into mixed cultures of  neurons and astrocytes. Such cultures could 
then be monitored for changes in metabolism using 13C-NMR or the Seahorse 
Bioscience XF Extracellular Flux analyser. Additionally changes in glycogen, 
NAD+/NADH ratio and ATP could be investigated as well as antioxidant defences 
using GSH assay.  
 
Alzheimer’s disease is devastating neurodegenerative condition with no beneficial 
treatment available. This is in part, due to a lack of relevant human models of the 
brain. Stem cells such as the NT2/D1 cell line or iPSC provide advantegous 
alternatives to animal models. These cells allow investigation of more than one cell 
type in a co-culture as well as individually, thus creating a more comprehensive 
approach. The ability to investigate functional postmitotic neurons and astrocytes 
could significantly enhance our understanding of neurodegenerative diseases, which 
could translate into better treatments. In addition, the use of patient specific iPSC 
would allow a more tailored patient (genotypic) specific approach to new treatments. 
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Appendix 1. Mini-PROTEAN Tetra Cell (Electrophoresis) protocol (Bio-rad) 
 
 
 
 
 
 
pH and pI
The pH of the electrophoresis buffer must be within the pH range over which the protein
of interest is stable and retains biological activity. In addition, the pH of the buffer must
impart sufficient charge to the protein for it to move through the gel. Changes in pH will
affect both the charge and size (hydrodynamic volume) of the protein of interest and will
affect migration rates. For example, a buffer with a pH greater than the pI of the protein will
impart a negative charge on the protein and it will migrate toward the positive electrode
(anode). Conversely, a buffer with a pH lower than the pI of the protein will impart a positive
charge and the protein will migrate to the negative electrode (cathode). A pH equal to the pI
will result in no net charge in the protein and it will not migrate in an electric field.
Protein mobilities are best modified by the buffer's pH. Buffers with a pH closer to the pI
will provide the best resolution. However run times may be lengthy. Conversely, buffers
with a pH further from the pI will migrate quickly but resolution may be compromised. The
choice of pH becomes a tradeoff between separation and speed.
How to Choose a Native PAGE system
1. Discontinuous Buffer Systems (Ornstein-Davis2)
This discontinuous buffer system should be the first nondenaturing gel system tried.
Detailed protocols are provided in Section 4.2. The advantage of a discontinuous system
is the use of a stacking gel to concentrate dilute protein samples. However, the stacking
phenomena can also cause aggregation of some proteins and interfere with resolution.
If protein aggregation occurs, a continuous buffer system should be used.
Note: The pH attained in the resolving gel of the Ornstein-Davis system approaches pH
9.5, which may be outside the range of stability for some proteins, causing denatura-
tion. Additionally, the pI of the protein of interest may be too close to or above the
Ornstein-Davis buffer pH (9.5), which may result in a very low net charge or a positive
net charge that may significantly reduce or even prohibit migration to the anode.
Alternative discontinuous systems can be found in an article by Chrambach and Jovin.3
Note:  It is very desirable to know the pI of the protein of interest before selecting a
buffer system.
2. Continuous Buffer Systems
A continuous buffer system will be required if discontinuous systems cannot be used
due to stacking-induced protein aggregation. In a continuous system the same buffer is
used in the upper and lower electrode chambers as in the gel. Since stacking does not
occur, proteins migrate in bands at least as wide as the applied sample. Consequently,
sample volumes should be minimized. The mobility of proteins in a continuous system
is dictated by pH rather than by sieving through the polyacrylamide gel. For this reason,
6% polyacrylamide gels are recommended for most applications. For very large proteins,
4% or 5% gels may be used. McLellan describes various continuous buffer systems
from pH 3.8–10.2.4 Detailed protocols are provided in Section 4.3.
Section 4
Reagent Preparation and Stock Solutions
4.1  Volumes Required Per Gel
The volumes listed are required to completely fill a gel cassette. Amounts may be
adjusted depending on the application (with or without comb, with or without stacking gel,
etc.).
13Gel Thickness (mm) Volume (ml)
0.5 2.8 
0.75 4.2
1.0 5.6
1.5 8.4
Note: 10 ml of monomer solution is sufficient for two stacking gels of any thickness.
4.2  SDS-PAGE (Laemmli)1 Buffer System
Stock Solutions and Buffers
1. Acrylamide/Bis (30% T, 2.67% C)
87.6 g acrylamide (29.2 g/100 ml)
2.4 g N'N'-bis-methylene-acrylamide (0.8 g/100 ml)
Make to 300 ml with deionized water. Filter and store at 4°C in the dark (30 days 
maximum).
or use:
Preweighed acrylamide/bis, 37.5:1 mixture (30%T, 2.67% C)
(Bio-Rad catalog #161-0125, 150 g)
30% acrylamide/bis solution, 37.5:1 mixture (30%T, 2.67% C)
(Bio-Rad catalog #161-0158, 500 ml)
(Bio-Rad catalog #161-0159, 2 x 500 ml)
2. 10% (w/v) SDS
Dissolve 10 g SDS in 90 ml water with gentle stirring and bring to 100 ml with deionized
water. Alternatively, 10% SDS solution (250 ml) can be used (Bio-Rad catalog #161-0416).
3. 1.5 M Tris-HCl, pH 8.8
27.23 g Tris base (18.15 g/100 ml)
80 ml deionized water
Adjust to pH 8.8 with 6 N HCl. Bring total volume to 150 ml with deionized water and
store at 4°C. Alternatively, 1.5 M Tris-HCl, pH 8.8 (1 L) premixed buffer can be used
(Bio-Rad catalog #161-0798).
4. 0.5 M Tris-HCl, pH 6.8
6 g Tris base
60 ml deionized water
Adjust to pH 6.8 with 6 N HCl. Bring total volume to 100 ml with deionized water and
store at 4°C. Alternatively, 0.5 M Tris-HCl, pH 6.8 (1 L) premixed buffer can be used
(Bio-Rad catalog #161-0799).
5. Sample Buffer (SDS Reducing Buffer)
3.55 ml deionized water
1.25 ml 0.5 M Tris-HCl, pH 6.8
2.5 ml glycerol
2.0 ml 10% (w/v) SDS
0.2 ml 0.5% (w/v) Bromophenol Blue
9.5 ml Total volume
Store at room temperature.
Use: Add 50 µl β-mercaptoethanol to 950 µl sample buffer prior to use. Dilute the sample
at least 1:2 with sample buffer and heat at 95°C for 4 minutes.
14
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Gel Thickness (mm) Volume (ml)
0.5 2.8 
0.75 4.2
1.0 5.6
1.5 8.4
Note: 10 ml of monomer solution is sufficient for two stacking gels of any thickness.
4.2  SDS-PAGE (Laemmli)1 Buffer System
Stock Solutions and Buffers
1. Acrylamide/Bis (30% T, 2.67% C)
87.6 g acrylamide (29.2 g/100 ml)
2.4 g N'N'-bis-methylene-acrylamide (0.8 g/100 ml)
Make to 300 ml with deionized water. Filter and store at 4°C in the dark (30 days 
maximum).
or use:
Preweighed acrylamide/bis, 37.5:1 mixture (30%T, 2.67% C)
(Bio-Rad catalog #161-0125, 150 g)
30% acrylamide/bis solution, 37.5:1 mixture (30%T, 2.67% C)
(Bio-Rad catalog #161-0158, 500 ml)
(Bio-Rad catalog #161-0159, 2 x 500 ml)
2. 10% (w/v) SDS
Dissolve 10 g SDS in 90 ml water with gentle stirring and bring to 100 ml with deionized
water. Alternatively, 10% SDS solution (250 ml) can be used (Bio-Rad catalog #161-0416).
3. 1.5 M Tris-HCl, pH 8.8
27.23 g Tris base (18.15 g/100 ml)
80 ml deionized water
Adjust to pH 8.8 with 6 N HCl. Bring total volume to 150 ml with deionized water and
store at 4°C. Alternatively, 1.5 M Tris-HCl, pH 8.8 (1 L) premixed buffer can be used
(Bio-Rad catalog #161-0798).
4. 0.5 M Tris-HCl, pH 6.8
6 g Tris base
60 ml deionized water
Adjust to pH 6.8 with 6 N HCl. Bring total volume to 100 ml with deionized water and
store at 4°C. Alternatively, 0.5 M Tris-HCl, pH 6.8 (1 L) premixed buffer can be used
(Bio-Rad catalog #161-0799).
5. Sample Buffer (SDS Reducing Buffer)
3.55 ml deionized water
1.25 ml 0.5 M Tris-HCl, pH 6.8
2.5 ml glycerol
2.0 ml 10% (w/v) SDS
0.2 ml 0.5% (w/v) Bromophenol Blue
9.5 ml Total volume
Store at room temperature.
Use: Add 50 µl β-mercaptoethanol to 950 µl sample buffer prior to use. Dilute the sample
at least 1:2 with sample buffer and heat at 95°C for 4 minutes.
146. 10x Electrode (Running) Buffer, pH 8.3 (makes 1 L)
30.3 g Tris base
144.0 g glycine
10.0 g SDS
Dissolve and bring total volume up to 1,000 ml with deionized water. Do not adjust pH
with acid or base. Store at 4°C. If precipitation occurs, warm to room temperature
before use. Alternatively, electrophoresis running buffer 10x Tris/glycine/SDS, 5 L cube
(Bio-Rad catalog #161-0772) can be used.
Use: Dilute 50 ml of 10x stock with 450 ml deionized water for each electrophoresis run.
Mix thoroughly before use.
7. 10% (w/v) APS (fresh daily)
100 mg ammonium persulfate 
Dissolve in 1 ml of deionized water.
Gel Formulations (10 ml)
1. Prepare the monomer solution by mixing all reagents except the TEMED and 10%
APS. Degas the mixture for 15 minutes.
30% Degassed
DDI H2O Acrylamide/Bis Gel Buffer* 10% w/v SDS
Percent Gel (ml) (ml) (ml) (ml)
4% 6.1 1.3 2.5 0.1
5% 5.7 1.7 2.5  0.1
6% 5.4 2.0 2.5 0.1
7% 5.1 2.3 2.5 0.1
8% 4.7 2.7 2.5 0.1
9% 4.4 3.0 2.5 0.1
10% 4.1 3.3 2.5 0.1
11% 3.7 3.7 2.5 0.1
12% 3.4 4.0 2.5 0.1
13% 3.1 4.3 2.5 0.1
14% 2.7 4.7 2.5 0.1
15% 2.4 5.0 2.5 0.1
16% 2.1 5.3 2.5 0.1
17% 1.7 5.7 2.5 0.1
* Resolving Gel Buffer – 1.5 M Tris-HCl, pH 8.8 
* Stacking Gel Buffer – 0.5 M Tris-HCl, pH 6.8
2. Immediately prior to pouring the gel, add:
For 10 ml monomer solution:
Resolving gel: 50 µl 10% APS and
5 µl TEMED
Stacking gel: 50 µl 10% APS and
10 µl TEMED
Swirl gently to initiate polymerization.
15
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6. 10x Electrode (Running) Buffer, pH 8.3 (makes 1 L)
30.3 g Tris base
144.0 g glycine
10.0 g SDS
Dissolve and bring total volume up to 1,000 ml with deionized water. Do not adjust pH
with acid or base. Store at 4°C. If precipitation occurs, warm to room temperature
before use. Alternatively, electrophoresis running buffer 10x Tris/glycine/SDS, 5 L cube
(Bio-Rad catalog #161-0772) can be used.
Use: Dilute 50 ml of 10x stock with 450 ml deionized water for each electrophoresis run.
Mix thoroughly before use.
7. 10% (w/v) APS (fresh daily)
100 mg ammonium persulfate 
Dissolve in 1 ml of deionized water.
Gel Formulations (10 ml)
1. Prepare the monomer solution by mixing all reagents except the TEMED and 10%
APS. Degas the mixture for 15 minutes.
30% Degassed
DDI H2O Acrylamide/Bis Gel Buffer* 10% w/v SDS
Percent Gel (ml) (ml) (ml) (ml)
4% 6.1 1.3 2.5 0.1
5% 5.7 1.7 2.5  0.1
6% 5.4 2.0 2.5 0.1
7% 5.1 2.3 2.5 0.1
8% 4.7 2.7 2.5 0.1
9% 4.4 3.0 2.5 0.1
10% 4.1 3.3 2.5 0.1
11% 3.7 3.7 2.5 0.1
12% 3.4 4.0 2.5 0.1
13% 3.1 4.3 2.5 0.1
14% 2.7 4.7 2.5 0.1
15% 2.4 5.0 2.5 0.1
16% 2.1 5.3 2.5 0.1
17% 1.7 5.7 2.5 0.1
* Resolving Gel Buffer – 1.5 M Tris-HCl, pH 8.8 
* Stacking Gel Buffer – 0.5 M Tris-HCl, pH 6.8
2. Immediately prior to pouring the gel, add:
For 10 ml monomer solution:
Resolving gel: 50 µl 10% APS and
5 µl TEMED
Stacking gel: 50 µl 10% APS and
10 µl TEMED
Swirl gently to initiate polymerization.
15
Note: Prepare any desired volume of monomer solution by using multiples of the 10 ml
recipe. The volumes of APS and TEMED must be adjusted accordingly.
Warning: The catalyst concentration is very important! Webbing and incomplete well
formulation can result from inaccurate catalyst concentration.
4.3  Discontinuous Native PAGE (Ornstein-Davis)2
Stock Solutions and Buffers
1. Acrylamide/Bis (30% T, 2.67% C)
87.6 g acrylamide (29.2 g/100 ml)
2.4 g N'N'-bis-methylene-acrylamide (0.8 g/100 ml)
Make to 300 ml with deionized water. Filter and store at 4°C in the dark (30 days 
maximum).
or, use:
Preweighed acrylamide/bis, 37.5:1 mixture
(Bio-Rad catalog #161-0125, 150 g)
30% acrylamide/bis solution, 37.5:1 mixture 
(Bio-Rad catalog #161-0158, 500 ml)
(Bio-Rad catalog #161-0159, 2 x 500 ml)
2. 1.5 M Tris-HCl, pH 8.8
27.23 g Tris base (18.15 g/100 ml)
80 ml deionized water
Adjust to pH 8.8 with 6 N HCl. Bring total volume up to 150 ml with deionized water and
store at 4°C. Alternatively, 1.5 M Tris-HCl, pH 8.8 (1 L) premixed buffer can be used
(Bio-Rad catalog #161-0798).
3. 0.5 M Tris-HCl, pH 6.8
6 g Tris base
60 ml deionized water
Adjust to pH 6.8 with 6 N HCl. Bring total volume up to 100 ml with deionized water and
store at 4°C. Alternatively, 0.5 M Tris-HCl, pH 6.8 (1 L) premixed buffer can be used
(Bio-Rad catalog #161-0799).
4. Sample Buffer
5.55 ml deionized water
1.25 ml 0.5 M Tris-HCl, pH 6.8
3.0 ml glycerol
0.2 ml 0.5% (w/v) Bromophenol Blue
10.0 ml Total volume
Store at room temperature.
Use:  Dilute the sample at least 1:2 with sample buffer and heat at 95°C for 4 minutes.
5. 10x Electrode (Running) Buffer, pH 8.3
30.3 g Tris base (15 g/L)
144.1 g glycine (72 g/L)
Bring total volume up to 1,000 ml with deionized water. Do not adjust pH. Alternatively,
electrophoresis running buffer 10x Tris/Glycine, 1 L (Bio-Rad catalog #161-0734) can
be used.
Usage: Dilute 100 ml of 10x stock with 900 ml deionized water for each electrophoresis
run.
16
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Note: Prepare any desired volume of monomer solution by using multiples of the 10 ml
recipe. The volumes of APS and TEMED must be adjusted accordingly.
Warning: The catalyst concentration is very important! Webbing and incomplete well
formulation can result from inaccurate catalyst concentration.
4.3  Discontinuous Native PAGE (Ornstein-Davis)2
Stock Solutions and Buffers
1. Acrylamide/Bis (30% T, 2.67% C)
87.6 g acrylamide (29.2 g/100 ml)
2.4 g N'N'-bis-methylene-acrylamide (0.8 g/100 ml)
Make to 300 ml with deionized water. Filter and store at 4°C in the dark (30 days 
maximum).
or, use:
Preweighed acrylamide/bis, 37.5:1 mixture
(Bio-Rad catalog #161-0125, 150 g)
30% acrylamide/bis solution, 37.5:1 mixture 
(Bio-Rad catalog #161-0158, 500 ml)
(Bio-Rad catalog #161-0159, 2 x 500 ml)
2. 1.5 M Tris-HCl, pH 8.8
27.23 g Tris base (18.15 g/100 ml)
80 ml deionized water
Adjust to pH 8.8 with 6 N HCl. Bring total volume up to 150 ml with deionized water and
store at 4°C. Alternatively, 1.5 M Tris-HCl, pH 8.8 (1 L) premixed buffer can be used
(Bio-Rad catalog #161-0798).
3. 0.5 M Tris-HCl, pH 6.8
6 g Tris base
60 ml deionized water
Adjust to pH 6.8 with 6 N HCl. Bring total volume up to 100 ml with deionized water and
store at 4°C. Alternatively, 0.5 M Tris-HCl, pH 6.8 (1 L) premixed buffer can be used
(Bio-Rad catalog #161-0799).
4. Sample Buffer
5.55 ml deionized water
1.25 ml 0.5 M Tris-HCl, pH 6.8
3.0 ml glycerol
0.2 ml 0.5% (w/v) Bromophenol Blue
10.0 ml Total volume
Store at room temperature.
Use:  Dilute the sample at least 1:2 with sample buffer and heat at 95°C for 4 minutes.
5. 10x Electrode (Running) Buffer, pH 8.3
30.3 g Tris base (15 g/L)
144.1 g glycine (72 g/L)
Bring total volume up to 1,000 ml with deionized water. Do not adjust pH. Alternatively,
electrophoresis running buffer 10x Tris/Glycine, 1 L (Bio-Rad catalog #161-0734) can
be used.
Usage: Dilute 100 ml of 10x stock with 900 ml deionized water for each electrophoresis
run.
16Gel Formulations (10 ml)
1. Prepare the monomer solution by mixing all reagents except the TEMED and 10%
APS. Degas the mixture for 15 minutes.
30% Degassed
Percent DDI H2O Acrylamide/Bis Gel Buffer*
Gel (ml) (ml) (ml)
4% 6.2 1.3 2.5
5% 5.8 1.7 2.5
6% 5.5 2.0 2.5
7% 5.2 2.3 2.5
8% 4.8 2.7 2.5
9% 4.5 3.0 2.5
10% 4.2 3.3 2.5
* Resolving Gel Buffer – 1.5 M Tris-HCl, pH 8.8 
* Stacking Gel Buffer – 0.5 M Tris-HCl, pH 6.8
2. Immediately prior to pouring the gel, add:
50 ml APS and 
TEMED (5 µl for resolving gels; 10 µl TEMED for stacking gels) 
Swirl gently to initiate polymerization. 
Note: Prepare any desired volume of monomer solution by using multiples of the 10 ml
recipe. The volumes of APS and TEMED must be adjusted accordingly.
4.4  Continuous Native PAGE
Stock Solutions and Buffers
1. Acrylamide/Bis (30% T, 2.67% C)
87.6 g acrylamide (29.2 g/100 ml)
2.4 g N'N'-bis-methylene-acrylamide (0.8 g/100 ml)
Make to 300 ml with deionized water. Filter and store at 4°C in the dark (30 days 
maximum.)
or use:
Preweighed acrylamide/bis, 37.5:1 mixture
(Bio-Rad catalog #161-0125, 150 g)
30% acrylamide/bis solution, 37.5:1 mixture 
(Bio-Rad catalog #161-0158, 500 ml)
(Bio-Rad catalog #161-0159, 2 x 500 ml)
2. Sample Buffer
1.0 ml electrophoresis Buffer
3.0 ml glycerol
0.2 ml 0.5% Bromophenol Blue
5.8 ml Deionized water
10.0 ml Total volume
3. Continuous Buffers (McLellan)4
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 Aβ(1-42) / DMSO 
Aβ(1-42) / 
HEPES Aβ(1-42) / F12 
Aβ(1-40) / 
HEPES 
6h >0.05 >0.05 >0.05 >0.05 
24h <0.0001 >0.05 <0.05 >0.05 
48h <0.0001 >0.05 <0.0001 >0.05 
72h <0.0001 >0.05 <0.0001 >0.05 
96h <0.0001 >0.05 <0.01 >0.05 
 
Appendix 2 Two-way ANOVA followed by Bonferroni post-test (Graphpad Prism). 
Aggregation of 20µM Aβ(1-42) and Aβ(1-40) preparations using ThT fluorescence. 
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 Aβ(1-42) / DMSO 
Aβ(1-42) / 
HEPES Aβ(1-42) / F12 
Aβ(1-40) / 
HEPES 
6h <0.001 >0.05 <0.0001 >0.05 
24h <0.0001 >0.05 <0.0001 <0.01 
48h <0.0001 >0.05 <0.0001 >0.05 
72h <0.0001 <0.001 <0.0001 >0.05 
96h <0.0001 <0.05 <0.001 >0.05 
 
Appendix 3 Two-way ANOVA followed by Bonferroni post-test (Graphpad Prism). 
Aggregation of 2µM Aβ(1-42) and Aβ(1-40) preparations using ThT fluorescence. 
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 Aβ(1-42) / DMSO 
Aβ(1-42) / 
HEPES Aβ(1-42) / F12 
Aβ(1-40) / 
HEPES 
6h >0.05 >0.05 >0.05 >0.05 
24h >0.05 >0.05 >0.05 >0.05 
48h >0.05 >0.05 >0.05 >0.05 
72h <0.05 >0.05 >0.05 >0.05 
96h >0.05 >0.05 <0.05 >0.05 
 
Appendix 4 Two-way ANOVA followed by Bonferroni post-test (Graphpad Prism). 
Aggregation of 0.2µM Aβ(1-42) and Aβ(1-40) preparations using ThT fluorescence. 
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Appendix 5 NAD+ and NADH inside control NT2.N/A cultures.  
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Appendix 6 NAD+ and NADH levels inside the cells following treatment of 
NT2.N/A with 2µM Aβ. 
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Appendix 7. CellTiter-Glo® Luminescent Cell Viability Assay (ATP) 
 
Promega Corporation · 2800 Woods Hollow Road · Madison, WI 53711-5399 USA 
Toll Free in USA 800-356-9526 · Phone 608-274-4330 · Fax 608-277-2516 · www.promega.com
Printed in USA. Part# TB288
Revised 12/12 Page 1
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Appendix 8. Gene table for Human Alzheimer’s Disease RT² Profiler™ PCR 
Array 
 
Symbol Well 
Fold Difference T-TEST 
Fold Up- or 
Down-
Regulation 
Test Sample 
/Control Sample p value 
Test Sample 
/Control 
Sample 
A2M A01 2.29 0.0319 2.29 
ABCA1 A02 0.75 0.4299 -1.34 
ACHE A03 0.87 0.6613 -1.15 
ADAM9 A04 1.75 0.0123 1.75 
APBA1 A05 1.18 0.6563 1.18 
APBA3 A06 0.82 0.4701 -1.22 
APBB1 A07 1.00 0.9942 -1.00 
APBB2 A08 3.50 0.0306 3.50 
APH1A A09 1.22 0.2494 1.22 
APLP1 A10 1.33 0.7060 1.33 
APLP2 A11 1.53 0.4551 1.53 
APOA1 A12 0.45 0.4840 -2.22 
APOE B01 0.89 0.8389 -1.13 
APP B02 1.27 0.5442 1.27 
NAE1 B03 1.18 0.5426 1.18 
BACE1 B04 2.32 0.0318 2.32 
BACE2 B05 1.10 0.7037 1.10 
BCHE B06 0.30 0.0487 -3.29 
BDNF B07 1.34 0.6582 1.34 
CASP3 B08 0.99 0.9686 -1.01 
CASP4 B09 4.76 0.0222 4.76 
CDC2 B10 0.51 0.2628 -1.98 
CDK5 B11 1.70 0.1146 1.70 
CDKL1 B12 1.80 0.4642 1.80 
CHAT C01 1.11 0.8317 1.11 
CLU C02 0.87 0.6690 -1.15 
CTSB C03 1.15 0.3800 1.15 
CTSC C04 1.01 0.9690 1.01 
CTSD C05 0.65 0.2725 -1.54 
CTSG C06 0.44 0.4181 -2.26 
CTSL1 C07 1.40 0.7344 1.40 
EP300 C08 1.77 0.3431 1.77 
ERN1 C09 0.45 0.2607 -2.20 
GAP43 C10 10.13 0.0433 10.13 
GNAO1 C11 1.86 0.1740 1.86 
GNAZ C12 1.66 0.0180 1.66 
GNB1 D01 1.10 0.7504 1.10 
GNB2 D02 1.07 0.8499 1.07 
GNB4 D03 1.18 0.4869 1.18 
GNB5 D04 1.00 0.9925 -1.00 
GNG10 D05 1.02 0.9263 1.02 
GNG11 D06 0.79 0.6561 -1.27 
GNG3 D07 1.57 0.1256 1.57 
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GNG4 D08 1.76 0.2165 1.76 
GNG5 D09 1.06 0.6924 1.06 
GNG7 D10 0.68 0.0893 -1.48 
GNG8 D11 2.27 0.0184 2.27 
GNGT1 D12 1.02 0.9623 1.02 
GNGT2 E01 0.42 0.2975 -2.39 
GSK3A E02 0.79 0.5520 -1.27 
GSK3B E03 3.41 0.0458 3.41 
HSD17B10 E04 1.01 0.9243 1.01 
IDE E05 3.23 0.0038 3.23 
IL1A E06 0.92 0.8771 -1.09 
INS E07 1.12 0.9042 1.12 
INSR E08 1.56 0.2286 1.56 
LPL E09 3.54 0.0454 3.54 
LRP1 E10 0.90 0.7607 -1.11 
LRP6 E11 1.65 0.1952 1.65 
LRP8 E12 1.02 0.9547 1.02 
MAP2 F01 1.73 0.1401 1.73 
MAPT F02 1.67 0.1709 1.67 
MPO F03 0.42 0.3312 -2.36 
NCSTN F04 1.11 0.8218 1.11 
PKP4 F05 0.86 0.5506 -1.16 
PLAT F06 1.44 0.2120 1.44 
PLAU F07 1.00 0.9993 1.00 
PLG F08 0.33 0.1175 -3.02 
PRKCA F09 1.00 0.9987 1.00 
PRKCB F10 1.00 0.9940 1.00 
PRKCD F11 0.63 0.2562 -1.59 
PRKCE F12 2.12 0.0897 2.12 
PRKCG G01 0.84 0.7726 -1.20 
PRKCI G02 1.61 0.0949 1.61 
PRKCQ G03 0.99 0.9796 -1.01 
PRKCZ G04 1.03 0.8931 1.03 
PSEN1 G05 1.17 0.6064 1.17 
PSEN2 G06 0.77 0.3168 -1.30 
SERPINA3 G07 1.52 0.5953 1.52 
SNCA G08 2.13 0.0165 2.13 
SNCB G09 0.86 0.7436 -1.17 
UBQLN1 G10 1.15 0.6545 1.15 
UQCRC1 G11 0.71 0.0768 -1.41 
UQCRC2 G12 0.88 0.3827 -1.14 
B2M H01 1.00 0.9789 -1.00 
HPRT1 H02 0.65 0.0241 -1.53 
RPL13A H03 1.09 0.6664 1.09 
GAPDH H04 0.88 0.2542 -1.14 
ACTB H05 1.60 0.0174 1.60 
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Appendix 9 Gene expression in NT2.N/A cultures following treatment with 20µM 
Aβ(1-42) for A) 48h, B) 72h, C) 96h. Results are expressed as the average fold 
change ± SEM (n=3) and considered significant above 2-fold change. 
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Appendix 10 Gene expression in NT2.N/A cultures following treatment with 2µM 
Aβ(1-42) for A) 48h, B) 72h, C) 96h. Results are expressed as the average fold 
change ± SEM (n=3) and considered significant above 2-fold change. 
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Appendix 11 Gene expression in NT2.N/A cultures following treatment with 0.2µM 
Aβ(1-42) for A) 48h, B) 72h, C) 96h. Results are expressed as the average fold 
change ± SEM (n=3) and considered significant above 2-fold change. 
 
	  
